
<html lang="en"     class="pb-page"  data-request-id="a1f79b44-ab11-4bd4-b757-ce325653742c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b01582;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2020.63.issue-2;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2" /></meta><meta name="dc.Creator" content="Jacek  Kwiatkowski" /></meta><meta name="dc.Creator" content="Boping  Liu" /></meta><meta name="dc.Creator" content="Shermaine  Pang" /></meta><meta name="dc.Creator" content="Nur Huda Binte  Ahmad" /></meta><meta name="dc.Creator" content="Gang  Wang" /></meta><meta name="dc.Creator" content="Anders  Poulsen" /></meta><meta name="dc.Creator" content="Haiyan  Yang" /></meta><meta name="dc.Creator" content="Yong Rui  Poh" /></meta><meta name="dc.Creator" content="Doris Hui Ying  Tee" /></meta><meta name="dc.Creator" content="Esther  Ong" /></meta><meta name="dc.Creator" content="Priya  Retna" /></meta><meta name="dc.Creator" content="Nurul  Dinie" /></meta><meta name="dc.Creator" content="Perlyn  Kwek" /></meta><meta name="dc.Creator" content="John Liang Kuan  Wee" /></meta><meta name="dc.Creator" content="Vithya  Manoharan" /></meta><meta name="dc.Creator" content="Choon Bing  Low" /></meta><meta name="dc.Creator" content="Peck Gee  Seah" /></meta><meta name="dc.Creator" content="Vishal  Pendharkar" /></meta><meta name="dc.Creator" content="Kanda  Sangthongpitag" /></meta><meta name="dc.Creator" content="Joma  Joy" /></meta><meta name="dc.Creator" content="Nithya  Baburajendran" /></meta><meta name="dc.Creator" content="Anna Elisabet  Jansson" /></meta><meta name="dc.Creator" content="Kassoum  Nacro" /></meta><meta name="dc.Creator" content="Jeffrey  Hill" /></meta><meta name="dc.Creator" content="Thomas H.  Keller" /></meta><meta name="dc.Creator" content="Alvin W.  Hung" /></meta><meta name="dc.Description" content="Dysregulation of translation initiation factor 4E (eIF4E) activity occurs in various cancers. Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) play a fundamental ..." /></meta><meta name="Description" content="Dysregulation of translation initiation factor 4E (eIF4E) activity occurs in various cancers. Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) play a fundamental ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 7, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01582" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01582" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01582" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01582" /></link>
        
    
    

<title>Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01582" /></meta><meta property="og:title" content="Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0005.jpeg" /></meta><meta property="og:description" content="Dysregulation of translation initiation factor 4E (eIF4E) activity occurs in various cancers. Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) play a fundamental role in activation of eIF4E. Structure–activity relationship-driven expansion of a fragment hit led to discovery of dual MNK1 and MNK2 inhibitors based on a novel pyridine-benzamide scaffold. The compounds possess promising in vitro and in vivo pharmacokinetic profiles and show potent on target inhibition of eIF4E phosphorylation in cells." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Dysregulation of translation initiation factor 4E (eIF4E) activity occurs in various cancers. Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) play a fundamental role in activation of eIF4E. Structure–activity relationship-driven expansion of a fragment hit led to discovery of dual MNK1 and MNK2 inhibitors based on a novel pyridine-benzamide scaffold. The compounds possess promising in vitro and in vivo pharmacokinetic profiles and show potent on target inhibition of eIF4E phosphorylation in cells." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0005.jpeg" /></meta><meta name="twitter:title" content="Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01582"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01582">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01582&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01582&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01582&amp;href=/doi/10.1021/acs.jmedchem.9b01582" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 621-637</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01560" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01585" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Jacek Kwiatkowski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jacek Kwiatkowski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jacek++Kwiatkowski">Jacek Kwiatkowski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Boping Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Boping Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Boping++Liu">Boping Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shermaine Pang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shermaine Pang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shermaine++Pang">Shermaine Pang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nur Huda Binte Ahmad</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nur Huda Binte Ahmad</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nur+Huda+Binte++Ahmad">Nur Huda Binte Ahmad</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gang Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gang Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gang++Wang">Gang Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anders Poulsen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anders Poulsen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anders++Poulsen">Anders Poulsen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haiyan Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haiyan Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haiyan++Yang">Haiyan Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yong Rui Poh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yong Rui Poh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yong+Rui++Poh">Yong Rui Poh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Doris Hui Ying Tee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Doris Hui Ying Tee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Doris+Hui+Ying++Tee">Doris Hui Ying Tee</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Esther Ong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Esther Ong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Esther++Ong">Esther Ong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Priya Retna</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Priya Retna</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Priya++Retna">Priya Retna</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nurul Dinie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nurul Dinie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nurul++Dinie">Nurul Dinie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Perlyn Kwek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Perlyn Kwek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Perlyn++Kwek">Perlyn Kwek</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John Liang Kuan Wee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John Liang Kuan Wee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+Liang+Kuan++Wee">John Liang Kuan Wee</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vithya Manoharan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vithya Manoharan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vithya++Manoharan">Vithya Manoharan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Choon Bing Low</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Choon Bing Low</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Choon+Bing++Low">Choon Bing Low</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peck Gee Seah</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peck Gee Seah</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peck+Gee++Seah">Peck Gee Seah</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vishal Pendharkar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vishal Pendharkar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vishal++Pendharkar">Vishal Pendharkar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kanda Sangthongpitag</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kanda Sangthongpitag</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kanda++Sangthongpitag">Kanda Sangthongpitag</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joma Joy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joma Joy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joma++Joy">Joma Joy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nithya Baburajendran</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nithya Baburajendran</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nithya++Baburajendran">Nithya Baburajendran</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna Elisabet Jansson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna Elisabet Jansson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna+Elisabet++Jansson">Anna Elisabet Jansson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kassoum Nacro</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kassoum Nacro</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kassoum++Nacro">Kassoum Nacro</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey Hill</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey Hill</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Hill">Jeffrey Hill</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas H. Keller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas H. Keller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+H.++Keller">Thomas H. Keller</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Alvin W. Hung</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alvin W. Hung</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Experimental Drug Development Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#6c1b0419020b2c0908080f420d411f180d1e42090819421f0b"><span class="__cf_email__" data-cfemail="7b0c130e151c3b1e1f1f18551a56080f1a09551e1f0e55081c">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alvin+W.++Hung">Alvin W. Hung</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9985-6794" title="Orcid link">http://orcid.org/0000-0002-9985-6794</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01582&amp;href=/doi/10.1021%2Facs.jmedchem.9b01582" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 621–637</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 7, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 September 2019</li><li><span class="item_label"><b>Published</b> online</span>7 January 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 January 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01582" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01582</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D621%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJacek%2BKwiatkowski%252C%2BBoping%2BLiu%252C%2BShermaine%2BPang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D2%26contentID%3Dacs.jmedchem.9b01582%26title%3DStepwise%2BEvolution%2Bof%2BFragment%2BHits%2Bagainst%2BMAPK%2BInteracting%2BKinases%2B1%2Band%2B2%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D637%26publicationDate%3DJanuary%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01582"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1689</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01582" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jacek&quot;,&quot;last_name&quot;:&quot;Kwiatkowski&quot;},{&quot;first_name&quot;:&quot;Boping&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Shermaine&quot;,&quot;last_name&quot;:&quot;Pang&quot;},{&quot;first_name&quot;:&quot;Nur&quot;,&quot;last_name&quot;:&quot;Huda Binte Ahmad&quot;},{&quot;first_name&quot;:&quot;Gang&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Anders&quot;,&quot;last_name&quot;:&quot;Poulsen&quot;},{&quot;first_name&quot;:&quot;Haiyan&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Rui Poh&quot;},{&quot;first_name&quot;:&quot;Doris&quot;,&quot;last_name&quot;:&quot;Hui Ying Tee&quot;},{&quot;first_name&quot;:&quot;Esther&quot;,&quot;last_name&quot;:&quot;Ong&quot;},{&quot;first_name&quot;:&quot;Priya&quot;,&quot;last_name&quot;:&quot;Retna&quot;},{&quot;first_name&quot;:&quot;Nurul&quot;,&quot;last_name&quot;:&quot;Dinie&quot;},{&quot;first_name&quot;:&quot;Perlyn&quot;,&quot;last_name&quot;:&quot;Kwek&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Liang Kuan Wee&quot;},{&quot;first_name&quot;:&quot;Vithya&quot;,&quot;last_name&quot;:&quot;Manoharan&quot;},{&quot;first_name&quot;:&quot;Choon&quot;,&quot;last_name&quot;:&quot;Bing Low&quot;},{&quot;first_name&quot;:&quot;Peck&quot;,&quot;last_name&quot;:&quot;Gee Seah&quot;},{&quot;first_name&quot;:&quot;Vishal&quot;,&quot;last_name&quot;:&quot;Pendharkar&quot;},{&quot;first_name&quot;:&quot;Kanda&quot;,&quot;last_name&quot;:&quot;Sangthongpitag&quot;},{&quot;first_name&quot;:&quot;Joma&quot;,&quot;last_name&quot;:&quot;Joy&quot;},{&quot;first_name&quot;:&quot;Nithya&quot;,&quot;last_name&quot;:&quot;Baburajendran&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Elisabet Jansson&quot;},{&quot;first_name&quot;:&quot;Kassoum&quot;,&quot;last_name&quot;:&quot;Nacro&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Hill&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;H. Keller&quot;},{&quot;first_name&quot;:&quot;Alvin&quot;,&quot;last_name&quot;:&quot;W. Hung&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;621-637&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01582&quot;},&quot;abstract&quot;:&quot;Dysregulation of translation initiation factor 4E (eIF4E) activity occurs in various cancers. Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) play a fundamental role in activation of eIF4E. Structure–activity relationship-driven expansion of a fragment hit led to discovery of dual MNK1 and MNK2 inhibitors based on a novel pyridine-benzamide scaffold. The compounds possess promising in vitro and in vivo pharmacokinetic profiles and show potent on target inhibition of eIF4E phosphorylation in cells.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01582&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01582" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01582&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01582" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01582&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01582" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01582&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01582&amp;href=/doi/10.1021/acs.jmedchem.9b01582" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01582" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01582" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01582%26sid%3Dliteratum%253Aachs%26pmid%3D31910010%26genre%3Darticle%26aulast%3DKwiatkowski%26date%3D2020%26atitle%3DStepwise%2BEvolution%2Bof%2BFragment%2BHits%2Bagainst%2BMAPK%2BInteracting%2BKinases%2B1%2Band%2B2%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D2%26spage%3D621%26epage%3D637%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290703" title="Pyridines">Pyridines</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291774" title="Nuclear magnetic resonance spectroscopy">Nuclear magnetic resonance spectroscopy</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/2" title="Go to Volume 63, Issue 2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/jmcmar.2020.63.issue-2/20200123/jmcmar.2020.63.issue-2.largecover.jpg" alt="Go to Volume 63, Issue 2"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0005.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Dysregulation of translation initiation factor 4E (eIF4E) activity occurs in various cancers. Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) play a fundamental role in activation of eIF4E. Structure–activity relationship-driven expansion of a fragment hit led to discovery of dual MNK1 and MNK2 inhibitors based on a novel pyridine-benzamide scaffold. The compounds possess promising in vitro and in vivo pharmacokinetic profiles and show potent on target inhibition of eIF4E phosphorylation in cells.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35544" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35544" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1 and MNK2) form an important class of enzymes activated by extracellular signal-regulated kinase (ERK) or p38 mitogen-activated protein (MAP) kinases. MNK1 and MNK2 are involved in regulation of transcription through phosphorylation of the translation initiation factor 4E (eIF4E), which in turn is important for ribosome assembly and protein synthesis.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Dysregulation of the MNK-eIF4E axis has been linked to the occurrence of various cancers.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref12">(2−12)</a> On the other hand, MNKs are redundant in growth of normal cells,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> and consequently inhibition appears not to elicit toxic responses.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1−5)</a> The redundancy of MNKs together with their role in priming eIF4E suggests that while modulation of MNKs alone might not elicit therapeutic response, MNK inhibitors may be useful to amplify effects of inhibition of other pathways, without increasing the risk of toxic response.</div><div class="NLM_p">In recent years, there has been considerable interest in developing selective MNK inhibitors for various cancer therapies (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22">(13−22)</a> Medicinal chemistry efforts in our institute have also led to the clinical candidate <b>ETC-206</b>.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Interestingly, regulation of MNK-dependent pathways in viruses<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> is investigated in oncolytic immunotherapy as well.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0018.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selected published MNK inhibitors. <b>eFT508</b><a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and <b>ETC-206</b><a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> are clinical candidates targeting MNK. Merestinib<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and <b>AST-487</b><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> target MNK nonselectively and show efficacy in animal models relevant to MNK-dependent disease progression. Compounds <b>53e</b> and <b>54e</b><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> are derivatives of <b>AST-487</b>, and both compounds show in vivo efficacy and suppression of leukemic stem cell renewal. Compound <b>8e</b> is a submicromolar MNK inhibitor suppressing acute myelocytic leukemia (MV4-11) cell growth and reducing expression of antiapoptotic Mcl-2 protein; in addition to MNK, CDK2 and CDK9 inhibition likely contributes to cellular activity.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Compound <b>9e</b> exhibits potent MNK inhibition in biochemical and cellular assays; however, no specific disease-relevant biological data has been revealed.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Taking into consideration challenges in suppression of eIF4E phosphorylation in cells via MNK inhibition, we decided to target both MNK isoforms. Herein, we describe fragment-based discovery of a novel class of dual MNK1 and MNK2 inhibitors affecting potent inhibition of eIF4E phosphorylation in cells.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72572" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72572" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In search of new starting points for the development of dual MNK1 and MNK2 inhibitors, a library of 1700 fragments<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30−32)</a> was screened against both isoenzymes using a Caliper-based biochemical assay.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Among the hits, 11 molecules were found to be inhibiting both enzymes with good potencies and high ligand efficiencies (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, 0.24 ≤ LE ≤ 0.72). Interestingly, most of the detected hits were found to be more active against MNK2 than MNK1. The screening results demonstrated that even at a fragment level, the compounds were able to discriminate between the ligandability of both isoenzymes. Particularly interesting were the structurally related fragment hits <b>4</b>–<b>6</b>. All three molecules contained a metasubstituted pyridine linked to an aryl with a hydrogen-bonding-capable group (COOH, NH<sub>2</sub>, OH). To assess the potential of the hits for further development, two analogs of compounds <b>4</b> and <b>6</b> were designed and synthesized (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The initial optimization by replacement of the thiophene ring in fragment <b>4</b> with a phenyl group led to compound <b>12</b>. Further conversion of the carboxylic acid moiety in compound <b>12</b> to an uncharged amide group afforded compound <b>13</b>, which, being an efficient molecule with no obvious liabilities, became the basis for subsequent fragment optimizations.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0019.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Assessment of fragment hits <b>4</b> and <b>6</b>. Minor modifications around the scaffold quickly revealed opportunities and limitations of the vectors for fragment growing. Compound <b>13</b> was chosen as the basis for subsequent fragment optimization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Fragment Screening against MNK1 and MNK2<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0009.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The top <b>11</b> hits inhibiting both MNK1 and MNK2 were identified in a high-concentration biochemical screen and sorted according to ligand efficiency.</p></div></div><div></div></div><div class="NLM_p">Our next move was to elucidate the importance of the primary amide. It was quickly established that unsubstituted amide was favored, with both modifications to <i>N</i>-methyl- and piperazineamide leading to a significant reduction in IC<sub>50</sub> (<b>13a–b</b>, IC<sub>50</sub> = 171–292 μM). Importantly, the generation of compounds <b>13a</b> and <b>13b</b> rapidly indicated the limited fragment growing opportunities out of the amide nitrogen. Unexpectedly, the following attempt to enhance the hypothesized pyridine hinge binder by addition of H-bond donor (<b>13c</b>–<b>13e</b>) was also unsuccessful. Between the three compounds, only <b>13e</b> displayed marginal improvement of potency for MNK2 alone.</div><div class="NLM_p">At this point, fragment <b>13</b> was docked into the X-ray crystal structure of MNK2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HW7">2HW7</a>) to guide further potency optimization (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>; details of generating the model are described in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_003.pdf" class="ext-link">Supporting Information</a>). Assuming, that pyridine forms H-bond with Met-162 NH (protein hinge residue), there are two possible binding orientations of 13: <b>I</b> and <b>II</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a,b). In both conformations, pyridine and benzamide phenyl ring partially fill the yellow ellipses, indicating hydrophobic regions of the binding site. Intuitively, pose <b>I</b> could appear to be preferred as the phenyl ring is buried in the hydrophobic region to a larger extent, in addition to forming edge-to-face interaction with the gatekeeper (c-Phe-159). The more substantial difference between the two binding conformations is the orientation of the amide group. In pose <b>II</b>, the amide is pointing out of the binding site; hence, growing out of the amide nitrogen should be well tolerated. On the contrary, substitution of the amide docked in binding conformation <b>I</b> would result in clashes with protein residues. As indicated by preliminary structure–activity relationship (SAR), the primary amide is preferred with methylation or internalization affecting a dramatic drop in activity (<b>13a</b>, <b>13b</b>). Taken together, binding conformation <b>I</b> became our working model, supporting evolution of fragment <b>13</b> in the absence of an X-ray crystal structure.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0010.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Docking of fragment 13 into MNK2; two possible orientations of <b>13</b> in the binding site are shown on (a) (<b>I</b>) and (b) (<b>II</b>). The yellow spheres indicate hydrophobic regions in the binding site; (c) the main interactions between <b>13</b> and MNK2 in binding mode <b>I</b> are the hydrogen bond with Met-162, the water-mediated hydrogen bond with Asp-226 and Glu-129 (only in binding conformation <b>I</b> and providing possibility of displacing the water), π–π interaction with Phe-159, and hydrophobic interactions with Cys-225, Leu-90, Leu-212, and Val-98; (d) grid is superimposed on the binding site showing areas favorable for binding ligand atoms with the following properties: hydrophobic (yellow), acceptor or negatively charged (red), and donor or positively charged (blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Drawing from the docking hypothesis for fragment <b>13</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>c, d), substitutions of the benzene ring of the amide were first probed (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). While not improving the potency, hydroxyl in the ortho position to the amide was well tolerated (compound <b>14</b>, MNK2/MNK1 IC<sub>50</sub> = 3.0/4.3 μM) in contrast to the more lipophilic chlorine (<b>15</b>) and methyl (<b>16</b>) substituents, both of which led to a slight reduction in inhibitory activity compared to the unsubstituted benzamide. It is hypothesized that this disparity could be due to the formation of an intramolecular hydrogen bond between the hydroxy- group and the amide, lending help to a more favorable amide conformation. On the other hand, more bulky substituents, especially devoid of hydrogen-bonding capabilities, might force the amide into a less favorable conformation. With the hydroxy- group being well tolerated at C-2, the next step was to probe for space by modifying the phenol to phenoxy-. Gratifyingly, the methoxy- group at C–2 brought 2–3-fold improvement in potency (<b>17</b>, MNK2/MNK1 IC<sub>50</sub> = 1.0/2.8 μM). While not impressive, the gain translated into a high LE and more importantly indicated expansion through the oxygen as a promising growing strategy. Prior to further expansion, the methoxy- group was shifted to C-3 to establish the most optimum substitution pattern. As demonstrated with compound <b>18</b>, substitution at C-3 was suboptimal, possibly due to modification of the dihedral angle between pyridine and benzamide. Consequently, further expansion through the oxygen was reinitiated at C-2. The substitutions with larger ethyl (<b>19</b>) and <i>iso</i>-propyl (<b>21</b>) groups brought a gradual improvement in IC<sub>50</sub> (MNK2/MNK1 IC<sub>50</sub> = 0.34/0.88 μM for <b>21</b>). However, substituents such as cyclobutyl (<b>22</b>) and the larger cyclohexyl (<b>23</b>) did not follow the trend of potency improvement on expansion. Interestingly, replacement of the ethoxy- group with ethylamino- affected a significant differentiation in activity against both isoforms (10-fold for compound <b>20</b>). Assuming that this part of the molecule might be exposed to the solvent, substitutions with polar groups were trialed at the C-2 position instead. The ethylamino- substituent (compound <b>24</b>) brought a slight 2-fold improvement in inhibitory activity as compared to the ethoxy-substituted amide <b>19</b>. The result warranted the synthesis of rigidified analogues <b>25</b> and <b>26</b> in hope of further improving the inhibitory activity; however, a slight loss in potency was observed instead. In summary, optimization of the benzamide part of the fragment led to a 10-fold improvement in potency by substitution of the C-2 position of the amide with a small <i>iso</i>-propoxy- group (<b>21</b>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Modifications of the Amide</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0013.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0021.gif" alt="" id="fx3" /></img><div></div></div><div class="NLM_p">The ADME properties of compound <b>21</b> were assessed at an early point in the fragment-to-hit-to-lead stage to identify potential liabilities of the core scaffold. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, the pyridine-benzamide <b>21</b> was stable in an in vitro mouse liver microsomal assay. Furthermore, the compound was highly soluble with good permeability in the CACO-2 assay, indicative of potentially good absorption. Pleasingly, despite the presence of monosubstituted pyridine, no CYP inhibition was detected.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Pharmacokinetic Properties of Benzamide <b>21</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0001.gif" alt="" id="fx4" /></img><div></div></div><div class="NLM_p">Prior to embarking on further potency optimization, we decided to further investigate the in vivo pharmacokinetic (PK) profile of compound <b>21</b>. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, at a low dose of 5 mg/kg, compound <b>21</b> reached the maximum concentration of 615 ng/mL in 10 min. While bioavailability was decent at 61%, the AUC (0–<i>t</i><sub>(last)</sub>) was relatively low, reaching 488 ng·h/mL until the last recorded time point (8 h). It is worth noting that compound <b>21</b> also showed high volume of distribution, suggesting high tissue distribution.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0016.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vivo pharmacokinetic properties of benzamide <b>21</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further enhance the activity of benzamide-pyridine inhibitors, we next probed expansion from the pyridine. This time, substituents were systematically introduced onto the pyridine group of <b>13</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). As shown, substitutions at C-5 with hydrophilic or hydrophobic aliphatic substituents resulted in only minor fluctuations of IC<sub>50</sub>s by up to 4-fold (compounds <b>27</b>–<b>29</b> and <b>32</b>). On the other hand, modifications at C-2 and C-6 of the pyridine were clearly detrimental (<b>30</b> and <b>31</b>, MNK2/MNK1 IC<sub>50</sub> = 108/61 and 43/170 μM, respectively), reinforcing our docking model and the importance of the predicted H-bond interaction of the pyridine nitrogen. Subsequent substitutions on the C-5 of pyridine revealed that aromatic rings are preferred (compounds <b>33</b>–<b>36</b>) and could increase inhibitory activity by ∼10-fold (compounds <b>35</b>–<b>36</b>, MNK2/MNK1 IC<sub>50</sub> = 0.31/1.1 and 0.35/0.80 μM, respectively). Pleasingly, this observation is again in agreement with the pose <b>I</b> model, as the π electrons of (hetero)aryl could act as a weak hydrogen-bond acceptor and interact with the Ser166 NH group pointing toward the space occupied by the C-5 substituent. Unfortunately, the size of the groups had a detrimental effect on the overall efficiency of the molecule as indicated by the decreasing ligand efficiency (MNK2/MNK1 LE = 0.42/0.39 and 0.42/0.40 for <b>35</b> and <b>36</b>, respectively), compared to the unsubstituted amide <b>13</b> (MNK2/MNK1 LE = 0.50/0.46).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Expansion from the Hinge-binding Pyridine</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0014.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0002.gif" alt="" id="fx6" /></img><div></div></div><div class="NLM_p">With preliminary SAR developed around the pyridine and amide, the next step was to modify the molecule at both sites simultaneously, in hope for a synergistic effect of substituents on potency. Considering that substitutions of the pyridine resulted in a greater variability of IC<sub>50</sub>s, compound <b>21</b> with the <i>iso</i>-propoxy-substituted amide was taken as a basis for expansion from C-5 of pyridine. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, the combination of amide and pyridine both substituted with the preferred groups (<i>iso</i>-propoxy- and <i>N</i>-methylpyrazolo-) did not lead to the anticipated additive gain in inhibitory activity. Instead, compound <b>37</b> was only 2-fold more potent than either one of the merged molecules alone (MNK2/MNK1 IC<sub>50</sub> = 0.16/0.4 μM). Correspondingly, the overall ligand efficiency of <b>37</b> dropped as well (MNK2/MNK1 LE = 0.37/0.35) and warranted a broader reassessment of substitution of the pyridine. This data illustrates the potential difficulty in maintaining the relevant interactions on one end of the molecule while exploring the other.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Substitutions of the Pyridine at the C-5 Position</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0003.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0004.gif" alt="" id="fx8" /></img><div></div></div><div class="NLM_p">The subsequently examined analogues containing aliphatic groups at C-5 of pyridine, pyrrolidine (<b>39</b>), morpholine (<b>40</b>), or <i>N</i>-methylamide (<b>41</b>), were 4–6-fold less active than <b>37</b>, while internalization of the amide through fusion with the neighboring substituent did not improve the inhibitory activity significantly (data shown in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_003.pdf" class="ext-link">SI</a>)). The only alternative offering improved IC<sub>50</sub> was tetrazole (<b>38</b>, MNK2/MNK1 IC<sub>50</sub> = 0.08/0.31 μM). However, the lack of avenues for further elaboration of tetrazole motivated the decision to reinvestigate the pyrazole substituent. Pleasingly, the increase in the size of the substituent on the pyrazole nitrogen brought an initial 4-fold improvement in potency against MNK2 (compound <b>42</b>, IC<sub>50</sub> = 0.042 μM), but the effect reached a plateau quickly, and further increasing the size of the substituent proved to be counterproductive (compounds <b>43</b>–<b>44</b>, MNK2/MNK1 IC<sub>50</sub> = 0.089/0.20 and 0.044/0.12 μM, respectively). Next, the alternative substitutions on pyrazole at C-3 were examined. While cyclopropyl- (<b>45</b>) maintained the potency at a similar level as N-substituted predecessors, a smaller methyl was found to be far superior at increasing the MNK2 inhibitory activity and improving the ligand efficiency (<b>46</b>, MNK2 IC<sub>50</sub> = 16 nM, LE = 0.43). Lastly, bis-methylation at C-3 and C-5 of the pyrazole (<b>47</b>) was also tolerated with good potency against both MNK isoforms (MNK2/MNK1 IC<sub>50</sub> = 14/33 nM). In summary, the hypothesized additive 100-fold gain in inhibitory activity by substituting the core scaffold <b>13</b> on both ends simultaneously was eventually achieved (compare <b>13</b> and <b>46</b> with <b>21</b> and <b>37</b>). However, as opposed to directly blending compounds <b>21</b> and <b>37</b> substituted on each end alone, a minor adjustment was needed. Namely, repositioning of the methyl group from pyrazole nitrogen to the neighboring carbon (C-5 of pyrazole) was required to enable the synergistic effect of expansion at both ends of the core.</div><div class="NLM_p">With potent MNK1 and MNK2 inhibitors in hand, the next step was to investigate the relevance of MNK inhibition in a cellular environment. We and others previously established that inhibition of MNK isoenzymes alone has no antiproliferative effect on most cancer cell lines. However, synergistic effects of MNK inhibition were observed across a broad range of cancers.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8 ref9 ref10 ref11">(5−11)</a> For example, reduction of eIF4E phosphorylation, which is performed exclusively by MNKs, disrupts leukemic stem cell renewal, a mechanism behind the resistance and progression of chronic myeloid leukemia.<a onclick="showRef(event, 'ref16 ref23'); return false;" href="javascript:void(0);" class="ref ref16 ref23">(16,23)</a> Accordingly, cellular assays were performed to measure the inhibition of phosphorylation of eIF4E in Hela cells (overexpressing eIF4E) using a previously developed functional assay.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> With the exception of compound <b>42</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), the degree of inhibitory activity in the cell corresponds to biochemical potency and reaches 160 nM for the most potent compound <b>47</b>. Notably, compound <b>21</b> shows the least fold shift between MNK inhibition and eIF4E phosphorylation, suggesting good cell penetration of the smaller bicyclic compound.</div><div class="NLM_p">Throughout the project, pharmacokinetic properties of selected compounds were monitored methodically to develop an understanding of the structure–property relationship within the series. Pharmacokinetic profiles of the four inhibitors were assessed in a series of in vitro ADME assays measuring thermodynamic solubility, permeability in the CACO-2 assay, metabolic stability when exposed to mouse and human liver microsomes, and inhibition of CYP enzymes 2D6 and 3A4 (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Characterization of MNK1 and MNK2 Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0015.gif" alt="" id="fx9" /></img><div></div></div><div class="NLM_p">Expectedly, substitutions of pyridine with hydrophobic groups resulted in a decrease in solubility, especially noticeable for compounds <b>46</b>, <b>47</b>, and <b>48</b> (sol. 11, 10, and 7.3 μg/mL, respectively) as compared to the unsubstituted compound <b>21</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, 45 μg/mL). However, the unfavorable trend could be partially offset by introduction of oxetane (<b>43</b>, sol. = 28 μg/mL). Additionally, the favorable profile of the early compound <b>21</b> with regard to the lack of inhibition of CYP enzymes and stability in the human liver microsomal assay was generally conserved throughout the series. On the other hand, the introduction of pyrazole correlated with increased vulnerability to mouse liver microsomes, with the 5-methylpyrazole-containing compound <b>46</b> cleared rapidly (CL = 251 μL·min<sup>–1</sup>·mg<sup>–1</sup>; compare with CL = 9.4 μL·min<sup>–1</sup>·mg<sup>–1</sup> for <b>21</b>). Fortunately, bis-methylation of pyrazole on C-3 and C-5 or C-5 and NH, as well as introduction of the oxetane group, was able to improve the mouse liver microsomal clearance of the molecule (CL = 62, 25.1, and 3.1 μL·min<sup>–1</sup>·mg<sup>–1</sup>, respectively). Compounds <b>43</b> and <b>47</b> were also tested for possible interference with the hERG channel using the manual patch clamp method and were both found inactive. To further gain insights into the selectivity of <b>43</b> across the kinome, measurements of point inhibition in a panel of 104 kinases at 1 μM were performed (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Compound <b>43</b> was found to inhibit only three other kinases significantly (>90%, ABL-1, JAK-3, and DRAK-1). Further improvement in selectivity was possible through an increase of the steric bulk on the phenolic hydroxyl, as illustrated by compound <b>49</b> containing cyclohexylmethylene and inhibiting only one kinase with over 95% inhibition (PHKG-2).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Selectivity of MNK1 and 2 inhibitors <b>43</b> and <b>49</b> in a panel of 104 kinases. Increasing the steric bulk on the phenolic oxygen resulted in a marked improvement in selectivity. KINOMEscan was performed by DiscoverX. The results are visualized using TREEspot. Kinases are sorted according to the phylogenetic tree, and the degree of inhibition is proportional to the size of the red sphere. S scores are as follows: S(35) = 0.102, S(10) = 0.031 for <b>43</b> and S(35) = 0.031, S(10) = 0.01 for <b>49</b>. IC<sub>50</sub>s for compound <b>49</b> were as follows: MNK2 = 0.025 μM, MNK1 = 0.19 μM, and eIF4E phosphorylation = 1.3 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>43</b>, having a balanced in vitro ADME profile, decent activity, and selectivity, was further evaluated in vivo (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The favorable in vitro ADME translated into good in vivo PK in mice. After intravenous administration at 1 mg/kg, the plasma concentration of <b>43</b> appeared to decline with a mean terminal elimination half-life of 2.2 h. The systemic plasma clearance of <b>43</b> was estimated at 1.7 L·h<sup>–1</sup>·kg<sup>–1</sup>. Oral administration at 5 mg/kg resulted in the mean maximal plasma concentration (<i>C</i><sub>max</sub>) reaching 658 ng/mL at 0.5 h after dosing. The mean exposure as calculated by AUC (0 → inf) was 2363 ng·h·mL<sup>–1</sup>, resulting in an absolute oral bioavailability of 73%. In comparison to compound <b>21</b>, both the exposure and clearance (PO) were improved nearly 5-fold, with similar <i>C</i><sub>max</sub> and bioavailability.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vivo PK of compound 43 at 5 mg/kg (PO) and 1 mg/kg (IV). The compound shows good PO <i>C</i><sub>max</sub> and excellent bioavailability of 73%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Throughout the fragment optimization campaign, crystallization of MNK2 and MNK1 proteins with evolving compounds was continuously attempted in hope of obtaining further insight into the binding mode of the molecules and aid in compound design. Eventually, the efforts were fruitful, and intermediate compound <b>36</b> was successfully crystallized in complex with MNK2 protein (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). The analysis of the binding conformation confirmed pyridine nitrogen’s engagement in the hydrogen-bonding interaction with the MNK2 hinge region residue Met-162. The phenyl ring of the benzamide was shown to involve Phe-159 and Phe-227 into edge-to-face π–π interactions, in addition to lipophilic interactions with Val-98, Leu-143, and Cys-225. Furthermore, the pyridine ring was found to form a number of hydrophobic contacts with Leu-212 and Ala-111, while the methylpyrazole with Leu-90 and Gly-165.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0017.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. X-ray analysis of MNK2 in complex with compound 36; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JLR">6JLR</a>. (a) Key interactions observed were the hydrogen bond of the central pyridine with the hinge-binding residue Met-162 and edge-to-face π–π interaction of the benzamide moiety with Phe-159 and Phe-227; (b) view of the binding site of MNK2 in complex with <b>36</b> with the surface applied; and (c) overlay of the X-ray crystal structure of <b>36</b> and the simulated binding pose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Importantly, the binding pose derived from the X-ray analysis is in a very good agreement with the SAR and postulated docking conformation. Notably, the methylpyrazole realized the envisioned hydrophobic contacts with Leu-90 and Gly-165, which likely contributed to a 10-fold gain in potency. The main difference between the observed and computed binding modes was the lack of a water-mediated H-bond of the benzamide with Asp-226 and Lys-113. Instead, Lys-113 was shown to form a salt bridge with Glu-129, located further away from the ligand.</div><div class="NLM_p">Mindful of the challenges associated with fragment optimization in the absence of structural information, we retrospectively analyzed project progression visualized as compounds’ potency plotted against the time taken for optimization (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). As evident from the plots, we observed a steady improvement in the inhibitory activity of the compounds for the first 32 weeks, achieving submicromolar inhibitors in week 15. Also obvious in both plots was a downward trend in potency from week 33 onward, which corresponds to the start of a more aggressive optimization stage focused on improving exposure and metabolic stability of the inhibitors. It is noteworthy that because the program was directed toward dual MNK1 and MNK2 inhibition, the graphs for both MNK isoforms appear to follow similar trends in terms of the potency progression (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a, b). Lastly, it is also worth mentioning that the starting fragment hits were potent (single-/double-digit micromolar), and this enabled the fragment optimization process to be relatively quick.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Fragment optimization timeline. Analysis of the progression of the fragment growing campaign against MNK1 and MNK2. With respect to the 3-phenylpyridine scaffold, ∼200 compounds were tested against MNK1 and MNK2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Synthesis</h3><div class="NLM_p">Benzamides <b>13</b> and <b>15–18</b> were synthesized through Suzuki cross-coupling of pyridine-3-boronic acid pinacol ester with the appropriate aryl bromide (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0011.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Pyridine-Benzamides (<b>13</b>, <b>15</b>–<b>18</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) pyridine-3-boronic acid pinacol ester (1.1 equiv), ArBr (1 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (5 mol %), K<sub>3</sub>PO<sub>4</sub> (3 equiv), dioxane/water (4/1), 100 °C, 0.5–2 h.</p></p></figure><div class="NLM_p">Compounds <b>27</b>–<b>32</b> exploring substitutions on pyridine were synthesized through Suzuki cross-coupling of benzamide-4-boronic acid with the substituted pyridine bromide (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0022.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of Compounds <b>27</b>–<b>32</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) benzamide-4-boronic acid (1.1 equiv), pyridine bromide (1 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (5 mol %), K<sub>3</sub>PO<sub>4</sub> (3 equiv), dioxane/water (4/1), 100 °C, 0.5–2 h.</p></p></figure><div class="NLM_p">Exploration of alcoxy- substituents was carried out through alkylation of <b>14</b> with different alkyl bromides (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). <b>14</b> was synthesized from commercially available 2-hydroxy-4-bromobenzamide through Miyaura coupling with bis-pinacolato-diboron. The subsequent Suzuki coupling of intermediate <b>II</b> with 3-bromopyridine completed preparation of <b>14</b>, while coupling with 3-bromo-5-chloropyridine led to compound <b>32</b> (alternative route to the one described above) and intermediate <b>IIIa</b>. Compound <b>32</b> led to compounds <b>33</b>–<b>36</b> through Suzuki coupling with the appropriate arylboronic acid (or pinacol ester). <b>IIIa</b> was reacted with <i>N</i>-Me-4-pyrazolboronic acid, leading to intermediate <b>IV</b>, which on alkylation with cyclohexylmethyl bromide gave compound <b>49</b>. Compound <b>50</b> was obtained in an analogical sequence starting from commercially available (1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)boronic acid coupled sequentially with 3-bromo-5-chloropyridine and <i>N</i>-methylpyrazol-4-boronic acid.</div><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Syntheses of Compounds <b>14</b>, <b>19</b>–<b>26</b>, <b>32</b>–<b>36</b>, and <b>49</b>–<b>50</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (BPin)<sub>2</sub> (1.2 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, AcOK (1.5 equiv), dioxane, 90 °C, 2 h; (b) 3-bromopyridine (1.1 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane/water (4/1), 100 °C, 0.5–2 h; (c) <b>i</b>: R-Br (3 equiv), K<sub>2</sub>CO<sub>3</sub> (3 equiv), dimethylformamide (DMF), 90 °C, 2–4 h; <b>ii</b> for <b>28</b> and <b>29</b> deprotection of the amino functionality was necessary: 10% trifluoroacetic acid (TFA) in CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h; (d) ArB(OH)<sub>2</sub> (1.2 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane/water (4/1), 100 °C, 0.5–2 h; (e) EtBr (4 equiv), NaH (4 equiv), DMF, 0–90 °C, 2 h.</p></p></figure><div class="NLM_p">Preparation of compounds <b>37</b>–<b>48</b> follows the synthetic route shown on <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Alkylation of commercially available 2-hydroxy-4-bromobenzamide was performed as the first step to simplify subsequent purifications (to streamline exploration of the alkoxy- substituent, alkylation was performed as the last step). Subsequent conversion into boronic ester furnished the key intermediate <b>V</b>. Finally, sequential cross-couplings of <b>V</b> with 3-bromo-5-chloropyridine followed by coupling with appropriate arylboronic acids/pinacol esters led to compounds <b>37</b>, <b>42</b>–<b>48</b>. Tetrazole was generated from 3-bromo-5-cyanopyridine, and the resulting intermediate <b>VIII</b> was cross-coupled with boronate <b>V</b>, yielding compound <b>38</b>.</div><figure id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0020.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of Compounds <b>37</b>–<b>48</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>i</i>-PrBr (3 equiv), K<sub>2</sub>CO<sub>3</sub> (3 equiv), DMF, 90 °C, 2–4 h; (b) (BPin)<sub>2</sub> (1.2 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, AcOK, dioxane, 90 °C, 2 h; (c) 3-bromo-5-chloropyridine (0.9 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane/water (4/1), 100 °C, 0.5–1 h; (d) ArB(OH)<sub>2</sub> (1.2 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane/water (4/1), 100 °C, 0.5–2 h; (e) ArBr (1.1 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane/water (4/1), 100 °C, 0.5–2 h; (f) sodium azide (2 equiv), ammonium chloride (2 equiv), DMF, 100 °C, 4 h; (g) <b>V</b> (0.9 equiv), <b>VIII</b> (1 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub> (3 equiv), dioxane/water (4/1), 100 °C, 2 h.</p></p></figure><div class="NLM_p last">Note: alkylation, all Suzuki, and Miyaura couplings were performed analogical to general procedures described for compounds <b>13</b>, <b>19</b>, and intermediate <b>IIa</b>, respectively.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72437" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72437" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In search of good-quality starting points toward development of dual MNK1 and MNK2 inhibitors, fragment screening was performed and afforded eleven ligand efficient hits against both isoenzymes. In the absence of X-ray crystallographic information,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> the hit-to-lead campaign relied on SAR and molecular modeling to optimize related hits based on the recurring pyridine-(hetero)arylamide core. The pyridine-phenylamide-based scaffold, exemplified by compound <b>21</b>, had balanced pharmacokinetic properties, which were assessed in the early fragment-to-hit-to-lead stage to identify intrinsic scaffold liabilities and mitigate the risk of failure in later stages of development. Further potency optimization through fragment expansion was performed mindful of the potential impact on PK and eventually led to compound <b>43</b> with 40-fold improved potency and 5-fold higher exposure in mice, compared to an early compound <b>21</b>.</div><div class="NLM_p last">An emphasis on structure-guided fragment expansion remains important in fragment-based drug discovery. This does not however exclude the possibility of generating potent, optimized fragments in the absence of fragment-target structural information. As shown in this study, even for a well-defined kinase active site, the docking models can be ambiguous, and it is crucial for initial fragment optimization processes to be guided primarily by the SAR data.<a onclick="showRef(event, 'ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36 ref37">(34−37)</a> Furthermore, as shown in our studies,<a onclick="showRef(event, 'ref34 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref34 ref36 ref37">(34,36,37)</a> the initiation of chemistry has often led to the generation of more potent, intermediate compounds that subsequently lend help toward our in-house crystallography efforts.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36462" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36462" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Generation of the computational model, details on the X-ray crystal structure of the MNK2 compound <b>36</b> complex, and the protein production protocol are provided in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_003.pdf" class="ext-link">SI</a>). Biochemical and cellular assay procedures can be found in our previous report.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> General Information</h4><div class="NLM_p last">All solvents and reagents were purchased from commercial sources and used without further purification. <sup>1</sup>H NMR spectra were obtained using a Bruker Ultrashield 400 PLUS/R system, operating at 400 MHz. <sup>13</sup>C NMR spectra were acquired on Bruker Cryoprobe 400 MHz. The compounds’ purities were ≥95% determined according to method A or B. Method A: VARIAN ProStar HPLC instrument using acetonitrile/water (with 0.1% formic acid) as the eluent, Phenomenex, Luna 5u, C18A (2) 100A, 150 mm × 4.60 mm reverse-phase column and mobile phase A: 0.1% formic acid in water and mobile phase B: 0.1% formic acid in acetonitrile; run time: 10.5 min; T/%B: 0.0/3, 3.0/3, 7.50/50, 8.0/95, 10/95, 10.5/3; flow rate: 2.0 mL/min; wavelength: 254 nm. Method B: Agilent UPLC using acetonitrile/water (with 0.1% formic acid) as the eluent; column: Phenomenex, Luna 5u, C18A (2) 100A, 50 mm × 4.60 mm, reverse-phase column; mobile phase A: 0.1% formic acid in water; mobile phase B: 0.1% formic acid in acetonitrile; run time: 2.0 min; T/%B: 0.0/5, 1.8/95, 2.0/5; flow rate: 2.0 mL/min; wavelength: 254 nm. High-resolution mass spectrometry (HRMS) spectra were acquired on a Thermo Scientific Orbitrap Fusion mass spectrometer coupled with Advion TriVersa NanoMate (ESI); mass spectrometer setting: detector Orbitrap (high resolution), resolution 60 000, mass accuracy <3 ppm.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Synthesis</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Representative Procedure for Suzuki Coupling: Preparation of Compound <b>13</b></h4><div class="NLM_p">To the solution of 4-bromobenzamide (0.2 mmol, 40 mg) in a mixture of dioxane and water (4/1, total 3 mL), pyridine-3-boronic acid pinacol ester (0.22 mmol, 45 mg) was added, followed by potassium phosphate (0.6 mmol, 127 mg). The reaction mixture was degassed by bubbling nitrogen through over 5 min. Subsequently, palladium catalyst Pd[DPPF]Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (5 mol %, 8 mg) was added, and the reaction mixture was heated to 110 °C under a nitrogen atmosphere. The reaction was complete in 30 min (liquid chromatography (LC)-mass analysis).</div><div class="NLM_p">Workup: The reaction mixture was filtered through a paper filter to a separating funnel, diluted with ethyl acetate, and washed with water. The aqueous phase was back-extracted with ethyl acetate once. Combined ethyl acetate layers were dried over sodium sulfate and evaporated. The crude product was purified by flash silica gel chromatography eluting with a gradient of ethyl acetate/hexane to afford 4-(pyridin-3-yl)benzamide (<b>13</b>) as a light-brown solid, 31 mg.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.88 (d, <i>J</i> = 2.3 Hz, 1H), 8.65 (dd, <i>J</i> = 4.8, 1.5 Hz, 1H), 7.97–7.87 (m, 3H), 7.68 (dt, <i>J</i> = 8.4, 1.8 Hz, 2H), 7.40 (dd, <i>J</i> = 7.9, 4.8 Hz, 1H), 6.10 (bs, 1H), 5.67 (bs, 1H); <sup>13</sup>C NMR (101 MHz, dimethyl sulfoxide (DMSO)) δ 166.77, 148.39, 147.20, 139.08, 134.08, 133.72, 133.12, 127.67, 126.09, 123.32; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>11</sub>N<sub>2</sub>O [M + H]<sup>+</sup> = 199.0866, found = 199.0865; purity > 99%, <i>t</i><sub>R</sub> = 4.87 min, method A.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>N</i>-Methyl-4-(pyridin-3-yl)benzamide (<b>13a</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.96 (s, 1H), 8.61 (s, 1H), 8.51 (t, <i>J</i> = 5.0 Hz, 1H), 8.14 (d, <i>J</i> = 8.1 Hz, 1H), 7.96 (d, <i>J</i> = 8.1 Hz, 2H), 7.84 (d, <i>J</i> = 8.1 Hz, 2H), 7.51 (dd, <i>J</i> = 8.1, 4.8 Hz, 1H), 2.81 (d, <i>J</i> = 4.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 166.56, 149.45, 148.25, 139.95, 135.13, 134.76, 134.41, 129.36, 128.31, 127.22, 124.40, 115.20, 26.75; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>13</sub>N<sub>2</sub>O [M + H]<sup>+</sup> = 213.1022, found = 213.1021; off-white solid; purity > 99%, <i>t</i><sub>R</sub> = 0.46 min, method B.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 1-[4-(Pyridin-3-yl)benzoyl]piperazine (<b>13b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.88 (d, <i>J</i> = 2.4 Hz, 1H), 8.65 (dd, <i>J</i> = 4.8, 1.6 Hz, 1H), 7.90 (ddd, <i>J</i> = 7.9, 2.4, 1.7 Hz, 1H), 7.70–7.61 (m, 2H), 7.60–7.50 (m, 2H), 7.41 (ddd, <i>J</i> = 8.0, 4.8, 0.9 Hz, 1H), 3.90–3.65 (m, 2H), 3.63–3.30 (m, 2H), 3.10–2.83 (m, 4H); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>18</sub>N<sub>3</sub>O [M + H]<sup>+</sup> = 268.14, found = 268.1; off-white solid; purity = 98%, <i>t</i><sub>R</sub> = 0.24 min, method B.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 4-(2-Aminopyridin-4-yl)benzamide (<b>13c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.09–7.90 (m, 4H), 7.74–7.67 (m, 2H), 7.43–7.38 (m, 1H), 6.82 (dd, <i>J</i> = 5.4, 1.7 Hz, 1H), 6.74 (d, <i>J</i> = 1.8 Hz, 1H), 6.00 (s, 2H); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>12</sub>N<sub>3</sub>O [M + H]<sup>+</sup> = 214.09, found = 214.1; off-white solid; purity 95%, <i>t</i><sub>R</sub> = 0.42 min, method B.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 4-(6-Aminopyridin-3-yl)benzamide (<b>13d</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.32 (d, <i>J</i> = 2.7 Hz, 1H), 7.77 (dd, <i>J</i> = 8.6, 2.6 Hz, 1H), 7.65 (d, <i>J</i> = 8.4 Hz, 2H), 7.28 (s, 1H), 6.54 (d, <i>J</i> = 8.7 Hz, 1H), 6.14 (s, 2H); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>12</sub>N<sub>3</sub>O [M + H]<sup>+</sup> = 214.09, found = 214.1; off-white solid; purity 95%, <i>t</i><sub>R</sub> = 0.37 min, method B.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 4-(2-Aminopyridin-3-yl)benzamide (<b>13e</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.09–7.90 (m, 4H), 7.59–7.48 (m, 2H), 7.37 (dd, <i>J</i> = 7.3, 1.8 Hz, 2H), 6.68 (dd, <i>J</i> = 7.3, 4.9 Hz, 1H), 5.63 (s, 2H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 167.92, 156.84, 147.94, 141.63, 138.07, 133.40, 128.72, 128.55, 120.08, 113.56; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>12</sub>N<sub>3</sub>O [M + H]<sup>+</sup> = 214.0975, found = 214.0974; off-white solid; purity > 99%, <i>t</i><sub>R</sub> = 0.4 min, method B.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 2-Chloro-4-(pyridin-3-yl)benzamide (<b>15</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.94 (dd, <i>J</i> = 2.4, 0.9 Hz, 1H), 8.62 (dd, <i>J</i> = 4.8, 1.6 Hz, 1H), 8.15 (ddd, <i>J</i> = 8.0, 2.5, 1.6 Hz, 1H), 7.92 (s, 1H), 7.87 (d, <i>J</i> = 1.8 Hz, 1H), 7.75 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 7.68–7.60 (m, 1H), 7.56 (d, <i>J</i> = 7.9 Hz, 1H), 7.51 (ddd, <i>J</i> = 7.9, 4.8, 0.9 Hz, 1H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 168.30, 149.76, 148.26, 139.84, 136.94, 134.90, 134.07, 131.06, 129.83, 128.25, 125.93, 124.42; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>10</sub>ClN<sub>2</sub>O [M + H]<sup>+</sup> = 233.0476, found = 233.0475; off-white solid; purity > 99%, <i>t</i><sub>R</sub> = 0.45 min, method B.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2-Methyl-4-(pyridin-3-yl)benzamide (<b>16</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.94–8.85 (m, 1H), 8.59 (dd, <i>J</i> = 4.8, 1.6 Hz, 1H), 8.09 (ddd, <i>J</i> = 8.0, 2.4, 1.6 Hz, 1H), 7.75 (s, 1H), 7.63–7.54 (m, 2H), 7.53–7.44 (m, 2H), 7.39 (s, 1H), 2.45 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 171.10, 149.19, 148.14, 138.25, 137.06, 136.71, 135.43, 134.62, 129.45, 128.39, 124.37, 124.35, 20.19; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>13</sub>N<sub>2</sub>O [M + H]<sup>+</sup> = 213.1022, found = 213.1022; light-brown solid; purity > 99%, <i>t</i><sub>R</sub> = 0.40 min, method B.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-Methoxy-4-(pyridin-3-yl)benzamide (<b>17</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.99 (d, <i>J</i> = 2.4 Hz, 1H), 8.62 (dd, <i>J</i> = 4.8, 1.6 Hz, 1H), 8.17 (ddd, <i>J</i> = 8.0, 2.4, 1.6 Hz, 1H), 7.91 (d, <i>J</i> = 8.0 Hz, 1H), 7.67 (s, 1H), 7.56 (s, 1H), 7.52 (ddd, <i>J</i> = 7.9, 4.7, 0.9 Hz, 1H), 7.44 (d, <i>J</i> = 1.7 Hz, 1H), 7.39 (dd, <i>J</i> = 8.0, 1.7 Hz, 1H), 4.01 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 166.38, 158.20, 149.57, 148.41, 141.63, 135.26, 134.94, 132.00, 124.34, 122.66, 119.35, 111.03, 56.57; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>13</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 229.0972, found = 229.0970; off-white solid; purity = 95%, <i>t</i><sub>R</sub> = 0.42 min, method B.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 3-Methoxy-4-(pyridin-3-yl)benzamide (<b>18</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.71 (d, <i>J</i> = 2.3 Hz, 1H), 8.55 (d, <i>J</i> = 4.7 Hz, 1H), 8.09 (s, 1H), 7.93 (dt, <i>J</i> = 7.9, 2.0 Hz, 1H), 7.65–7.56 (m, 2H), 7.51–7.41 (m, 3H), 3.85 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 168.01, 149.68, 148.91, 140.94, 136.85, 136.56, 135.68, 134.26, 130.16, 130.12, 125.70, 123.82, 20.58; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>13</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 228.2, found = 228.1; off-white solid; purity > 99%, <i>t</i><sub>R</sub> = 4.6 min, method A.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 4-(5-Methoxypyridin-3-yl)benzamide (<b>27</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm: 8.56 (d, <i>J</i> = 1.8 Hz, 1H), 8.33 (d, <i>J</i> = 2.7 Hz, 1H), 8.10 (s, 1H), 8.04–7.97 (m, 2H), 7.87 (d, <i>J</i> = 8.4 Hz, 2H), 7.70 (t, <i>J</i> = 2.3 Hz, 1H), 7.48 (s, 1H), 3.93 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 166.75, 155.04, 139.28, 138.90, 136.46, 134.88, 133.21, 127.58, 126.31, 117.78, 55.08; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>13</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 229.0972, found = 229.0970; light-yellow solid; purity = 97%, <i>t</i><sub>R</sub> = 4.3 min, method A.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 4-(5-Acetylpyridin-3-yl)benzamide (<b>28</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm: 9.16 (dd, <i>J</i> = 22.0, 2.2 Hz, 2H), 8.57 (d, <i>J</i> = 2.3 Hz, 1H), 8.11 (s, 1H), 8.04 (d, <i>J</i> = 7.9 Hz, 2H), 7.94 (d, <i>J</i> = 8.2 Hz, 2H), 7.49 (s, 1H), 2.72 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 198.00, 167.77, 151.92, 149.03, 139.22, 135.16, 134.58, 134.08, 132.55, 128.80, 127.48, 27.68; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>13</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 241.0972, found = 241.0967; light-brown solid; purity = 97%, <i>t</i><sub>R</sub> = 4.4 min, method A.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 5-(4-Carbamoylphenyl)pyridine-3-carboxylic Acid (<b>29</b>)</h4><div class="NLM_p">Reaction conditions were modified: To 5-bromonicotinic acid (200 mg, 0.99 mmol, 1.0 equiv) and (4-carbamoylphenyl)boronic acid (245 mg, 1.48 mmol, 1.5 equiv) in DME (1.6 mL) was added Na<sub>2</sub>CO<sub>3</sub> (420 mg, 4 mmol, 4 equiv) in water (0.4 mL), followed by [Pd(Ph<sub>3</sub>)]<sub>4</sub> (45 mg, 0.03960 mmol, 0.05 equiv.) and heated at 100 °C for 16 h. Workup was according to the procedure described above for <b>13</b>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) <i>δ</i> (ppm): δ 9.10 (s, 1H), 8.91 (s, 1H), 8.62 (t, <i>J</i> = 2.0 Hz, 1H), 8.08–8.01 (m, 2H), 7.88–7.81 (m, 2H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>11</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> = 243.0764, found = 243.0762; off-white solid; purity = 96%, <i>t</i><sub>R</sub> = 4.4 min, method A.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4-(6-Methoxypyridin-3-yl)benzamide (<b>30</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm: 8.57 (d, <i>J</i> = 2.5 Hz, 1H), 8.09 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 8.04 (s, 1H), 7.97 (d, <i>J</i> = 7.9 Hz, 2H), 7.76 (d, <i>J</i> = 8.1 Hz, 2H), 7.42 (s, 1H), 6.94 (d, <i>J</i> = 8.6 Hz, 1H), 3.91 (s, 3H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>13</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 229.0972, found = 229.0970; yellow solid; purity = 97%, <i>t</i><sub>R</sub> = 5.4 min, method A.</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-(2-Methylpyridin-3-yl)benzamide (<b>31</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm: 8.49 (dd, <i>J</i> = 4.9, 1.8 Hz, 1H), 8.07 (s, 1H), 7.97 (d, <i>J</i> = 8.2 Hz, 2H), 7.64 (dd, <i>J</i> = 7.7, 1.8 Hz, 1H), 7.53–7.43 (m, 3H), 7.33 (dd, <i>J</i> = 7.7, 4.8 Hz, 1H), 2.44 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 166.90, 154.31, 147.49, 141.66, 136.38, 134.92, 132.70, 128.27, 127.01, 120.79, 22.62; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>13</sub>N<sub>2</sub>O [M + H]<sup>+</sup> = 213.1022, found = 213.1022; beige solid; purity = 97%, <i>t</i><sub>R</sub> = 4.5 min, method A.</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 4-(5-Chloropyridin-3-yl)benzamide (<b>32</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 8.94 (d, 1H, <i>J</i> = 2.0 Hz), 8.67 (d, 1H, <i>J</i> = 2.2 Hz), 8.34 (t, 1H, <i>J</i> = 2.1 Hz), 8.08 (s, 1H), 8.01, (d, 2H, <i>J</i> = 8.5 Hz), 7.90 (d, 2H, <i>J</i> = 8.5 Hz), 7.45 (s, 1H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 166.65, 146.74, 145.55, 137.41, 135.56, 133.65, 133.31, 130.93, 127.67, 126.44; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>10</sub>ClN<sub>2</sub>O [M + H]<sup>+</sup> = 233.0476, found = 233.0475; white solid; purity> 99%, <i>t</i><sub>R</sub> = 0.77 min, method A.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Representative Procedure: Miyaura Coupling—Preparation of Intermediate <b>IIa</b></h3><div class="NLM_p">To the solution of 4-bromobenzamide (1 mmol, 200 mg) in dry dioxane (8 mL) were added bis(pinacolato)diboron (1.2 mmol, 305 mg) and potassium acetate (1.5 mmol, 147 mg). The reaction mixture was degassed by bubbling nitrogen through over 5 min. Subsequently, palladium catalyst Pd[DPPF]Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (5 mol %, 41 mg) was added, and the reaction mixture was heated to 90 °C under a nitrogen atmosphere. The reaction was complete in 2 h (LC-mass analysis).</div><div class="NLM_p">Workup: The reaction mixture was filtered through a paper filter to a separating funnel, diluted with ethyl acetate, and washed with water. The aqueous phase was back-extracted with ethyl acetate once. Combined ethyl acetate layers were dried over sodium sulfate and evaporated. The crude product was purified by flash silica gel chromatography eluting with a gradient of ethyl acetate/hexane to afford 3-hydroxy-4-carbamidephenylboronic acid pinacol ester (<b>IIa</b>, 186 mg) as an off-white solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>11</sub>N<sub>2</sub>O [M + H]<sup>+</sup> = 264.1, found = 264.0 The intermediate was used for subsequent steps without additional characterization.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-Hydroxy-4-(pyridin-3-yl)benzamide (<b>14</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.44–13.00 (m, 1H), 8.91 (s, 1H), 8.68 (d, <i>J</i> = 3.4 Hz, 1H), 8.60 (d, <i>J</i> = 5.0 Hz, 1H), 8.11 (d, <i>J</i> = 7.9 Hz, 1H), 8.03–7.79 (m, 2H), 7.49 (dd, <i>J</i> = 7.7, 5.3 Hz, 1H), 7.20 (d, <i>J</i> = 8.7 Hz, 2H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 172.33, 162.12, 149.72, 148.25, 143.02, 134.82, 134.80, 129.36, 124.36, 117.40, 115.84, 114.32; HRMS <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>11</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 215.0815, found = 215.0815; off-white solid; purity = 97%, <i>t</i><sub>R</sub> = 0.75 min, method A.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Representative Procedure: Alkylation of Phenol—Preparation of Compound <b>19</b></h4><div class="NLM_p">To the solution of compound <b>14</b> (0.2 mmol, 42 mg) in dry DMF (3 mL) was added potassium carbonate (0.6 mmol, 83 mg) followed by ethyl bromide (0.3 mmol, 33 mg) at room temperature, and the reaction mixture was brought to 90 °C and stirred for 1 h. After this time, the heating bath was removed and additional ethyl bromide was added (0.3 mmol, 33 mg). The reaction was then continued at 90 °C for additional 2 h. On completion (LC-mass monitoring), the reaction mixture was cooled to room temperature, diluted with ethyl acetate (20 mL), and washed with water (1×) and brine (2×). The organic layer was then dried over sodium sulfate and evaporated. The crude product was purified by flash silica gel chromatography eluting with a gradient of ethyl acetate/hexane to afford 2-ethoxy-4-(pyridin-3-yl)benzamide (<b>19</b>, 39 mg) as an off-white solid.</div><div class="NLM_p">In the case of compounds <b>24</b>–<b>26</b>, deprotection of the amino- functionality was carried out first on the crude product of alkylation: the compound (∼0.2 mmol) was dissolved in dichloromethane (2 mL), and trifluoroacetic acid (0.2 mL) was added. The reaction mixture was stirred at room temperature over an hour, until deprotection was complete. Volatiles were then removed in vacuo, and the crude residue was dissolved in methanol, filtered, and purified on preparative HPLC eluting with a gradient of acetonitrile in water (both eluents containing 0.1% formic acid).</div><div class="NLM_p last">Note: Alkylation with less volatile alkyl bromides (cyclohexylmethyl-,cyclobutyl-, cyclohexyl-, Boc-aminoethyl, and Boc-pyrrolidinyl-) did not require replenishing of alkyl bromide during the course of the reaction.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-Ethoxy-4-(pyridin-3-yl)benzamide (<b>19</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.97 (d, <i>J</i> = 2.3 Hz, 1H), 8.61 (dd, <i>J</i> = 4.8, 1.6 Hz, 1H), 8.21–8.11 (m, 1H), 7.93 (d, <i>J</i> = 8.0 Hz, 1H), 7.61 (d, <i>J</i> = 8.8 Hz, 2H), 7.51 (ddd, <i>J</i> = 7.9, 4.8, 0.9 Hz, 1H), 7.43 (d, <i>J</i> = 1.6 Hz, 1H), 7.38 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 4.32 (q, <i>J</i> = 7.0 Hz, 2H), 1.43 (t, <i>J</i> = 7.0 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 166.42, 157.47, 149.57, 148.41, 141.64, 135.21, 134.95, 132.09, 124.32, 122.67, 119.38, 111.91, 64.99, 14.95; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>15</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 243.1128, found = 243.1128; off-white solid; purity = 96%, <i>t</i><sub>R</sub> = 0.56 min, method B.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-(Propan-2-yloxy)-4-(pyridin-3-yl)benzamide (<b>21</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.96 (s, 1H), 8.62 (s, 1H), 8.15 (dt, <i>J</i> = 8.1, 1.9 Hz, 1H), 7.95 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.60 (d, <i>J</i> = 6.4 Hz, 2H), 7.51 (dd, <i>J</i> = 8.1, 4.8 Hz, 1H), 7.46 (s, 1H), 7.37 (dd, <i>J</i> = 8.1, 1.7 Hz, 1H), 5.12–4.93 (m, 1H), 1.38 (d, <i>J</i> = 6.1 Hz, 6H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 165.37, 155.40, 148.48, 147.35, 140.59, 134.11, 133.92, 131.24, 123.26, 122.32, 118.42, 112.30, 70.76, 21.18; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 257.1285, found = 257.1282; off-white solid; purity > 99%, <i>t</i><sub>R</sub> = 0.61 min, method B.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 2-Cyclobutoxy-4-(pyridin-3-yl)benzamide (<b>22</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.94 (s, 1H), 8.60 (d, <i>J</i> = 12.8 Hz, 1H), 8.17–8.03 (m, 1H), 7.91 (dt, <i>J</i> = 8.8, 4.4 Hz, 1H), 7.60 (s, 2H), 7.52 (dd, <i>J</i> = 8.0, 4.9 Hz, 1H), 7.43–7.32 (m, 1H), 5.04 (p, <i>J</i> = 7.2 Hz, 1H), 2.49 (s, 2H), 2.18 (dq, <i>J</i> = 20.0, 10.1, 9.4 Hz, 2H), 1.83 (q, <i>J</i> = 10.5 Hz, 1H), 1.69 (p, <i>J</i> = 9.5 Hz, 1H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 166.38, 155.91, 149.59, 148.34, 141.56, 135.13, 134.94, 132.21, 124.38, 122.86, 119.51, 112.25, 72.06, 30.50, 13.24; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 269.1285, found = 269.1281; off-white solid; purity = 97%, <i>t</i><sub>R</sub> = 1.00 min, method B.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-(Cyclohexyloxy)-4-(pyridin-3-yl)benzamide (<b>23</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (s, 1H), 8.61 (d, <i>J</i> = 4.7 Hz, 1H), 8.14 (d, <i>J</i> = 8.0 Hz, 1H), 7.94 (d, <i>J</i> = 8.1 Hz, 1H), 7.63 (s, 2H), 7.55–7.45 (m, 2H), 7.36 (d, <i>J</i> = 8.1 Hz, 1H), 4.86–4.74 (m, 1H), 2.05–1.89 (m, 2H), 1.76–1.22 (m, 8H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 166.46, 156.28, 149.54, 148.46, 141.67, 135.19, 135.02, 132.31, 124.31, 123.42, 119.54, 113.47, 76.22, 31.50, 25.47, 23.45; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 297.1598, found = 297.1595; pale-yellow oil; purity = 95.4%, <i>t</i><sub>R</sub> = 0.71 min, method B.</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-(2-Aminoethoxy)-4-(pyridin-3-yl)benzamide (<b>24</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.97 (d, <i>J</i> = 2.4 Hz, 1H), 8.61 (dd, <i>J</i> = 4.8, 1.6 Hz, 1H), 8.15 (dt, <i>J</i> = 7.9, 2.0 Hz, 1H), 8.05 (s, 1H), 7.91 (d, <i>J</i> = 8.0 Hz, 1H), 7.54–7.47 (m, 2H), 7.46 (d, <i>J</i> = 1.7 Hz, 1H), 7.39 (dd, <i>J</i> = 8.1, 1.7 Hz, 1H), 4.23 (t, <i>J</i> = 5.4 Hz, 2H), 2.96 (t, <i>J</i> = 5.4 Hz, 2H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 166.55, 157.74, 149.56, 148.38, 141.56, 135.16, 134.93, 132.08, 124.32, 123.17, 119.54, 112.50, 71.60, 41.14; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>16</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 258.1237, found = 258.1235; light-brown solid; purity > 99%, <i>t</i><sub>R</sub> = 0.24 min, method B.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 4-(Pyridin-3-yl)-2-(pyrrolidin-3-yloxy)benzamide (<b>25</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.06 (s, 1H), 8.71 (s, 1H), 8.34 (d, <i>J</i> = 8.0 Hz, 1H), 7.85 (d, <i>J</i> = 8.3 Hz, 1H), 7.69 (dd, <i>J</i> = 8.1, 4.8 Hz, 1H), 7.53–7.38 (m, 2H), 5.46 (s, 1H), 3.53–3.48 (m, 2H), 3.42–3.30 (m, 2H), 2.31 (td, <i>J</i> = 8.7, 5.1 Hz, 2H); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>18</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 284.3, found = 284.1; light-brown solid; purity > 99%, <i>t</i><sub>R</sub> = 0.24 min, method B.</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-(Piperidin-4-yloxy)-4-(pyridin-3-yl)benzamide (<b>26</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.94 (d, <i>J</i> = 2.6 Hz, 1H), 8.61 (dd, <i>J</i> = 4.8, 1.8 Hz, 1H), 8.15 (dt, <i>J</i> = 8.1, 2.2 Hz, 1H), 7.94 (d, <i>J</i> = 8.1 Hz, 1H), 7.53 (dd, <i>J</i> = 7.9, 4.8 Hz, 1H), 7.48 (d, <i>J</i> = 1.7 Hz, 1H), 7.39 (dd, <i>J</i> = 8.1, 1.8 Hz, 1H), 4.88 (hept, <i>J</i> = 3.9 Hz, 1H), 2.93 (td, <i>J</i> = 9.8, 9.2, 5.3 Hz, 3H), 2.66 (ddd, <i>J</i> = 12.6, 9.3, 3.2 Hz, 2H), 2.06–1.93 (m, 2H), 1.63 (dtd, <i>J</i> = 12.8, 9.0, 3.9 Hz, 2H); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C17H20N3O2 [M + H]<sup>+</sup> = 298.15, found = 298.1; light-brown solid; purity = 96%, <i>t</i><sub>R</sub> = 0.40 min, method B.</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-(5-Phenylpyridin-3-yl)benzamide (<b>33</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 8.94 (dd, 2H, <i>J</i> = 2.2, 12.1 Hz), 8.38 (t, 1H, <i>J</i> = 2.2 Hz), 8.08 (s, 1H), 8.04 (d, 2H, <i>J</i> = 8.3 Hz), 7.93 (d, 2H, <i>J</i> = 8.3 Hz), 7.89–7.87 (m, 2H), 7.55 (t, 2H, <i>J</i> = 7.42 Hz), 7.49–7.43 (m, 2H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 166.46, 156.46, 146.11, 145.77, 141.67, 137.12, 135.30, 132.23, 130.69, 129.13, 129.10, 123.46, 119.70, 118.78, 113.54; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>15</sub>N<sub>2</sub>O [M + H]<sup>+</sup> = 275.1179, found = 275.1177; off-white solid; purity = 98%, <i>t</i><sub>R</sub> = 0.79 min, method B.</div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 4-{[3,3′-Bipyridin]-5-yl}benzamide (<b>34</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 9.10–9.09 (m, 1H), 8.99 (dd, 2H, <i>J</i> = 2.2, 10.9 Hz), 8.16 (dd, 1H, <i>J</i> = 1.5, 4.8 Hz), 8.48 (t, 1H, <i>J</i> = 2.18 Hz), 8.32–8.29 (m, 1H), 8.08 (s, 1H), 8.03 (d, 2H, <i>J</i> = 8.5 Hz), 7.98 (d, 2H, <i>J</i> = 8.5 Hz), 7.58–7.55 (m, 1H), 7.44 (s, 1H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 167.85, 149.77, 148.56, 147.76, 147.58, 139.82, 135.35, 135.21, 134.35, 133.37, 133.10, 133.00, 128.71, 127.51, 124.43; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>14</sub>N<sub>3</sub>O [M + H]<sup>+</sup> = 276.1131, found = 276.1129; white solid; purity > 99%, <i>t</i><sub>R</sub> = 0.53 min, method B.</div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 4-[5-(1-Methyl-1<i>H</i>-pyrazol-3-yl)pyridin-3-yl]benzamide (<b>35</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 9.03 (d, 1H, <i>J</i> = 2.0 Hz), 8.56 (d, 1H, <i>J</i> = 2.2 Hz), 8.41 (t, 1H, <i>J</i> = 2.1 Hz), 8.07 (s, 1H), 8.02 (d, 2H, <i>J</i> = 8.4 Hz), 7.89 (d, 2H, <i>J</i> = 8.44 Hz), 7.82 (d, 1H, <i>J</i> = 2.2 Hz), 7.43 (s, 1H), 6.96 (d, 1H, <i>J</i> = 2.3 Hz), 3.93 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 167.86, 147.47, 146.95, 146.06, 140.02, 135.19, 134.29, 133.19, 130.51, 129.72, 128.75, 127.28, 103.97; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>15</sub>N<sub>4</sub>O [M + H]<sup>+</sup> = 279.1240, found 279.1238; white solid; purity = 99%, <i>t</i><sub>R</sub> = 0.59 min, method B.</div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 4-[5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)pyridin-3-yl]benzamide (<b>36</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 8.86 (S, 1H), 8.77 (s, 1H), 8.38 (s, 1H), 8.30 (s, 1H), 8.10 (s, 1H), 8.07 (s, 1H), 8.02 (d, 2H, <i>J</i> = 8.3 Hz), 7.90 (d, 2H, <i>J</i> = 8.3 Hz), 7.43 (s, 1H), 3.90 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 167.85, 145.98, 145.55, 140.09, 137.08, 136.36, 135.21, 134.22, 130.49, 129.17, 129.12, 128.67, 127.25, 118.81; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>15</sub>N<sub>4</sub>O [M + H]<sup>+</sup> = 279.1249, found 279.1238; white solid; purity = 99%, <i>t</i><sub>R</sub> = 0.54 min, method B.</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 2-(Cyclohexylmethoxy)-4-[5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-3-yl]benzamide (<b>49</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.85 (d, <i>J</i> = 2.1 Hz, 1H), 8.77 (d, <i>J</i> = 2.2 Hz, 1H), 8.36 (s, 1H), 8.27 (d, <i>J</i> = 2.2 Hz, 1H), 8.09 (s, 1H), 7.92 (d, <i>J</i> = 8.0 Hz, 1H), 7.61 (d, <i>J</i> = 26.5 Hz, 2H), 7.49–7.41 (m, 2H), 3.90 (s, 3H), 1.93–1.61 (m, 7H), 1.18 (ddd, <i>J</i> = 50.4, 25.4, 12.3 Hz, 6H); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>27</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 390.5, found 390.3; pale-yellow oil; purity > 99%, <i>t</i><sub>R</sub> = 0.95 min, method B.</div></div><div id="sec4_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 7-[5-(1-Methyl-1H-pyrazol-4-yl)pyridin-3-yl]-1,2,3,4-tetrahydroisoquinolin-1-one (<b>50</b>, SI <a href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_003.pdf" class="ext-link">Table 1</a>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.85 (d, <i>J</i> = 2.1 Hz, 1H), 8.74 (d, <i>J</i> = 2.2 Hz, 1H), 8.37 (s, 1H), 8.29 (t, <i>J</i> = 2.1 Hz, 1H), 8.09 (s, 1H), 7.98 (s, 1H), 7.95 (d, <i>J</i> = 8.7 Hz, 1H), 7.79 (d, <i>J</i> = 2.1 Hz, 1H), 7.77 (d, <i>J</i> = 2.0 Hz, 1H), 3.90 (s, 3H), 3.43 (td, <i>J</i> = 6.2, 2.5 Hz, 2H), 3.00 (t, <i>J</i> = 6.5 Hz, 2H); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>17</sub>N<sub>4</sub>O [M + H]<sup>+</sup> = 305.13, found 305.2; off-white solid; purity > 99%, <i>t</i><sub>R</sub> = 0.59 min, method B.</div></div><div id="sec4_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Alkylation of Aniline: Preparation of Compound <b>20</b></h4><div class="NLM_p">To the solution of intermediate <b>IIIb</b> (0.2 mmol, 42 mg) in dry DMF (3 mL) was added sodium hydride (57% suspension in mineral oil, 0.4 mmol, 17 mg) at 0 °C, followed by ethyl bromide (0.4 mmol, 44 mg), and the reaction mixture was brought to 90 °C and stirred for 1 h. After this time, the heating bath was removed and additional sodium hydride (0.4 mmol, 17 mg) and ethyl bromide were added (0.4 mmol, 44 mg). The reaction was then continued at 90 °C for an additional 1 h. On completion (LC-mass monitoring), the reaction mixture was cooled to room temperature, diluted with ethyl acetate (20 mL), and washed with water (1×) and brine (2×). The organic layer was then dried over sodium sulfate and evaporated. The crude product was purified by flash silica gel chromatography eluting with a gradient of ethyl acetate/hexane to afford 2-(ethylamino)-4-(pyridin-3-yl)benzamide (<b>20</b>, 19 mg) as an off-white solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.91 (d, <i>J</i> = 2.4 Hz, 1H), 8.59 (dd, <i>J</i> = 4.8, 1.6 Hz, 1H), 8.18 (t, <i>J</i> = 5.1 Hz, 1H), 8.09 (dt, <i>J</i> = 7.9, 2.0 Hz, 1H), 7.88 (s, 1H), 7.73 (d, <i>J</i> = 8.2 Hz, 1H), 7.48 (dd, <i>J</i> = 7.9, 4.8 Hz, 1H), 7.17 (s, 1H), 6.90 (d, <i>J</i> = 2.0 Hz, 1H), 6.85 (dd, <i>J</i> = 8.1, 1.8 Hz, 1H), 3.24 (qd, <i>J</i> = 7.1, 5.0 Hz, 2H), 1.22 (t, <i>J</i> = 7.2 Hz, 3H); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>16</sub>N<sub>3</sub>O [M + H]<sup>+</sup> = 242.12, found = 242.1; purity %, <i>t</i><sub>R</sub> = 0.56 min, method B.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Generation of Tetrazole</h3><div class="NLM_p">To the solution of 3-bromo-5-cyanopyridine (183 mg, 1 mmol) in DMF (10 mL) were added ammonium chloride (105 mg, 2 mmol) and sodium azide (130 mg, 2 mmol). The reaction mixture was then stirred at 100 °C for 4 h and monitored by LC mass. Upon completion, the reaction mixture was cooled to room temperature and 10 mL of 1M aqueous hydrochloric acid was added, resulting in precipitation of the desired product. After stirring of the mixture for an additional 10 min, the precipitate was collected, washed with water, dried in vacuo, and identified via LC mass (purity = 92%, <i>t</i><sub>R</sub> = 0.36 min, method B) as the desired intermediate <b>VIII</b> (quantitative yield). No further characterization was undertaken, and the intermediate was used for the next step (Suzuki coupling according to the general procedure described above), leading to the final compound <b>38</b>.</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 2-(Propan-2-yloxy)-4-[5-(5<i>H</i>-1,2,3,4-tetrazol-5-yl)pyridin-3-yl]benzamide (<b>38</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.03 (s, 1H), 8.86 (s, 1H), 8.38 (t, <i>J</i> = 2.1 Hz, 1H), 7.97 (d, <i>J</i> = 8.1 Hz, 1H), 7.82 (d, <i>J</i> = 2.3 Hz, 1H), 7.62 (d, <i>J</i> = 8.9 Hz, 2H), 7.51 (d, <i>J</i> = 1.6 Hz, 1H), 7.42 (dd, <i>J</i> = 8.1, 1.6 Hz, 1H), 6.95 (d, <i>J</i> = 2.3 Hz, 1H), 5.05 (hept, <i>J</i> = 6.0 Hz, 1H), 3.93 (s, 3H), 1.38 (d, <i>J</i> = 6.0 Hz, 6H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 166.46, 156.48, 147.49, 147.18, 146.18, 141.61, 133.17, 132.33, 130.73, 123.51, 119.73, 113.54, 104.03, 71.87, 22.26; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>15</sub>N<sub>6</sub>O<sub>2</sub> [M-H]<sup>−</sup> = 323.3, found 323.1; beige solid; purity > 99%, <i>t</i><sub>R</sub> = 0.70 min, method B.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 4-[5-(1-Methyl-1<i>H</i>-pyrazol-4-yl)pyridin-3-yl]-2-(propan-2-yloxy)benzamide (<b>37</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.85 (d, <i>J</i> = 2.1 Hz, 1H), 8.76 (d, <i>J</i> = 2.2 Hz, 1H), 8.36 (s, 1H), 8.26 (t, <i>J</i> = 2.1 Hz, 1H), 8.09 (d, <i>J</i> = 0.9 Hz, 1H), 7.96 (d, <i>J</i> = 8.1 Hz, 1H), 7.62 (d, <i>J</i> = 9.2 Hz, 2H), 5.05 (p, <i>J</i> = 6.1 Hz, 1H), 3.90 (s, 3H), 1.38 (d, <i>J</i> = 6.0 Hz, 6H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 337.1659, found 337.1656; off-white solid; purity > 99%, <i>t</i><sub>R</sub> = 0.72 min, method B.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 2-(Propan-2-yloxy)-4-[5-(pyrrolidin-1-yl)pyridin-3-yl]benzamide (<b>39</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.15 (d, <i>J</i> = 1.9 Hz, 1H), 7.97 (d, <i>J</i> = 2.7 Hz, 1H), 7.94 (s, 1H), 7.59 (d, <i>J</i> = 10.9 Hz, 2H), 7.38 (d, <i>J</i> = 1.6 Hz, 1H), 7.33 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 7.09 (t, <i>J</i> = 2.3 Hz, 1H), 5.00 (p, <i>J</i> = 6.0 Hz, 1H), 3.39–3.34 (m, 4H), 2.02–1.95 (m, 4H), 1.37 (d, <i>J</i> = 6.0 Hz, 6H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 166.48, 156.35, 143.97, 142.85, 135.32, 135.19, 134.15, 132.17, 123.07, 119.67, 116.21, 113.47, 71.77, 47.58, 25.37, 22.23; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 326.1863, found 326.1861; pale-yellow oil; purity > 99%, <i>t</i><sub>R</sub> = 0.67 min, method B.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 4-[5-(Morpholin-4-yl)pyridin-3-yl]-2-(propan-2-yloxy)benzamide (<b>40</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) d (ppm) 8.37 (d, 1H, <i>J</i> = 1.8 Hz), 8.34 (d, 1H <i>J</i> = 2.8 Hz), 7.93 (d, 1H, <i>J</i> = 8.0 Hz), 7.61–7.59 (m, 2H), 7.55 (t, 1H, <i>J</i> = 4.6 Hz), 7.42–7.41 (m, 1H), 7.36 (dd, 1H, <i>J</i> = 1.58, 8.08 Hz), 5.05–4.99 (m, 1H), 3.79–3.77 (m, 4H), 3.29–3.26 (m, 4H), 1.37 (d, 6H, <i>J</i> = 6.0 Hz); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> = 342.2, found 342.2; light-brown solid; purity = 99%, <i>t</i><sub>R</sub> = 0.65 min, method A.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 5-[4-Carbamoyl-3-(propan-2-yloxy)phenyl]-<i>N</i>-methylpyridine-3-carboxamide (<b>41</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.08 (d, <i>J</i> = 2.3 Hz, 1H), 8.99 (d, <i>J</i> = 2.1 Hz, 1H), 8.76 (d, <i>J</i> = 4.7 Hz, 1H), 8.46 (t, <i>J</i> = 2.2 Hz, 1H), 7.97 (d, <i>J</i> = 8.0 Hz, 1H), 7.63 (s, 2H), 7.53 (d, <i>J</i> = 1.7 Hz, 1H), 7.43 (dd, <i>J</i> = 8.1, 1.6 Hz, 1H), 5.03 (p, <i>J</i> = 6.0 Hz, 1H), 2.85 (d, <i>J</i> = 4.5 Hz, 3H), 1.38 (d, <i>J</i> = 5.9 Hz, 6H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 166.44, 165.53, 156.50, 150.46, 148.29, 140.99, 134.74, 133.34, 132.33, 130.48, 123.77, 119.72, 113.61, 71.93, 26.69, 22.24; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> = 314.1499, found 314.1495; off-white solid; purity = 95%, <i>t</i><sub>R</sub> = 0.67 min, method B.</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 4-{5-[1-(Propan-2-yl)-1<i>H</i>-pyrazol-4-yl]pyridin-3-yl}-2-(propan-2-yloxy)benzamide (<b>42</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.87 (d, <i>J</i> = 2.1 Hz, 1H), 8.75 (d, <i>J</i> = 2.2 Hz, 1H), 8.46 (d, <i>J</i> = 0.8 Hz, 1H), 8.28 (t, <i>J</i> = 2.2 Hz, 1H), 8.09 (d, <i>J</i> = 0.8 Hz, 1H), 7.96 (d, <i>J</i> = 8.0 Hz, 1H), 7.62 (d, <i>J</i> = 6.0 Hz, 2H), 7.51 (d, <i>J</i> = 1.7 Hz, 1H), 7.44 (dd, <i>J</i> = 8.1, 1.6 Hz, 1H), 5.05 (hept, <i>J</i> = 5.9 Hz, 1H), 4.54 (hept, <i>J</i> = 6.6 Hz, 1H), 1.47 (d, <i>J</i> = 6.7 Hz, 6H), 1.38 (d, <i>J</i> = 6.0 Hz, 6H); <sup>13</sup>C NMR (101 MHz, DMSO) δ 166.46, 156.45, 146.12, 145.70, 141.74, 136.61, 135.28, 132.22, 130.66, 129.29, 126.05, 123.43, 119.75, 118.29, 113.56, 71.87, 53.76, 23.16, 22.26; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 365.1972, found 365.1971; off-white solid; purity 95%, <i>t</i><sub>R</sub> = 6.67 min, method A.</div></div><div id="sec4_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 4-{5-[1-(Oxetan-3-yl)-1<i>H</i>-pyrazol-4-yl]pyridin-3-yl}-2-(propan-2-yloxy)benzamide (<b>43</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 8.89 (d, 1H, <i>J</i> = 2.1 Hz), 8.78 (d, 1H, <i>J</i> = 2.2 Hz), 8.63 (s, 1H), 8.32 (t, 1H, <i>J</i> = 2.1 Hz), 8.26 (s, 1H), 7.97 (d, 1H, <i>J</i> = 8.1 Hz), 7.62–7.61 (m, 2H), 7.51–7.50 (m, 1H), 7.45 (dd, 1H, <i>J</i> = 1.6, 8.1 Hz), 5.66–5.59 (m, 1H), 5.08–5.02 (m, 1H), 4.99–4.92 (m, 1H), 1.38 (d, 6H, <i>J</i> = 6.0 Hz); <sup>13</sup>C NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 165.4, 155.4, 145.2, 144.9, 140.6, 136.9, 134.2, 131.2, 129.8, 127.8, 126.9, 122.4, 118.7, 118.1, 112.5, 75.9, 70.8, 54.2, 21.2; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>23</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> = 379.4, found 379.2; brown solid; purity 95%, <i>t</i><sub>R</sub> = 6.67 min, method A.</div></div><div id="sec4_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 4-{5-[1-(Oxolan-3-yl)-1<i>H</i>-pyrazol-4-yl]pyridin-3-yl}-2-(propan-2-yloxy)benzamide (<b>44</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.89 (d, <i>J</i> = 2.1 Hz, 1H), 8.76 (d, <i>J</i> = 2.2 Hz, 1H), 8.49 (d, <i>J</i> = 0.9 Hz, 1H), 8.30 (t, <i>J</i> = 2.2 Hz, 1H), 8.15 (d, <i>J</i> = 0.8 Hz, 1H), 7.97 (d, <i>J</i> = 8.1 Hz, 1H), 7.62 (s, 2H), 7.51 (d, <i>J</i> = 1.6 Hz, 1H), 7.45 (dd, <i>J</i> = 8.1, 1.6 Hz, 1H), 5.13–4.99 (m, 2H), 4.09–4.00 (m, 2H), 4.00–3.93 (m, 1H), 3.85 (td, <i>J</i> = 8.3, 5.4 Hz, 1H), 2.47–2.40 (m, 1H), 2.35 (ddd, <i>J</i> = 8.0, 5.6, 3.9 Hz, 1H), 1.38 (d, <i>J</i> = 6.0 Hz, 6H); HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> = 393.1921, found 393.1917; light-yellow solid; purity 95%, <i>t</i><sub>R</sub> = 1.17 min, method B.</div></div><div id="sec4_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 4-[5-(3-Cyclopropyl-1<i>H</i>-pyrazol-4-yl)pyridin-3-yl]-2-(propan-2-yloxy)benzamide (<b>45</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.80 (s, 1H), 9.09 (s, 1H), 9.00 (s, 1H), 7.96 (d, <i>J</i> = 8.1 Hz, 1H), 7.90 (d, <i>J</i> = 1.5 Hz, 1H), 7.82 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.63 (s, 2H), 4.91 (p, <i>J</i> = 6.1 Hz, 1H), 2.87–2.73 (m, 1H), 1.39 (d, <i>J</i> = 6.0 Hz, 6H), 1.10–0.85 (m, 4H); 166.45, 156.32, 149.40, 148.94, 141.50, 140.52, 138.51, 134.03, 132.18, 125.05, 119.12, 116.36, 112.69, 71.90, 22.15, 8.35; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 362.4, found 362.2; off-white solid; purity> 99%, <i>t</i><sub>R</sub> = 0.86 min, method B.</div></div><div id="sec4_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 4-[5-(3-Methyl-1<i>H</i>-pyrazol-4-yl)pyridin-3-yl]-2-(propan-2-yloxy)benzamide (<b>46</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 12.83 (s, 1H), 8.79 (d, 1H, <i>J</i> = 2.2 Hz), 8.72 (d, 1H, <i>J</i> = 2.0 Hz), 8.12 (s, 1H), 7.95 (9d, 1H, <i>J</i> = 8.0 Hz), 7.62–7.61 (m, 2H),7.49 (d, 1H, <i>J</i> = 1.4 Hz), 7.42 (dd, 1H, <i>J</i> = 1.5, 8.1 Hz), 5.04 (quin, 1H, <i>J</i> = 6.0 Hz), 2.45–2.40 (m, 3H), 1.38 (d, 6H, <i>J</i> = 6.0 Hz); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 337.4, found 337.2; white solid; purity 95%, <i>t</i><sub>R</sub> = 0.68 min, method B.</div></div><div id="sec4_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 4-[5-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)pyridin-3-yl]-2-(propan-2-yloxy)benzamide (<b>47</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.55 (d, <i>J</i> = 2.1 Hz, 1H), 8.02 (t, <i>J</i> = 2.2 Hz, 1H), 7.95 (d, <i>J</i> = 8.0 Hz, 1H), 7.60 (d, <i>J</i> = 6.8 Hz, 2H), 7.48 (d, <i>J</i> = 1.6 Hz, 1H), 7.40 (dd, <i>J</i> = 8.1, 1.6 Hz, 1H), 5.03 (p, <i>J</i> = 6.0 Hz, 1H), 2.26 (s, 6H), 1.37 (d, <i>J</i> = 6.0 Hz, 6H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 183.4, 166.5, 163.8, 156.5, 149.2, 145.7, 141.7, 135.1, 134.4, 132.3, 130.5, 123.4, 119.6, 113.8, 113.5, 71.8, 22.3, 11.9; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 351.4, found 351.2; purity > 99%, <i>t</i><sub>R</sub> = 0.69 min, method B.</div></div><div id="sec4_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 4-[5-(1,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)pyridin-3-yl]-2-(propan-2-yloxy)benzamid (<b>48</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 8.81 (d, 1H, <i>J</i> = 2.2 Hz), 8.86 (d, 1H, <i>J</i> = 2.1 Hz), 8.07 (t, 1H, <i>J</i> = 2.2 Hz), 7.95 (d, 1H, <i>J</i> = 8.0 Hz), 7.79 (s, 1H), 7.61–7.60 (m, 2H), 7.49–7.48 (m, 1H), 7.42 (dd, 1H, J = 1.6, 8.1 Hz), 5.04 (quin, 1H, <i>J</i> = 6.1 Hz), 3.82 (s, 3H), 2.44 (s, 3H), 1.38 (d, 6H, <i>J</i> = 6.0 Hz); <sup>13</sup>C NMR (101 MHz, DMSO) δ 166.46, 156.45, 147.65, 145.73, 141.72, 137.35, 136.35, 135.29, 132.93, 132.27, 130.18, 123.42, 119.70, 116.47, 113.59, 71.79, 36.87, 22.24, 10.63; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> = 351.1816, found 351.1813; off-white solid; purity 96%, <i>t</i><sub>R</sub> = 0.75 min, method B.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i66"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01582" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14105" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14105" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01582?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01582</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Full protein sequences from Uniprot crystalized residues in black (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_001.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (compounds <b>1</b>–<b>49</b>) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Inhibitory activity of additional compounds; in vitro and in vivo PK compilation and mouse PK for compounds <b>44</b> and <b>48</b>; molecular modeling and analysis of MNK isoform similarity; X-ray crystal structure details; synthesis and characterization of additional compounds; HPLC spectrograms for advanced compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_003.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_001.pdb">jm9b01582_si_001.pdb (340.78 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_002.csv">jm9b01582_si_002.csv (2.77 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_003.pdf">jm9b01582_si_003.pdf (757.88 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">X-ray crystal structure of compound <b>36</b> in complex with MNK2, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JLR">6JLR</a>. Authors will release the atomic coordinates upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b01582" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50835" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50835" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alvin W. Hung</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9985-6794" title="Orcid link">http://orcid.org/0000-0002-9985-6794</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a4d3ccd1cac3e4c1c0c0c78ac589d7d0c5d68ac1c0d18ad7c3"><span class="__cf_email__" data-cfemail="ceb9a6bba0a98eabaaaaade0afe3bdbaafbce0abaabbe0bda9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacek Kwiatkowski</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Boping Liu</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shermaine Pang</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nur Huda Binte Ahmad</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gang Wang</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anders Poulsen</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haiyan Yang</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Rui Poh</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Doris Hui Ying Tee</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Esther Ong</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Priya Retna</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nurul Dinie</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Perlyn Kwek</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Liang Kuan Wee</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vithya Manoharan</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Choon Bing Low</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peck Gee Seah</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vishal Pendharkar</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kanda Sangthongpitag</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joma Joy</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nithya Baburajendran</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Elisabet Jansson</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kassoum Nacro</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Hill</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas H. Keller</span> - <span class="hlFld-Affiliation affiliation">Experimental Drug Development
Centre, Agency for Science, Technology and Research (A*STAR), 10 Biopolis Way, Chromos #05-01/06, 138670 Singapore</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d7e4498-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i68">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18884" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18884" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was in part supported by the Agency for Science, Technology and Research (A*STAR).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations used</td></tr><tr><td class="NLM_term">MNK1 and MNK2</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase-interacting kinase 1 and 2</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">MAP</td><td class="NLM_def"><p class="first last">p38 mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">eIF4E</td><td class="NLM_def"><p class="first last">translation initiation factor 4E</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsomes</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23085" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23085" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 37 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waskiewicz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimball, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, J. A.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of the Cap-binding Protein Eukaryotic Translation Initiation Factor 4E by Protein Kinase Mnk1 in vivo</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1871</span>– <span class="NLM_lpage">1880</span>, <span class="refDoi"> DOI: 10.1128/MCB.19.3.1871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1128%2FMCB.19.3.1871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10022874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADyaK1MXhsFeqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=1871-1880&author=A.+J.+Waskiewiczauthor=J.+C.+Johnsonauthor=B.+Pennauthor=M.+Mahalingamauthor=S.+R.+Kimballauthor=J.+A.+Cooper&title=Phosphorylation+of+the+Cap-binding+Protein+Eukaryotic+Translation+Initiation+Factor+4E+by+Protein+Kinase+Mnk1+in+vivo&doi=10.1128%2FMCB.19.3.1871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo</span></div><div class="casAuthors">Waskiewicz, Andrew Jan; Johnson, Jeffrey C.; Penn, Bennett; Mahalingam, Malathy; Kimball, Scot R.; Cooper, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1871-1880</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Eukaryotic translation initiation factor 4E (eIF4E) binds to the mRNA 5' cap and brings the mRNA into a complex with other protein synthesis initiation factors and ribosomes.  The activity of mammalian eIF4E is important for the translation of capped mRNAs and is thought to be regulated by two mechanisms.  First, eIF4E is sequestered by binding proteins, such as 4EBP1, in quiescent cells.  Mitogens induce the release of eIF4E by stimulating the phosphorylation of 4EBP1.  Second, mitogens and stresses induce the phosphorylation of eIF4E at Ser 209, increasing the affinity of eIF4E for capped mRNA and for an assocd. scaffolding protein, eIF4G.  We previously showed that a mitogen- and stress-activated kinase, Mnk1, phosphorylates eIF4E in vitro at the physiol. site.  Here we show that Mnk1 regulates eIF4E phosphorylation in vivo.  Mnk1 binds directly to eIF4G and copurifies with eIF4G and eIF4E.  We identified activating phosphorylation sites in Mnk1 and developed dominant-neg. and activated mutants.  Expression of dominant-neg. Mnk1 reduces mitogen-induced eIF4E phosphorylation, while expression of activated Mnk1 increases basal eIF4E phosphorylation.  Activated mutant Mnk1 also induces extensive phosphorylation of eIF4E in cells overexpressing 4EBP1.  This suggests that phosphorylation of eIF4E is catalyzed by Mnk1 or a very similar kinase in cells and is independent of other mitogenic signals that release eIF4E from 4EBP1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyB7rKOyL2XLVg90H21EOLACvtfcHk0linIkydg_1pJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsFeqtLo%253D&md5=b4b07e97e90a0c03e5b0d2320ac12508</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1128%2FMCB.19.3.1871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.19.3.1871%26sid%3Dliteratum%253Aachs%26aulast%3DWaskiewicz%26aufirst%3DA.%2BJ.%26aulast%3DJohnson%26aufirst%3DJ.%2BC.%26aulast%3DPenn%26aufirst%3DB.%26aulast%3DMahalingam%26aufirst%3DM.%26aulast%3DKimball%26aufirst%3DS.%2BR.%26aulast%3DCooper%26aufirst%3DJ.%2BA.%26atitle%3DPhosphorylation%2520of%2520the%2520Cap-binding%2520Protein%2520Eukaryotic%2520Translation%2520Initiation%2520Factor%25204E%2520by%2520Protein%2520Kinase%2520Mnk1%2520in%2520vivo%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D1871%26epage%3D1880%26doi%3D10.1128%2FMCB.19.3.1871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polunovsky, V. A.</span></span> <span> </span><span class="NLM_article-title">eIF4E-Mediated Translational Control of Cancer Incidence</span>. <i>Biochim. Biophys. Acta, Gene Regul. Mech.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1849</i></span>,  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1016/j.bbagrm.2014.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1016%2Fj.bbagrm.2014.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Kltb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1849&publication_year=2015&pages=774-780&author=P.+B.+Bittermanauthor=V.+A.+Polunovsky&title=eIF4E-Mediated+Translational+Control+of+Cancer+Incidence&doi=10.1016%2Fj.bbagrm.2014.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">eIF4E-mediated translational control of cancer incidence</span></div><div class="casAuthors">Bitterman, Peter B.; Polunovsky, Vitaly A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Regulatory Mechanisms</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1849</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">774-780</span>CODEN:
                <span class="NLM_cas:coden">BBAGC6</span>;
        ISSN:<span class="NLM_cas:issn">1874-9399</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mitogen activated translation initiation factor eIF4E mediates normal cell proliferation, yet induces tumorigenesis when deregulated and overexpressed.  It remains unknown, how activated eIF4E directs such distinct biol. outputs.  Our exptl. data provide evidence that distinct threshold levels of eIF4E govern its biol. output in lactating mammary glands and that eIF4E overexpression in the context of cell population expansion can initiate malignant transformation by enabling cells to evade DNA damage checkpoints caused by hyperproliferative oncogenic stimuli.  These findings point at the cellular level of eIF4E as an important sensor for normal or pro-neoplastic propagation of cells.  Here, we describe a model that links the pro-neoplastic function of eIF4F to its ability to disable oncogene-activated tumor surveillance programs; and propose a novel therapeutic strategy for cancer prevention based upon targeting aberrant eIF4E with safe doses of small-mol. antagonists to ensure the maintenance of eIF4E levels below the pro-neoplastic threshold.  This article is part of a Special Issue entitled: Translation and Cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIKLe6m68gmLVg90H21EOLACvtfcHk0linIkydg_1pJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Kltb%252FM&md5=a6522861c1834d11c677c6e9cfb74b6a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagrm.2014.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagrm.2014.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26aulast%3DPolunovsky%26aufirst%3DV.%2BA.%26atitle%3DeIF4E-Mediated%2520Translational%2520Control%2520of%2520Cancer%2520Incidence%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Regul.%2520Mech.%26date%3D2015%26volume%3D1849%26spage%3D774%26epage%3D780%26doi%3D10.1016%2Fj.bbagrm.2014.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumarasiri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">MAP Kinase-Interacting Kinases—Emerging Targets against Cancer</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2014.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1016%2Fj.chembiol.2014.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=24613018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslyitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=441-452&author=S.+Diabauthor=M.+Kumarasiriauthor=M.+Yuauthor=T.+Teoauthor=C.+Proudauthor=R.+Milneauthor=S.+Wang&title=MAP+Kinase-Interacting+Kinases%E2%80%94Emerging+Targets+against+Cancer&doi=10.1016%2Fj.chembiol.2014.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">MAP Kinase-Interacting Kinases-Emerging Targets against Cancer</span></div><div class="casAuthors">Diab, Sarah; Kumarasiri, Malika; Yu, Mingfeng; Teo, Theodosia; Proud, Christopher; Milne, Robert; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK)-interacting kinases (Mnks) regulate the initiation of translation through phosphorylation of eukaryotic initiation factor 4E (eIF4E).  Mnk-mediated eIF4E activation promotes cancer development and progression.  While the phosphorylation of eIF4E is necessary for oncogenic transformation, the kinase activity of Mnks seems dispensable for normal development.  For this reason, pharmacol. inhibition of Mnks could represent an ideal mechanism-based and nontoxic therapeutic strategy for cancer treatment.  In this review, we discuss the current understanding of Mnk biol. roles, structures, and functions, as well as clin. implications.  Importantly, we propose different strategies for identification of highly selective small mol. inhibitors of Mnks, including exploring a structural feature of their kinase domain, DFD motif, which is unique within the human kinome.  We also argue that a combined targeting of Mnks and other pathways should be considered given the complexity of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8J4FNfWRq27Vg90H21EOLACvtfcHk0lj8tAYzix8RAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslyitb0%253D&md5=472ef0f62dc9dc457139367b3a573c49</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2014.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2014.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DProud%26aufirst%3DC.%26aulast%3DMilne%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DMAP%2520Kinase-Interacting%2520Kinases%25E2%2580%2594Emerging%2520Targets%2520against%2520Cancer%26jtitle%3DChem.%2520Biol.%26date%3D2014%26volume%3D21%26spage%3D441%26epage%3D452%26doi%3D10.1016%2Fj.chembiol.2014.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe-Fukunaga, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukunaga, R.</span></span> <span> </span><span class="NLM_article-title">Mnk2 and Mnk1 Are Essential for Constitutive and Inducible Phosphorylation of Eukaryotic Initiation Factor 4E but Not for Cell Growth or Development</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6539</span>– <span class="NLM_lpage">6549</span>, <span class="refDoi"> DOI: 10.1128/MCB.24.15.6539-6549.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1128%2FMCB.24.15.6539-6549.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=15254222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlKltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=6539-6549&author=T.+Uedaauthor=R.+Watanabe-Fukunagaauthor=H.+Fukuyamaauthor=S.+Nagataauthor=R.+Fukunaga&title=Mnk2+and+Mnk1+Are+Essential+for+Constitutive+and+Inducible+Phosphorylation+of+Eukaryotic+Initiation+Factor+4E+but+Not+for+Cell+Growth+or+Development&doi=10.1128%2FMCB.24.15.6539-6549.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development</span></div><div class="casAuthors">Ueda, Takeshi; Watanabe-Fukunaga, Rie; Fukuyama, Hidehiro; Nagata, Shigekazu; Fukunaga, Rikiro</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6539-6549</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Mnk1 and Mnk2 are protein kinases that are directly phosphorylated and activated by extracellular signal-regulated kinase (ERK) or p38 mitogen-activated protein (MAP) kinases and implicated in the regulation of protein synthesis through their phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) at Ser209.  To investigate their physiol. functions, we generated mice lacking the Mnk1 or Mnk2 gene or both; the resulting KO mice were viable, fertile, and developed normally.  In embryonic fibroblasts prepd. from Mnk1-Mnk2 DKO mice, eIF4E was not detectably phosphorylated at Ser209, even when the ERK and/or p38 MAP kinases were activated.  Anal. of embryonic fibroblasts from single KO mice revealed that Mnk1 is responsible for the inducible phosphorylation of eIF4E in response to MAP kinase activation, whereas Mnk2 mainly contributes to eIF4E's basal, constitutive phosphorylation.  Lipopolysaccharide (LPS)- or insulin-induced upregulation of eIF4E phosphorylation in the spleen, liver, or skeletal muscle was abolished in Mnk1-/- mice, whereas the basal eIF4E phosphorylation levels were decreased in Mnk2-/- mice.  In Mnk1-Mnk2 DKO mice, no phosphorylated eIF4E was detected in any tissue studied, even after LPS or insulin injection.  However, neither general protein synthesis nor cap-dependent translation, as assayed by a bicistronic reporter assay system, was affected in Mnk-deficient embryonic fibroblasts, despite the absence of phosphorylated eIF4E.  Thus, Mnk1 and Mnk2 are exclusive eIF4E kinases both in cultured fibroblasts and adult tissues, and they regulate inducible and constitutive eIF4E phosphorylation, resp.  These results strongly suggest that eIF4E phosphorylation at Ser209 is not essential for cell growth during development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6LIGS-bIJs7Vg90H21EOLACvtfcHk0lj8tAYzix8RAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlKltLw%253D&md5=8ad9391afbf76148f4609f38d60b82aa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.15.6539-6549.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.15.6539-6549.2004%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DWatanabe-Fukunaga%26aufirst%3DR.%26aulast%3DFukuyama%26aufirst%3DH.%26aulast%3DNagata%26aufirst%3DS.%26aulast%3DFukunaga%26aufirst%3DR.%26atitle%3DMnk2%2520and%2520Mnk1%2520Are%2520Essential%2520for%2520Constitutive%2520and%2520Inducible%2520Phosphorylation%2520of%2520Eukaryotic%2520Initiation%2520Factor%25204E%2520but%2520Not%2520for%2520Cell%2520Growth%2520or%2520Development%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D6539%26epage%3D6549%26doi%3D10.1128%2FMCB.24.15.6539-6549.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saw, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzieri, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuah, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, S. T.</span></span> <span> </span><span class="NLM_article-title">Targeting of the MNK-eIF4E Axis in Blast Crisis Chronic Myeloid Leukemia Inhibits Leukemia Stem Cell Function</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">E2298</span>– <span class="NLM_lpage">E2307</span>, <span class="refDoi"> DOI: 10.1073/pnas.1301838110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1073%2Fpnas.1301838110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=23737503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOrtLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=E2298-E2307&author=S.+Limauthor=T.+Y.+Sawauthor=M.+Zhangauthor=M.+R.+Janesauthor=K.+Nacroauthor=J.+Hillauthor=A.+Q.+Limauthor=C.+T.+Changauthor=D.+A.+Frumanauthor=D.+A.+Rizzieriauthor=S.+Y.+Tanauthor=H.+Fanauthor=C.+T.+Chuahauthor=S.+T.+Ong&title=Targeting+of+the+MNK-eIF4E+Axis+in+Blast+Crisis+Chronic+Myeloid+Leukemia+Inhibits+Leukemia+Stem+Cell+Function&doi=10.1073%2Fpnas.1301838110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function</span></div><div class="casAuthors">Lim, Sharon; Saw, Tzuen Yih; Zhang, Min; Janes, Matthew R.; Nacro, Kassoum; Hill, Jeffrey; Lim, An Qi; Chang, Chia-Tien; Fruman, David A.; Rizzieri, David A.; Tan, Soo Yong; Fan, Hung; Chuah, Charles T. H.; Ong, S. Tiong</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">E2298-E2307, SE2298/1-SE2298/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Chronic myeloid leukemia responds well to therapy targeting the oncogenic fusion protein BCR-ABL1 in chronic phase, but is resistant to treatment after it progresses to blast crisis (BC).  BC is characterized by elevated β-catenin signaling in granulocyte macrophage progenitors (GMPs), which enables this population to function as leukemia stem cells (LSCs) and act as a reservoir for resistance.  Because normal hematopoietic stem cells (HSCs) and LSCs depend on β-catenin signaling for self-renewal, strategies to specifically target BC will require identification of drugable factors capable of distinguishing between self-renewal in BC LSCs and normal HSCs.  Here, we show that the MAP kinase interacting serine/threonine kinase (MNK)-eukaryotic translation initiation factor 4E (eIF4E) axis is overexpressed in BC GMPs but not normal HSCs, and that MNK kinase-dependent eIF4E phosphorylation at serine 209 activates β-catenin signaling in BC GMPs.  Mechanistically, eIF4E overexpression and phosphorylation leads to increased β-catenin protein synthesis, whereas MNK-dependent eIF4E phosphorylation is required for nuclear translocation and activation of β-catenin.  Accordingly, we found that a panel of small mol. MNK kinase inhibitors prevented eIF4E phosphorylation, β-catenin activation, and BC LSC function in vitro and in vivo.  Our findings identify the MNK-eIF4E axis as a specific and crit. regulator of BC self-renewal, and suggest that pharmacol. inhibition of the MNK kinases may be therapeutically useful in BC chronic myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsgaGxrYdhi7Vg90H21EOLACvtfcHk0ljJk3pQR1F9JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOrtLvO&md5=941bd3adbe64ba804179d77829636e40</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1301838110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1301838110%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%26aulast%3DSaw%26aufirst%3DT.%2BY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DNacro%26aufirst%3DK.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DA.%2BQ.%26aulast%3DChang%26aufirst%3DC.%2BT.%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRizzieri%26aufirst%3DD.%2BA.%26aulast%3DTan%26aufirst%3DS.%2BY.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DChuah%26aufirst%3DC.%2BT.%26aulast%3DOng%26aufirst%3DS.%2BT.%26atitle%3DTargeting%2520of%2520the%2520MNK-eIF4E%2520Axis%2520in%2520Blast%2520Crisis%2520Chronic%2520Myeloid%2520Leukemia%2520Inhibits%2520Leukemia%2520Stem%2520Cell%2520Function%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2013%26volume%3D110%26spage%3DE2298%26epage%3DE2307%26doi%3D10.1073%2Fpnas.1301838110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Mnk-eIF4E Pathway Sensitizes the Efficacy to Chemotherapy in Anaplastic Thyroid Cancer</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.2217/fon-2016-0320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.2217%2Ffon-2016-0320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=27785922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFChtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=489-498&author=K.+Huauthor=J.+Zhangauthor=M.+Yuauthor=C.+Xiong&title=Inhibition+of+Mnk-eIF4E+Pathway+Sensitizes+the+Efficacy+to+Chemotherapy+in+Anaplastic+Thyroid+Cancer&doi=10.2217%2Ffon-2016-0320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Mnk-eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer</span></div><div class="casAuthors">Hu, Kun; Zhang, Juan; Yu, Min; Xiong, Chang'e</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">489-498</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Aim: We investigated whether MAPK-interacting kinase (Mnk) inhibition sensitizes anaplastic thyroid cancer (ATC) cellular response to chemotherapy.  Materials & methods: In vitro and in vivo methods were used to examine the combinatory effects of cisplatin with Mnk inhibition and its underlying mechanism.  Results: Mnk inhibition by pharmacol. or genetic approaches inhibits proliferation and induces apoptosis of ATC cells and enhances the effects of cisplatin in in vitro and in vivo.  Mechanistically, cisplatin increases eIF4E phosphorylation in a dose- and time-dependent manner in ATC cells.  Mnk inhibitors sensitize the efficacy of cisplatin by inhibiting cisplatin-induced eIF4E phosphorylation.  Conclusion: Targeting Mnk-eIF4E pathway provides a therapeutic strategy by sensitizing ATC response to chemotherapeutic drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon-gxGzHGDx7Vg90H21EOLACvtfcHk0lhPuKQj6Wovuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFChtL8%253D&md5=829b3f57e9a27b7f47cb512d22be53f6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2217%2Ffon-2016-0320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2016-0320%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DXiong%26aufirst%3DC.%26atitle%3DInhibition%2520of%2520Mnk-eIF4E%2520Pathway%2520Sensitizes%2520the%2520Efficacy%2520to%2520Chemotherapy%2520in%2520Anaplastic%2520Thyroid%2520Cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2017%26volume%3D13%26spage%3D489%26epage%3D498%26doi%3D10.2217%2Ffon-2016-0320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span> <span> </span><span class="NLM_article-title">Inhibiting the MNK-eIF4E-beta-catenin Axis Increases the Responsiveness of Aggressive Breast Cancer Cells to Chemotherapy</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2906</span>– <span class="NLM_lpage">2915</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.18632%2Foncotarget.13772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=27926520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A280%3ADC%252BC2sjksVSmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=2906-2915&author=Z.+Liauthor=Y.+Sunauthor=M.+Quauthor=H.+Wanauthor=F.+Caiauthor=P.+Zhang&title=Inhibiting+the+MNK-eIF4E-beta-catenin+Axis+Increases+the+Responsiveness+of+Aggressive+Breast+Cancer+Cells+to+Chemotherapy&doi=10.18632%2Foncotarget.13772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting the MNK-eIF4E-β-catenin axis increases the responsiveness of aggressive breast cancer cells to chemotherapy</span></div><div class="casAuthors">Li Zhiqiang; Sun Yang; Wan Hongxing; Qu Miao; Cai Fang; Zhang Peng</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2906-2915</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Advanced breast cancer (eg. stage IV) is resistant to chemotherapy.  In this work, we identified potentially druggable targets that are critically involved in chemoresistance.  We showed that eIF4E is highly phosphorylated at serine 209 in breast cancer patients in response to chemotherapy, which significantly correlated with poorer clinical responses and outcomes.  Depletion of eIF4E enhanced the anti-proliferative and pro-apoptotic effects of chemotherapeutic drugs in breast cancer cells.  Chemotherapy activated the Wnt/β-catenin signaling in an eIF4E-dependent manner.  However, MNK inhibitors prevented chemotherapeutic drug-induced eIF4E phosphorylation and β-catenin activation, which enhanced the breast cancer cell response to chemotherapy in vitro and in vivo.  These findings indicate MNK-eIF4E-β-catenin is an activator of the breast cancer cell response to chemotherapy and highlights the therapeutic value of inhibiting MNK to overcome chemoresistance in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFLMaYGUFFINy3lHz94U-GfW6udTcc2eYM4VgfghTCsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjksVSmtw%253D%253D&md5=4a2f75dc03a3918b7f261b655a9855d8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13772%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DCai%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DP.%26atitle%3DInhibiting%2520the%2520MNK-eIF4E-beta-catenin%2520Axis%2520Increases%2520the%2520Responsiveness%2520of%2520Aggressive%2520Breast%2520Cancer%2520Cells%2520to%2520Chemotherapy%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D2906%26epage%3D2915%26doi%3D10.18632%2Foncotarget.13772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zha, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, M.</span></span> <span> </span><span class="NLM_article-title">Inhibiting ERK/Mnk/eIF4E Broadly Sensitizes Ovarian Cancer Response to Chemotherapy</span>. <i>Clin. Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1007/s12094-017-1724-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1007%2Fs12094-017-1724-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=28766096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1KqtL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=374-381&author=S.+Liuauthor=J.+Zhaauthor=M.+Lei&title=Inhibiting+ERK%2FMnk%2FeIF4E+Broadly+Sensitizes+Ovarian+Cancer+Response+to+Chemotherapy&doi=10.1007%2Fs12094-017-1724-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy</span></div><div class="casAuthors">Liu, S.; Zha, J.; Lei, M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">374-381</span>CODEN:
                <span class="NLM_cas:coden">CTOLAM</span>;
        ISSN:<span class="NLM_cas:issn">1699-048X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Italia S.r.l.</span>)
        </div><div class="casAbstract">To investigate whether ERK/MNK/eIF4E contributes chemoresistance in ovarian cancer.  The phosphorylated levels of Erk, Mnk, and eIF4E were systematically analyzed in ovarian cancer patients before and after chemotherapy, and ovarian cancer cells exposed to short- and long-term chemo-agent treatment.  The roles of Erk/Mnk/eIF4E were investigated using pharmacol. and genetic approaches.  Increased phosphorylation levels of ERK, Mnk1, and eIF4E were obsd. in ovarian cancer cell exposed to chemotherapeutic agents, and paclitaxel-resistant SK-OV-3-r cells, and is a common response of ovarian cancer patients undergoing chemotherapy.  MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner. eIF4E overexpression promotes ovarian cancer cell growth without affecting migration.  In addn., ovarian cancer cells with eIF4E overexpression are more resistant to chemotherapeutic agents in aspect of growth inhibition and apoptosis induction compared to control cells.  In contrast, eIF4E depletion augments chemotherapeutic agents' effect in ovarian cancer cells.  These demonstrate that eIF4E play roles in growth and chemoresistance in ovarian cancer.  MEK inhibitor U0126 also significantly enhances chemotherapeutic agents' inhibitory effects.  Our work shows that ERK/Mnk/eIF4E activation is critically involved in ovarian cancer chemoresistance and inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy9L6zDnxpNbVg90H21EOLACvtfcHk0lhPuKQj6Wovuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1KqtL3K&md5=c05ae9a8db7d198ccdab8b8e9a87d568</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs12094-017-1724-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12094-017-1724-0%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZha%26aufirst%3DJ.%26aulast%3DLei%26aufirst%3DM.%26atitle%3DInhibiting%2520ERK%252FMnk%252FeIF4E%2520Broadly%2520Sensitizes%2520Ovarian%2520Cancer%2520Response%2520to%2520Chemotherapy%26jtitle%3DClin.%2520Transl.%2520Oncol.%26date%3D2018%26volume%3D20%26spage%3D374%26epage%3D381%26doi%3D10.1007%2Fs12094-017-1724-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Targeting the eIF4E/beta-catenin Axis Sensitizes Cervical Carcinoma Squamous Cells to Chemotherapy</span>. <i>Am. J. Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1203</span>– <span class="NLM_lpage">1212</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=28386346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFelsrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1203-1212&author=H.+Xuauthor=Z.+Wangauthor=L.+Xuauthor=G.+Moauthor=G.+Duanauthor=Y.+Wangauthor=Z.+Sunauthor=H.+Chen&title=Targeting+the+eIF4E%2Fbeta-catenin+Axis+Sensitizes+Cervical+Carcinoma+Squamous+Cells+to+Chemotherapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the eIF4E/β-catenin axis sensitizes cervical carcinoma squamous cells to chemotherapy</span></div><div class="casAuthors">Xu, Hai; Wang, Zhiyin; Xu, Lang; Mo, Guoyan; Duan, Gangfeng; Wang, Yali; Sun, Zhengang; Chen, Hao</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Translational Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1203-1212</span>CODEN:
                <span class="NLM_cas:coden">AJTRA7</span>;
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Chemotherapy has improved the clin. outcomes of cervical cancer patients.  However, patients develop chemoresistance, whose underlying mechanisms are not well understood.  In this study, we investigated the phosphorylation levels of eukaryotic translation initiation factor 4E (eIF4E) in cervical cancer cells subjected to chemotherapy.  Results showed that chemotherapeutic drugs significantly increased eIF4E phosphorylation at S209 in HeLa and SiHa cells.  Upregulation of phosphorylated eIF4E (p-eIF4E) levels has also been shown in cisplatin-resistant HeLa cells and has been obsd. to be a common response of cervical cancer patients undergoing chemotherapy.  We further showed that chemotherapeutic drugs increase β-catenin activity and mRNA levels of Wnt/β-catenin target genes in cervical cancer cells but not in eIF4E-depleted cells, suggesting that chemotherapeutic drugs activate Wnt/β-catenin signaling in an eIF4E-dependent manner.  Inhibiting eIF4E via siRNA knockdown or Wnt/β-catenin using the Wnt inhibitor pyrvinium effectively enhanced the anti-proliferative and pro-apoptotic effects of cisplatin in cervical cancer cells both in vitro and in vivo.  Our findings demonstrate that eIF4E/β-catenin signaling plays a pos. regulatory role in the resistance of cervical cancer cell to chemotherapy and thus highlight the therapeutic value of eIF4E or β-catenin inhibition in overcoming chemoresistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaWWocBFM5A7Vg90H21EOLACvtfcHk0lg_4ko3Agm3tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFelsrjO&md5=07445b6e9ec17f389f32b7a0fb5e92ca</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DMo%26aufirst%3DG.%26aulast%3DDuan%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DTargeting%2520the%2520eIF4E%252Fbeta-catenin%2520Axis%2520Sensitizes%2520Cervical%2520Carcinoma%2520Squamous%2520Cells%2520to%2520Chemotherapy%26jtitle%3DAm.%2520J.%2520Transl.%2520Res.%26date%3D2017%26volume%3D9%26spage%3D1203%26epage%3D1212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-b.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-m.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.-b.</span></span> <span> </span><span class="NLM_article-title">MNK1 Inhibitor CGP57380 Overcomes MTOR Inhibitor-Induced Activation of EIF4E: The Mechanism of Synergic Killing of Human T-ALL Cells</span>. <i>Acta Pharmacologica Sinica</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1894</span>– <span class="NLM_lpage">1901</span>, <span class="refDoi"> DOI: 10.1038/s41401-018-0161-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1038%2Fs41401-018-0161-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=30297804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVyhurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=1894-1901&author=X.-b.+Huangauthor=C.-m.+Yangauthor=Q.-M.+Hanauthor=X.-J.+Yeauthor=W.+Leiauthor=W.-b.+Qian&title=MNK1+Inhibitor+CGP57380+Overcomes+MTOR+Inhibitor-Induced+Activation+of+EIF4E%3A+The+Mechanism+of+Synergic+Killing+of+Human+T-ALL+Cells&doi=10.1038%2Fs41401-018-0161-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells</span></div><div class="casAuthors">Huang, Xian-bo; Yang, Chun-mei; Han, Qing-mei; Ye, Xiu-jin; Lei, Wen; Qian, Wen-bin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1894-1901</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Although the treatment of adult T-cell acute lymphoblastic leukemia (T-ALL) has been significantly improved, the heterogeneous genetic landscape of the disease often causes relapse.  Aberrant activation of mammalian target of rapamycin (mTOR) pathway in T-ALL is responsible for treatment failure and relapse, suggesting that mTOR inhibition may represents a new therapeutic strategy.  In this study, we investigated whether the mTOR complex 1 (mTORC1) inhibitor everolimus could be used as a therapeutic agent against human T-ALL.  We showed that rapamycin and its analog RAD001 (everolimus) exerted only mild inhibition on the viability of Jurkat, CEM and Molt-4 cell lines (for everolimus the max. inhibition was <40% at 100 nM), but greatly enhanced the phosphorylation of eIF4E, a downstream substrate of MAPK-interacting kinase (MNK) that was involved in promoting cell survival.  Furthermore, we demonstrated in Jurkat cells that mTOR inhibitor-induced eIF4E phosphorylation was independent of insulin-like growth factor-1/insulin-like growth factor-1 receptor axis, but was secondary to mTOR inhibition.  Then we examd. the antileukemia effects of CGP57380, a MNK1 inhibitor, and we found that CGP57380 (4-16 μM) dose-dependently suppressed the expression of both phosphor-MNK1 and phosphor-eIF4E, thereby inhibiting downstream targets such as c-Myc and survivin in T-ALL cells.  Importantly, CGP57380 produced a synergistic growth inhibitory effect with everolimus in T-ALL cells, and treatment with this targeted therapy overcame everolimus-induced eIF4E phosphorylation.  In conclusion, our results suggest that dual-targeting of mTOR and MNK1/eIF4E signaling pathways may represent a novel therapeutic strategy for the treatment of human T-ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY6QPQhjjBz7Vg90H21EOLACvtfcHk0lg_4ko3Agm3tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVyhurjK&md5=557809deb55f8915f93f6f02ab7091be</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fs41401-018-0161-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-018-0161-0%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.-b.%26aulast%3DYang%26aufirst%3DC.-m.%26aulast%3DHan%26aufirst%3DQ.-M.%26aulast%3DYe%26aufirst%3DX.-J.%26aulast%3DLei%26aufirst%3DW.%26aulast%3DQian%26aufirst%3DW.-b.%26atitle%3DMNK1%2520Inhibitor%2520CGP57380%2520Overcomes%2520MTOR%2520Inhibitor-Induced%2520Activation%2520of%2520EIF4E%253A%2520The%2520Mechanism%2520of%2520Synergic%2520Killing%2520of%2520Human%2520T-ALL%2520Cells%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26date%3D2018%26volume%3D39%26spage%3D1894%26epage%3D1901%26doi%3D10.1038%2Fs41401-018-0161-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alnemah, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span> <span> </span><span class="NLM_article-title">CGP57380 Enhances Efficacy of RAD001 in Non-Small Cell Lung Cancer through Abrogating MTOR Inhibition-Induced Phosphorylation of EIF4E and Activating Mitochondrial Apoptotic Pathway</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">27787</span>– <span class="NLM_lpage">27801</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.18632%2Foncotarget.8497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=27050281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A280%3ADC%252BC28fntV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=27787-27801&author=Q.+Wenauthor=W.+Wangauthor=J.+Luoauthor=S.+Chuauthor=L.+Chenauthor=L.+Xuauthor=H.+Zangauthor=M.+M.+Alnemahauthor=J.+Maauthor=S.+Fan&title=CGP57380+Enhances+Efficacy+of+RAD001+in+Non-Small+Cell+Lung+Cancer+through+Abrogating+MTOR+Inhibition-Induced+Phosphorylation+of+EIF4E+and+Activating+Mitochondrial+Apoptotic+Pathway&doi=10.18632%2Foncotarget.8497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway</span></div><div class="casAuthors">Wen Qiuyuan; Wang Weiyuan; Luo Jiadi; Chu Shuzhou; Chen Lingjiao; Xu Lina; Zang Hongjing; Alnemah Mohannad Ma; Fan Songqing; Ma Jian</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">27787-801</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) is a potentially important therapeutic target in a broad range of cancer types. mTOR inhibitors such as rapamycin and its analogs (rapalogs) have been proven effective as anticancer agents in non-small cell lung cancer (NSCLC), whereas they strongly enhance phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) and activation of Akt, which cause resistance to mTOR-targeted therapy after an initial response.  Rapamycin induces eIF4E phosphorylation by activating MAPK-interacting kinases (Mnks), and therefore targeting Mnk/eIF4E pathway represents a potential therapeutic strategy for the treatment of NSCLC.  Here, our results showed that over-expression of p-Mnk1 and p-eIF4E was significantly associated with poor overall survival of NSCLC patients and high expression of p-Mnk1 might act as an independent prognostic biomarker for these patients.  Meanwhile, inhibiting Mnk1 expression by Mnk inhibitor (CGP57380) could abrogate rapalogs (RAD001)-induced eIF4E phosphorylation and Akt activation.  Furthermore, combination of CGP57380 and RAD001 could induce NSCLC cells apoptosis via activating intrinsic mitochondrial pathway, and exert synergistic antitumor efficacy both in vitro and in vivo.  In conclusion, combination of targeting both mTOR and Mnk/eIF4E signaling pathways to enhance effectiveness of mTOR-targeted cancer therapy might be significant innovation for the personalized treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFBfYlcnA1Rzjk2McQZ6XmfW6udTcc2eb8z9KHceP01rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fntV2ktg%253D%253D&md5=f9c54c7e35d37d04d0d039039883c5fb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8497%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DChu%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DZang%26aufirst%3DH.%26aulast%3DAlnemah%26aufirst%3DM.%2BM.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DS.%26atitle%3DCGP57380%2520Enhances%2520Efficacy%2520of%2520RAD001%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520through%2520Abrogating%2520MTOR%2520Inhibition-Induced%2520Phosphorylation%2520of%2520EIF4E%2520and%2520Activating%2520Mitochondrial%2520Apoptotic%2520Pathway%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D27787%26epage%3D27801%26doi%3D10.18632%2Foncotarget.8497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Significance of MNK1 in Prognostic Prediction and Chemotherapy Development of Epithelial Ovarian Cancer</span>. <i>Clin. Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1116</span>, <span class="refDoi"> DOI: 10.1007/s12094-017-1646-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1007%2Fs12094-017-1646-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=28332091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslOlu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=1107-1116&author=S.+Houauthor=P.+Duauthor=P.+Wangauthor=C.+Wangauthor=P.+Liuauthor=H.+Liu&title=Significance+of+MNK1+in+Prognostic+Prediction+and+Chemotherapy+Development+of+Epithelial+Ovarian+Cancer&doi=10.1007%2Fs12094-017-1646-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer</span></div><div class="casAuthors">Hou, S.; Du, P.; Wang, P.; Wang, C.; Liu, P.; Liu, H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1107-1116</span>CODEN:
                <span class="NLM_cas:coden">CTOLAM</span>;
        ISSN:<span class="NLM_cas:issn">1699-048X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Italia S.r.l.</span>)
        </div><div class="casAbstract">Background: Ovarian cancer is the most lethal gynecol. malignancy worldwide with surgery as the only curative treatment.  Long-term overall survival (OS) of ovarian cancer is far from satisfactory, even though significant improvement has been made in post-operative chemotherapy.  One of the most important death cause is the chemoresistance due to consecutive chemotherapy.  Therefore, understanding the mol. mechanisms involved in ovarian cancer development and identification of novel therapeutic targets are urgently required.  Methods: Immunohistochem. (IHC) staining was used to explore the expression pattern of mitogen-activated protein kinase (MAPK)-interacting kinase 1 (MNK1) in tumor tissues from 138 epithelial ovarian cancer (EOC) patients.  Clinicopathol. data were subjected to Kaplan-Meier survival and Cox multivariate analyses to evaluate the prognostic value of MNK1 in EOC.  Overexpression and silencing procedures were performed on OVCAR-5 cells to investigate the mechanisms of MNK1 in regulating EOC development.  The anti-tumor effects of CGP57380, a specific MNK inhibitor, were examd. by cell viability assay.  Results: Higher MNK1 expression showed significant relationship with advanced FIGO stage and pos. lymph node metastasis of EOC.  Univariate and multivariate analyses revealed that MNK1 was an independent prognostic factor for OS of EOC patients.  In vitro study demonstrated that MNK1 can promote cell proliferation through regulating the phosphorylation level of eukaryotic initiation factor 4E.  In addn., inhibition of MNK1 by CGP57380 significantly down-regulated the OVCAR-5 cell viability.  Conclusion: High MNK1 expression in EOC tissues indicates poor clin. outcomes, and MNK1 can act as a potential target for novel chemotherapy development towards EOC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9D2pcdqzgXbVg90H21EOLACvtfcHk0liq-Wt3Q4RGPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslOlu7k%253D&md5=b92796f616edab6ee14557021bb1d77f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs12094-017-1646-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12094-017-1646-x%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DSignificance%2520of%2520MNK1%2520in%2520Prognostic%2520Prediction%2520and%2520Chemotherapy%2520Development%2520of%2520Epithelial%2520Ovarian%2520Cancer%26jtitle%3DClin.%2520Transl.%2520Oncol.%26date%3D2017%26volume%3D19%26spage%3D1107%26epage%3D1116%26doi%3D10.1007%2Fs12094-017-1646-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dreas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikulski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabritius, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzózka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rzymski, T.</span></span> <span> </span><span class="NLM_article-title">Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3025</span>– <span class="NLM_lpage">3053</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170203123427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.2174%2F0929867324666170203123427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=28164761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1SqsrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=3025-3053&author=A.+Dreasauthor=M.+Mikulskiauthor=M.+Milikauthor=C.+H.+Fabritiusauthor=K.+Brz%C3%B3zkaauthor=T.+Rzymski&title=Mitogen-activated+Protein+Kinase+%28MAPK%29+Interacting+Kinases+1+and+2+%28MNK1+and+MNK2%29+as+Targets+for+Cancer+Therapy%3A+Recent+Progress+in+the+Development+of+MNK+Inhibitors&doi=10.2174%2F0929867324666170203123427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors</span></div><div class="casAuthors">Dreas, Agnieszka; Mikulski, Maciej; Milik, Mariusz; Fabritius, Charles-Henry; Brzozka, Krzysztof; Rzymski, Tomasz</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3025-3053</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">MAP kinase-interacting kinases (MNK1 and MNK2) are often activated downstream of ERK and p38 MAPK in the MAP kinase family.  The role of MNKs in the development and progression of solid tumors and hematol. malignancies has been widely discussed, particularly in the context of cap dependent translation, regulated by phosphorylation of eIF4E.  MNK/eIF4E axis is involved in the expression of pro angiogenic, antiapoptotic, cell cycle, and motility proteins, such as MCL1, VEGF, MMP3, SNAIL, SMAD2, β-catenin or cyclin D1, and is essential during Ras and c Myc-induced transformation.  MNK1/2 emerged as eligible targets for drug discovery in oncol., based on the antitumor effects obsd. in genetic knockout and RNA interference expts. and at the same time lack of adverse effects in dual knockout animals. </P><P> There is a high interest in the development of pharmacol. inhibitors of MNK1/2 as not only tools for further basic research studies but also potential drugs in diseases characterized by deregulated translation.  Unfortunately, the role of MNK1/2 in cancer still remains elusive due to the absence of potent and selective probes.  Moreover, in many instances, hypotheses have been built reliant upon unspecific MNK1/2 inhibitors such as CGP57380 or cercosporamide.  Lately, the first two clin. programs targeting MNKs in oncol. have been revealed (eFT508 and BAY 1143269), although several other MNK programs are currently running at the preclin. stage.  This review aims to provide an overview of recent progress in the development of MNK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjWDeCrlHD07Vg90H21EOLACvtfcHk0ljVxGObwIrsmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1SqsrnI&md5=c2a37d37d69521b11a38bb100e7964af</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170203123427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170203123427%26sid%3Dliteratum%253Aachs%26aulast%3DDreas%26aufirst%3DA.%26aulast%3DMikulski%26aufirst%3DM.%26aulast%3DMilik%26aufirst%3DM.%26aulast%3DFabritius%26aufirst%3DC.%2BH.%26aulast%3DBrz%25C3%25B3zka%26aufirst%3DK.%26aulast%3DRzymski%26aufirst%3DT.%26atitle%3DMitogen-activated%2520Protein%2520Kinase%2520%2528MAPK%2529%2520Interacting%2520Kinases%25201%2520and%25202%2520%2528MNK1%2520and%2520MNK2%2529%2520as%2520Targets%2520for%2520Cancer%2520Therapy%253A%2520Recent%2520Progress%2520in%2520the%2520Development%2520of%2520MNK%2520Inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26volume%3D24%26spage%3D3025%26epage%3D3053%26doi%3D10.2174%2F0929867324666170203123427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santag, S.</span>; <span class="NLM_string-name">Siegel, F.</span>; <span class="NLM_string-name">Wegner, A. M.</span>; <span class="NLM_string-name">Schneider, C.</span>; <span class="NLM_string-name">Boemer, U.</span>; <span class="NLM_string-name">Eis, K.</span>; <span class="NLM_string-name">Puehler, F.</span>; <span class="NLM_string-name">Michels, M.</span>; <span class="NLM_string-name">von Nussbaum, F.</span>; <span class="NLM_string-name">Ziegelbauer, K.</span>; <span class="NLM_string-name">Mumberg, D.</span>; <span class="NLM_string-name">Petersen, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical Anti-Tumor Efficacy and Mode of Action of a Novel, Orally Available, Selective MKNK1 Inhibitor (BAY1143269)</span>. Annual Meeting of the American Association for Cancer Research <span class="NLM_year">2015</span>. 1143269.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+Santag&author=F.+Siegel&author=A.+M.+Wegner&author=C.+Schneider&author=U.+Boemer&author=K.+Eis&author=F.+Puehler&author=M.+Michels&author=F.+von+Nussbaum&author=K.+Ziegelbauer&author=D.+Mumberg&author=K.+Petersen&title=Preclinical+Anti-Tumor+Efficacy+and+Mode+of+Action+of+a+Novel%2C+Orally+Available%2C+Selective+MKNK1+Inhibitor+%28BAY1143269%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DSantag%26aufirst%3DS.%26atitle%3DPreclinical%2520Anti-Tumor%2520Efficacy%2520and%2520Mode%2520of%2520Action%2520of%2520a%2520Novel%252C%2520Orally%2520Available%252C%2520Selective%2520MKNK1%2520Inhibitor%2520%2528BAY1143269%2529%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelaziz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basnet, S. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekonnen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.2174/1573406415666181219111511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.2174%2F1573406415666181219111511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=30569866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslWrs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=602-623&author=A.+M.+Abdelazizauthor=S.+Diabauthor=S.+Islamauthor=S.+K.+C.+Basnetauthor=B.+Nollauthor=P.+Liauthor=L.+B.+Mekonnenauthor=J.+Luauthor=H.+Albrechtauthor=R.+W.+Milneauthor=C.+Gerberauthor=M.+Yuauthor=S.+Wang&title=Discovery+of+N-phenyl-4-%281H-pyrrol-3-yl%29pyrimidin-2-amine+Derivatives+as+Potent+Mnk2+Inhibitors%3A+Design%2C+Synthesis%2C+SAR+Analysis%2C+and+Evaluation+of+in+vitro+Anti-leukaemic+Activity&doi=10.2174%2F1573406415666181219111511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity</span></div><div class="casAuthors">Abdelaziz, Ahmed M.; Diab, Sarah; Islam, Saiful; Basnet, Sunita K. C.; Noll, Benjamin; Li, Peng; Mekonnen, Laychiluh B.; Lu, Jingfeng; Albrecht, Hugo; Milne, Robert W.; Gerber, Cobus; Yu, Mingfeng; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">602-623</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Aberrant expression of eukaryotic translation initiation factor 4E (eIF4E) is common in many types of cancer including acute myeloid leukemia (AML).  Phosphorylation of eIF4E by MAPK-interacting kinases (Mnks) is essential for the eIF4E-mediated oncogenic activity.  As such, the pharmacol. inhibition of Mnks can be an effective strategy for the treatment of cancer.  Methods: A series of N-phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine derivs. was designed and synthesized.  The Mnk inhibitory activity of these derivs. as well as their anti-proliferative activity against MV4-11 AML cells was detd.  Results: These compds. were identified as potent Mnk2 inhibitors.  Most of them demonstrated potent anti-proliferative activity against MV4-11 AML cells.  The cellular mechanistic studies of the representative inhibitors revealed that they reduced the level of phosphorylated eIF4E and induced apoptosis by down-regulating the anti-apoptotic protein myeloid cell leukemia 1 (Mcl-1) and by cleaving poly(ADP-ribose)polymerase (PARP).  The lead compd. 7k possessed desirable pharmacokinetic properties and oral bioavailability.  Conclusion: This work proposes that exploration of the structural diversity in the context of Nphenyl- 4-(1H-pyrrol-3-yl)pyrimidin-2-amine would offer potent and selective Mnk inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou_LM2pLMYxbVg90H21EOLACvtfcHk0ljTURbhupXRdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslWrs7zN&md5=fac36273eab8d9ee46dd221f488250eb</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F1573406415666181219111511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573406415666181219111511%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelaziz%26aufirst%3DA.%2BM.%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DIslam%26aufirst%3DS.%26aulast%3DBasnet%26aufirst%3DS.%2BK.%2BC.%26aulast%3DNoll%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DMekonnen%26aufirst%3DL.%2BB.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DMilne%26aufirst%3DR.%2BW.%26aulast%3DGerber%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520N-phenyl-4-%25281H-pyrrol-3-yl%2529pyrimidin-2-amine%2520Derivatives%2520as%2520Potent%2520Mnk2%2520Inhibitors%253A%2520Design%252C%2520Synthesis%252C%2520SAR%2520Analysis%252C%2520and%2520Evaluation%2520of%2520in%2520vitro%2520Anti-leukaemic%2520Activity%26jtitle%3DMed.%2520Chem.%26date%3D2019%26volume%3D15%26spage%3D602%26epage%3D623%26doi%3D10.2174%2F1573406415666181219111511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poh, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaraj, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joy, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwek, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wee, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choong, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendharkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangthongpitag, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3063</span>– <span class="NLM_lpage">3078</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVaisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3063-3078&author=J.+Cherianauthor=K.+Nacroauthor=Z.+Y.+Pohauthor=S.+Guoauthor=D.+A.+Jeyarajauthor=Y.+X.+Wongauthor=M.+Hoauthor=H.+Y.+Yangauthor=J.+K.+Joyauthor=Z.+P.+Kwekauthor=B.+Liuauthor=J.+L.+Weeauthor=E.+H.+Ongauthor=M.+L.+Choongauthor=A.+Poulsenauthor=M.+A.+Leeauthor=V.+Pendharkarauthor=L.+J.+Dingauthor=V.+Manoharanauthor=Y.+S.+Chewauthor=K.+Sangthongpitagauthor=S.+Limauthor=S.+T.+Ongauthor=J.+Hillauthor=T.+H.+Keller&title=Structure-Activity+Relationship+Studies+of+Mitogen+Activated+Protein+Kinase+Interacting+Kinase+%28MNK%29+1+and+2+and+BCR-ABL1+Inhibitors+Targeting+Chronic+Myeloid+Leukemic+Cells&doi=10.1021%2Facs.jmedchem.5b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells</span></div><div class="casAuthors">Cherian, Joseph; Nacro, Kassoum; Poh, Zhi Ying; Guo, Samantha; Jeyaraj, Duraiswamy A.; Wong, Yun Xuan; Ho, Melvyn; Yang, Hai Yan; Joy, Joma Kanikadu; Kwek, Zekui Perlyn; Liu, Boping; Wee, John Liang Kuan; Ong, Esther HQ; Choong, Meng Ling; Poulsen, Anders; Lee, May Ann; Pendharkar, Vishal; Ding, Li Jun; Manoharan, Vithya; Chew, Yun Shan; Sangthongpitag, Kanda; Lim, Sharon; Ong, S. Tiong; Hill, Jeffrey; Keller, Thomas H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3063-3078</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin. used BCR-ABL1 inhibitors for the treatment of chronic myeloid leukemia do not eliminate leukemic stem cells (LSC).  It has been shown that MNK1 and 2 inhibitors prevent phosphorylation of eIF4E and eliminate the self-renewal capacity of LSCs.  Herein, the authors describe the identification of novel dual MNK1 and 2 and BCR-ABL1 inhibitors, starting from the known kinase inhibitor.  Initial structure-activity relationship studies resulted in a compd. with loss of BCR-ABL1 inhibition.  Further modification led to orally bioavailable dual MNK1 and 2 and BCR-ABL1 inhibitors I and II, which are efficacious in a mouse xenograft model and also reduce the level of phosphorylated eukaryotic translation initiation factor 4E in the tumor tissues.  Kinase selectivity of these compds. is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4wVNbiR5xDrVg90H21EOLACvtfcHk0ljTURbhupXRdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVaisbk%253D&md5=4adfe2099cc1bb7fa5e0db8cb9358844</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCherian%26aufirst%3DJ.%26aulast%3DNacro%26aufirst%3DK.%26aulast%3DPoh%26aufirst%3DZ.%2BY.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DJeyaraj%26aufirst%3DD.%2BA.%26aulast%3DWong%26aufirst%3DY.%2BX.%26aulast%3DHo%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DJoy%26aufirst%3DJ.%2BK.%26aulast%3DKwek%26aufirst%3DZ.%2BP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DWee%26aufirst%3DJ.%2BL.%26aulast%3DOng%26aufirst%3DE.%2BH.%26aulast%3DChoong%26aufirst%3DM.%2BL.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DM.%2BA.%26aulast%3DPendharkar%26aufirst%3DV.%26aulast%3DDing%26aufirst%3DL.%2BJ.%26aulast%3DManoharan%26aufirst%3DV.%26aulast%3DChew%26aufirst%3DY.%2BS.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DLim%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DS.%2BT.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26atitle%3DStructure-Activity%2520Relationship%2520Studies%2520of%2520Mitogen%2520Activated%2520Protein%2520Kinase%2520Interacting%2520Kinase%2520%2528MNK%2529%25201%2520and%25202%2520and%2520BCR-ABL1%2520Inhibitors%2520Targeting%2520Chronic%2520Myeloid%2520Leukemic%2520Cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3063%26epage%3D3078%26doi%3D10.1021%2Facs.jmedchem.5b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basnet, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Unveiling New Chemical Scaffolds as Mnk Inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.4155/fmc.15.190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.4155%2Ffmc.15.190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=26910782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtlKjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=271-285&author=S.+Diabauthor=P.+Liauthor=S.+K.+Basnetauthor=J.+Luauthor=M.+Yuauthor=H.+Albrechtauthor=R.+W.+Milneauthor=S.+Wang&title=Unveiling+New+Chemical+Scaffolds+as+Mnk+Inhibitors&doi=10.4155%2Ffmc.15.190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Unveiling new chemical scaffolds as Mnk inhibitors</span></div><div class="casAuthors">Diab, Sarah; Li, Peng; Basnet, Sunita; Lu, Jingfeng; Yu, Mingfeng; Albrecht, Hugo; Milne, Robert W.; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-285</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The discovery of small mols. that selectively inhibit Mnks is considered of paramount importance towards deciphering the exact role of these proteins in carcinogenesis and to further validate them as anti-cancer drug targets.  However, the dearth of structural information of Mnks is a major hurdle.  This study unveils the 7H-pyrrolo[2,3-d]pyrimidine derivs. as potent inhibitors of Mnks.  ATP and substrate competition assays showed that this scaffold interacts with the ATP binding site, but not with the substrate site.  Screened against a panel of cancer cells, Mnk inhibitors were most potent against MV4-11 acute myeloid leukemia cells.  The induction of apoptosis was shown to be mediated by downregulation of Mcl-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOx0Xl19uq77Vg90H21EOLACvtfcHk0liEIzp1M4UjSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtlKjsrg%253D&md5=96a4d887691ff1162b703dffc2ccc352</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4155%2Ffmc.15.190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.15.190%26sid%3Dliteratum%253Aachs%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DBasnet%26aufirst%3DS.%2BK.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DMilne%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DUnveiling%2520New%2520Chemical%2520Scaffolds%2520as%2520Mnk%2520Inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D271%26epage%3D285%26doi%3D10.4155%2Ffmc.15.190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanidi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, C. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1&2) Utilizing Structure-Based Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3034</span>– <span class="NLM_lpage">3045</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01657</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01657" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1eit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3034-3045&author=W.+Hanauthor=Y.+Dingauthor=Y.+Xuauthor=K.+Pfisterauthor=S.+Zhuauthor=B.+Warneauthor=M.+Doyleauthor=M.+Aikawaauthor=P.+Amiriauthor=B.+Appletonauthor=D.+D.+Stuartauthor=A.+Fanidiauthor=C.+M.+Shafer&title=Discovery+of+a+Selective+and+Potent+Inhibitor+of+Mitogen-Activated+Protein+Kinase-Interacting+Kinases+1+and+2+%28MNK1%262%29+Utilizing+Structure-Based+Drug+Design&doi=10.1021%2Facs.jmedchem.5b01657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design</span></div><div class="casAuthors">Han, Wooseok; Ding, Yu; Xu, Yongjin; Pfister, Keith; Zhu, Shejin; Warne, Bob; Doyle, Mike; Aikawa, Mina; Amiri, Payman; Appleton, Brent; Stuart, Darrin D.; Fanidi, Abdallah; Shafer, Cynthia M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3034-3045</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of a highly potent and selective small mol. inhibitor I for in vitro target validation of MNK1/2 kinases is described.  The aminopyrazine benzimidazole series was derived from an HTS hit and optimized by utilization of a docking model, conformation anal., and binding pocket comparison against antitargets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBT5jenqIBHLVg90H21EOLACvtfcHk0liEIzp1M4UjSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1eit7s%253D&md5=b4c3eb8122635da657fa52daddb6879a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01657%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DWarne%26aufirst%3DB.%26aulast%3DDoyle%26aufirst%3DM.%26aulast%3DAikawa%26aufirst%3DM.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DAppleton%26aufirst%3DB.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26aulast%3DFanidi%26aufirst%3DA.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26atitle%3DDiscovery%2520of%2520a%2520Selective%2520and%2520Potent%2520Inhibitor%2520of%2520Mitogen-Activated%2520Protein%2520Kinase-Interacting%2520Kinases%25201%2520and%25202%2520%2528MNK1%25262%2529%2520Utilizing%2520Structure-Based%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3034%26epage%3D3045%26doi%3D10.1021%2Facs.jmedchem.5b01657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albarran, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacios, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbano-Cuadrado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reymundo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrionero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fominaya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, J. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of Mitogen-Activated Protein Kinase-Interacting Kinase 1 Inhibitors by a Comprehensive Fragment-Oriented Virtual Screening Approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6618</span>– <span class="NLM_lpage">6628</span>, <span class="refDoi"> DOI: 10.1021/jm1005513</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1005513" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCns7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6618-6628&author=J.+Oyarzabalauthor=N.+Zarichauthor=M.+I.+Albarranauthor=I.+Palaciosauthor=M.+Urbano-Cuadradoauthor=G.+Mateosauthor=I.+Reymundoauthor=O.+Rabalauthor=A.+Salgadoauthor=A.+Corrioneroauthor=J.+Fominayaauthor=J.+Pastorauthor=J.+R.+Bischoff&title=Discovery+of+Mitogen-Activated+Protein+Kinase-Interacting+Kinase+1+Inhibitors+by+a+Comprehensive+Fragment-Oriented+Virtual+Screening+Approach&doi=10.1021%2Fjm1005513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Mitogen-Activated Protein Kinase-Interacting Kinase 1 Inhibitors by a Comprehensive Fragment-Oriented Virtual Screening Approach</span></div><div class="casAuthors">Oyarzabal, Julen; Zarich, Natasha; Albarran, Maria Isabel; Palacios, Irene; Urbano-Cuadrado, Manuel; Mateos, Genoveva; Reymundo, Isabel; Rabal, Obdulia; Salgado, Antonio; Corrionero, Ana; Fominaya, Jesus; Pastor, Joaquin; Bischoff, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6618-6628</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1 and MNK2) phosphorylate the oncogene eIF4E on serine 209.  This phosphorylation has been reported to be required for its oncogenic activity.  To investigate if pharmacol. inhibition of MNK1 could be useful for the treatment of cancers, we pursued a comprehensive virtual screening approach to rapidly identify pharmacol. tools for target validation and to find optimal starting points for a plausible medicinal chem. project.  A collection of 1236 compds., selected from a library of 42 168 compds. and a database of 18.8 million structures, were assayed.  Of the identified hits, 26 were found to have IC50 values less than 10 μM (2.10% hit rate).  The most potent compd. had an IC50 value of 117 nM, and 73.1% of these hits were fragments.  The hits were characterized by a high ligand efficiency (0.32-0.52 kcal/mol per heavy atom).  Ten different chem. scaffolds were represented, giving a chemotype/hit ratio of 0.38.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWli1zSitx8LVg90H21EOLACvtfcHk0li_Cb7B-AJDjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCns7nM&md5=2ce8787b149c9175c52b01b2ea4adb3b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm1005513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1005513%26sid%3Dliteratum%253Aachs%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DZarich%26aufirst%3DN.%26aulast%3DAlbarran%26aufirst%3DM.%2BI.%26aulast%3DPalacios%26aufirst%3DI.%26aulast%3DUrbano-Cuadrado%26aufirst%3DM.%26aulast%3DMateos%26aufirst%3DG.%26aulast%3DReymundo%26aufirst%3DI.%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DSalgado%26aufirst%3DA.%26aulast%3DCorrionero%26aufirst%3DA.%26aulast%3DFominaya%26aufirst%3DJ.%26aulast%3DPastor%26aufirst%3DJ.%26aulast%3DBischoff%26aufirst%3DJ.%2BR.%26atitle%3DDiscovery%2520of%2520Mitogen-Activated%2520Protein%2520Kinase-Interacting%2520Kinase%25201%2520Inhibitors%2520by%2520a%2520Comprehensive%2520Fragment-Oriented%2520Virtual%2520Screening%2520Approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6618%26epage%3D6628%26doi%3D10.1021%2Fjm1005513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flower, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Activity of Mnk1 and Mnk2 Selective Inhibitors Containing Thieno[2,3-d]pyrimidine Scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.10.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1016%2Fj.ejmech.2018.10.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=30496989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlKjs7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2019&pages=735-751&author=X.+Jinauthor=J.+Merrettauthor=S.+Tongauthor=B.+Flowerauthor=J.+Xieauthor=R.+Yuauthor=S.+Tianauthor=L.+Gaoauthor=J.+Zhaoauthor=X.+Wangauthor=T.+Jiangauthor=C.+G.+Proud&title=Design%2C+Synthesis+and+Activity+of+Mnk1+and+Mnk2+Selective+Inhibitors+Containing+Thieno%5B2%2C3-d%5Dpyrimidine+Scaffold&doi=10.1016%2Fj.ejmech.2018.10.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold</span></div><div class="casAuthors">Jin, Xin; Merrett, James; Tong, Sheng; Flower, Bartholomew; Xie, Jianling; Yu, Rilei; Tian, Shuye; Gao, Ling; Zhao, Jiajun; Wang, Xuemin; Jiang, Tao; Proud, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">735-751</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1 and MNK2) phosphorylate eukaryotic initiation factor 4E (eIF4E) and play important roles in promoting tumorigenesis and metabolic disease.  Thus, inhibiting these enzymes might be valuable in the treatment of such conditions.  We designed and synthesized a series of 4-((4-fluoro-2-isopropoxyphenyl)amino)-5-methylthieno[2,3-d]pyrimidine derivs., and evaluated their inhibitory activity against the MNKs.  We found 15 compds. that were active as MNK inhibitors and that one in particular, designated MNK-7g, which was potent against MNK1 and substantially more potent against MNK2.  The compd. MNK-7g did not affect other signaling pathways tested and had no adverse effects on cell viability.  As expected from earlier studies, MNK-7g also inhibited cell migration.  Therefore, the compd. MNK-7g, which forms an ionic bond with Asp226 in MNK2 and possesses a substituted aniline in a thieno[2,3-d] pyrimidine structure, is a promising starting point for the future development of novel drugs for treating or managing cancer and metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1WLYsoUMgW7Vg90H21EOLACvtfcHk0licHxxRadN_QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlKjs7fN&md5=6d291e57bcacfad40145b96d3442209c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.10.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.10.070%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DX.%26aulast%3DMerrett%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DS.%26aulast%3DFlower%26aufirst%3DB.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DR.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Activity%2520of%2520Mnk1%2520and%2520Mnk2%2520Selective%2520Inhibitors%2520Containing%2520Thieno%255B2%252C3-d%255Dpyrimidine%2520Scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D162%26spage%3D735%26epage%3D751%26doi%3D10.1016%2Fj.ejmech.2018.10.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, E. Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, I. N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemison, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaghafi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpf, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webber, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegerski, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span> <span> </span><span class="NLM_article-title">Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1&2) Inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3516</span>– <span class="NLM_lpage">3540</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01795</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01795" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3516-3540&author=S.+H.+Reichauthor=P.+A.+Sprengelerauthor=G.+G.+Chiangauthor=J.+R.+Applemanauthor=J.+Chenauthor=J.+Clarineauthor=B.+Eamauthor=J.+T.+Ernstauthor=Q.+Hanauthor=V.+K.+Goelauthor=E.+Z.+R.+Hanauthor=V.+Huangauthor=I.+N.+J.+Hungauthor=A.+Jemisonauthor=K.+A.+Jessenauthor=J.+Molterauthor=D.+Murphyauthor=M.+Nealauthor=G.+S.+Parkerauthor=M.+Shaghafiauthor=S.+Sperryauthor=J.+Stauntonauthor=C.+R.+Stumpfauthor=P.+A.+Thompsonauthor=C.+Tranauthor=S.+E.+Webberauthor=C.+J.+Wegerskiauthor=H.+Zhengauthor=K.+R.+Webster&title=Structure-based+Design+of+Pyridone-Aminal+eFT508+Targeting+Dysregulated+Translation+by+Selective+Mitogen-activated+Protein+Kinase+Interacting+Kinases+1+and+2+%28MNK1%262%29+Inhibition&doi=10.1021%2Facs.jmedchem.7b01795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition</span></div><div class="casAuthors">Reich, Siegfried H.; Sprengeler, Paul A.; Chiang, Gary G.; Appleman, James R.; Chen, Joan; Clarine, Jeff; Eam, Boreth; Ernst, Justin T.; Han, Qing; Goel, Vikas K.; Han, Edward Z. R.; Huang, Vera; Hung, Ivy N. J.; Jemison, Adrianna; Jessen, Katti A.; Molter, Jolene; Murphy, Douglas; Neal, Melissa; Parker, Gregory S.; Shaghafi, Michael; Sperry, Samuel; Staunton, Jocelyn; Stumpf, Craig R.; Thompson, Peggy A.; Tran, Chinh; Webber, Stephen E.; Wegerski, Christopher J.; Zheng, Hong; Webster, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3516-3540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulated translation of mRNA plays a major role in tumorigenesis.  Mitogen-activated protein kinase interacting kinases (MNK)1/2 are key regulators of mRNA translation integrating signals from oncogenic and immune signaling pathways through phosphorylation of eIF4E and other mRNA binding proteins.  Modulation of these key effector proteins regulates mRNA, which controls tumor/stromal cell signaling.  Compd. 23 (eFT508, 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro-[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione hydrochloride), an exquisitely selective, potent dual MNK1/2 inhibitor, was designed to assess the potential for control of oncogene signaling at the level of mRNA translation.  The crystal structure-guided design leverages stereoelectronic interactions unique to MNK culminating in a novel pyridone-aminal structure described for the first time in the kinase literature.  Compd. 23 has potent in vivo antitumor activity in models of diffuse large cell B-cell lymphoma and solid tumors, suggesting that controlling dysregulated translation has real therapeutic potential.  Compd. 23 is currently being evaluated in Phase 2 clin. trials in solid tumors and lymphoma.  Compd. 23 is the first highly selective dual MNK inhibitor targeting dysregulated translation being assessed clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAp-3GOuZu8bVg90H21EOLACvtfcHk0licHxxRadN_QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGhs7s%253D&md5=1254b674aa7e6d2037a06bc10e64e4da</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01795%26sid%3Dliteratum%253Aachs%26aulast%3DReich%26aufirst%3DS.%2BH.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DAppleman%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DClarine%26aufirst%3DJ.%26aulast%3DEam%26aufirst%3DB.%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DGoel%26aufirst%3DV.%2BK.%26aulast%3DHan%26aufirst%3DE.%2BZ.%2BR.%26aulast%3DHuang%26aufirst%3DV.%26aulast%3DHung%26aufirst%3DI.%2BN.%2BJ.%26aulast%3DJemison%26aufirst%3DA.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DMolter%26aufirst%3DJ.%26aulast%3DMurphy%26aufirst%3DD.%26aulast%3DNeal%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DG.%2BS.%26aulast%3DShaghafi%26aufirst%3DM.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DStaunton%26aufirst%3DJ.%26aulast%3DStumpf%26aufirst%3DC.%2BR.%26aulast%3DThompson%26aufirst%3DP.%2BA.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DWegerski%26aufirst%3DC.%2BJ.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3DStructure-based%2520Design%2520of%2520Pyridone-Aminal%2520eFT508%2520Targeting%2520Dysregulated%2520Translation%2520by%2520Selective%2520Mitogen-activated%2520Protein%2520Kinase%2520Interacting%2520Kinases%25201%2520and%25202%2520%2528MNK1%25262%2529%2520Inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3516%26epage%3D3540%26doi%3D10.1021%2Facs.jmedchem.7b01795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckerdt, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arslan, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clymer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horbinsky, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davuluru, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platanias, L. C.</span></span> <span> </span><span class="NLM_article-title">MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">993</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-16-0172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1158%2F1541-7786.MCR-16-0172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=27364770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGisbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=984-993&author=J.+B.+Bellauthor=F.+D.+Eckerdtauthor=K.+Alleyauthor=L.+P.+Magnussonauthor=H.+Hussainauthor=Y.+Biauthor=A.+D.+Arslanauthor=J.+Clymerauthor=A.+A.+Alvarezauthor=S.+Goldmanauthor=S.-Y.+Chengauthor=I.+Nakanoauthor=C.+Horbinskyauthor=R.+V.+Davuluruauthor=C.+D.+Jamesauthor=L.+C.+Platanias&title=MNK+Inhibition+Disrupts+Mesenchymal+Glioma+Stem+Cells+and+Prolongs+Survival+in+a+Mouse+Model+of+Glioblastoma&doi=10.1158%2F1541-7786.MCR-16-0172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma</span></div><div class="casAuthors">Bell, Jonathan B.; Eckerdt, Frank D.; Alley, Kristen; Magnusson, Lisa P.; Hussain, Hridi; Bi, Yingtao; Arslan, Ahmet Dirim; Clymer, Jessica; Alvarez, Angel A.; Goldman, Stewart; Cheng, Shi-Yuan; Nakano, Ichiro; Horbinski, Craig; Davuluri, Ramana V.; James, C. David; Platanias, Leonidas C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">984-993</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Glioblastoma multiforme remains the deadliest malignant brain tumor, with glioma stem cells (GSC) contributing to treatment resistance and tumor recurrence.  We have identified MAPK-interacting kinases (MNK) as potential targets for the GSC population in glioblastoma multiforme.  Isoform-level subtyping using The Cancer Genome Atlas revealed that both MNK genes (MKNK1 and MKNK2) are upregulated in mesenchymal glioblastoma multiforme as compared with other subtypes.  Expression of MKNK1 is assocd. with increased glioma grade and correlated with the mesenchymal GSC marker, CD44, and coexpression of MKNK1 and CD44 predicts poor survival in glioblastoma multiforme.  In established and patient-derived cell lines, pharmacol. MNK inhibition using LY2801653 (merestinib) inhibited phosphorylation of the eukaryotic translation initiation factor 4E, a crucial effector for MNK-induced mRNA translation in cancer cells and a marker of transformation.  Importantly, merestinib inhibited growth of GSCs grown as neurospheres as detd. by extreme limiting diln. anal.  When the effects of merestinib were assessed in vivo using an intracranial xenograft mouse model, improved overall survival was obsd. in merestinib-treated mice.  Taken together, these data provide strong preclin. evidence that pharmacol. MNK inhibition targets mesenchymal glioblastoma multiforme and its GSC population.  These findings raise the possibility of MNK inhibition as a viable therapeutic approach to target the mesenchymal subtype of glioblastoma multiforme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzbXOivkr8_7Vg90H21EOLACvtfcHk0li7IBeXUpdZyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGisbbM&md5=690d5b41dbbdfa81a470c54e09ad3a92</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-16-0172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-16-0172%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DJ.%2BB.%26aulast%3DEckerdt%26aufirst%3DF.%2BD.%26aulast%3DAlley%26aufirst%3DK.%26aulast%3DMagnusson%26aufirst%3DL.%2BP.%26aulast%3DHussain%26aufirst%3DH.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DArslan%26aufirst%3DA.%2BD.%26aulast%3DClymer%26aufirst%3DJ.%26aulast%3DAlvarez%26aufirst%3DA.%2BA.%26aulast%3DGoldman%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DS.-Y.%26aulast%3DNakano%26aufirst%3DI.%26aulast%3DHorbinsky%26aufirst%3DC.%26aulast%3DDavuluru%26aufirst%3DR.%2BV.%26aulast%3DJames%26aufirst%3DC.%2BD.%26aulast%3DPlatanias%26aufirst%3DL.%2BC.%26atitle%3DMNK%2520Inhibition%2520Disrupts%2520Mesenchymal%2520Glioma%2520Stem%2520Cells%2520and%2520Prolongs%2520Survival%2520in%2520a%2520Mouse%2520Model%2520of%2520Glioblastoma%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2016%26volume%3D14%26spage%3D984%26epage%3D993%26doi%3D10.1158%2F1541-7786.MCR-16-0172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chennamaneni, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M. W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaraj, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joy, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wee, J. L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Retna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendharkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuddagiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangthongpitag, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choong, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kannan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuah, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacro, K.</span></span> <span> </span><span class="NLM_article-title">Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4348</span>– <span class="NLM_lpage">4369</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01714</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01714" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXot1eqsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4348-4369&author=H.+Yangauthor=L.+R.+Chennamaneniauthor=M.+W.+T.+Hoauthor=S.+H.+Angauthor=E.+S.+W.+Tanauthor=D.+A.+Jeyarajauthor=Y.+S.+Yeapauthor=B.+Liuauthor=E.+H.+Ongauthor=J.+K.+Joyauthor=J.+L.+K.+Weeauthor=P.+Kwekauthor=P.+Retnaauthor=N.+Dinieauthor=T.+T.+H.+Nguyenauthor=S.+J.+Taiauthor=V.+Manoharanauthor=V.+Pendharkarauthor=C.+B.+Lowauthor=Y.+S.+Chewauthor=S.+Vuddagiriauthor=K.+Sangthongpitagauthor=M.+L.+Choongauthor=M.+A.+Leeauthor=S.+Kannanauthor=C.+S.+Vermaauthor=A.+Poulsenauthor=S.+Limauthor=C.+Chuahauthor=T.+S.+Ongauthor=J.+Hillauthor=A.+Matterauthor=K.+Nacro&title=Optimization+of+Selective+Mitogen-Activated+Protein+Kinase+Interacting+Kinases+1+and+2+Inhibitors+for+the+Treatment+of+Blast+Crisis+Leukemia&doi=10.1021%2Facs.jmedchem.7b01714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia</span></div><div class="casAuthors">Yang, Haiyan; Chennamaneni, Lohitha Rao; Ho, Melvyn Wai Tuck; Ang, Shi Hua; Tan, Eldwin Sum Wai; Jeyaraj, Duraiswamy Athisayamani; Yeap, Yoon Sheng; Liu, Boping; Ong, Esther Hq; Joy, Joma Kanikadu; Wee, John Liang Kuan; Kwek, Perlyn; Retna, Priya; Dinie, Nurul; Nguyen, Thuy Thi Hanh; Tai, Shi Jing; Manoharan, Vithya; Pendharkar, Vishal; Low, Choon Bing; Chew, Yun Shan; Vuddagiri, Susmitha; Sangthongpitag, Kanda; Choong, Meng Ling; Lee, May Ann; Kannan, Srinivasaraghavan; Verma, Chandra S.; Poulsen, Anders; Lim, Sharon; Chuah, Charles; Ong, Tiong Sin; Hill, Jeffrey; Matter, Alex; Nacro, Kassoum</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4348-4369</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by bcr-abl1, a constitutively active tyrosine kinase fusion gene responsible for an abnormal proliferation of leukemic stem cells (LSCs).  Inhibition of BCR-ABL1 kinase activity offers long-term relief to CML patients.  However, for a proportion of them, BCR-ABL1 inhibition will become ineffective at treating the disease, and CML will progress to blast crisis (BC) CML with poor prognosis.  BC-CML is often assocd. with excessive phosphorylated eukaryotic translation initiation factor 4E (eIF4E), which renders LSCs capable of proliferating via self-renewal, oblivious to BCR-ABL1 inhibition.  In vivo, eIF4E is exclusively phosphorylated on Ser209 by MNK1/2.  Consequently, a selective inhibitor of MNK1/2 should reduce the level of phosphorylated eIF4E and re-sensitize LSCs to BCR-ABL1 inhibition, thus hindering the proliferation of BC LSCs.  We report herein the structure-activity relationships and pharmacokinetic properties of a selective MNK1/2 inhibitor clin. candidate, ETC-206, which in combination with dasatinib prevents BC-CML LSC self-renewal in vitro and enhances dasatinib antitumor activity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwF5EekxyqUrVg90H21EOLACvtfcHk0lgOBaWpWcg43g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXot1eqsbw%253D&md5=6818f494dd765080aec49cc11a9c34bb</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01714%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DChennamaneni%26aufirst%3DL.%2BR.%26aulast%3DHo%26aufirst%3DM.%2BW.%2BT.%26aulast%3DAng%26aufirst%3DS.%2BH.%26aulast%3DTan%26aufirst%3DE.%2BS.%2BW.%26aulast%3DJeyaraj%26aufirst%3DD.%2BA.%26aulast%3DYeap%26aufirst%3DY.%2BS.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DOng%26aufirst%3DE.%2BH.%26aulast%3DJoy%26aufirst%3DJ.%2BK.%26aulast%3DWee%26aufirst%3DJ.%2BL.%2BK.%26aulast%3DKwek%26aufirst%3DP.%26aulast%3DRetna%26aufirst%3DP.%26aulast%3DDinie%26aufirst%3DN.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%2BH.%26aulast%3DTai%26aufirst%3DS.%2BJ.%26aulast%3DManoharan%26aufirst%3DV.%26aulast%3DPendharkar%26aufirst%3DV.%26aulast%3DLow%26aufirst%3DC.%2BB.%26aulast%3DChew%26aufirst%3DY.%2BS.%26aulast%3DVuddagiri%26aufirst%3DS.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DChoong%26aufirst%3DM.%2BL.%26aulast%3DLee%26aufirst%3DM.%2BA.%26aulast%3DKannan%26aufirst%3DS.%26aulast%3DVerma%26aufirst%3DC.%2BS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DLim%26aufirst%3DS.%26aulast%3DChuah%26aufirst%3DC.%26aulast%3DOng%26aufirst%3DT.%2BS.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26aulast%3DNacro%26aufirst%3DK.%26atitle%3DOptimization%2520of%2520Selective%2520Mitogen-Activated%2520Protein%2520Kinase%2520Interacting%2520Kinases%25201%2520and%25202%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Blast%2520Crisis%2520Leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4348%26epage%3D4369%26doi%3D10.1021%2Facs.jmedchem.7b01714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thachamvally, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashyap, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maherchandani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span> <span> </span><span class="NLM_article-title">Role of MAPK/MNK1 Signaling in Virus Replication</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>253</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.virusres.2018.05.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1016%2Fj.virusres.2018.05.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=29864503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFSgtL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=2018&pages=48-61&author=R.+Kumarauthor=N.+Khandelwalauthor=R.+Thachamvallyauthor=B.+N.+Tripathiauthor=S.+Baruaauthor=S.+K.+Kashyapauthor=S.+Maherchandaniauthor=N.+Kumar&title=Role+of+MAPK%2FMNK1+Signaling+in+Virus+Replication&doi=10.1016%2Fj.virusres.2018.05.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Role of MAPK/MNK1 signaling in virus replication</span></div><div class="casAuthors">Kumar, Ram; Khandelwal, Nitin; Thachamvally, Riyesh; Tripathi, Bhupendra Nath; Barua, Sanjay; Kashyap, Sudhir Kumar; Maherchandani, Sunil; Kumar, Naveen</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-61</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Viruses are obligate intracellular parasites; they heavily depend on the host cell machinery to effectively replicate and produce new progeny virus particles.  Following viral infection, diverse cell signaling pathways are initiated by the cells, with the major goal of establishing an antiviral state.  However, viruses have been shown to exploit cellular signaling pathways for their own effective replication.  Genome-wide siRNA screens have also identified numerous host factors that either support (proviral) or inhibit (antiviral) virus replication.  Some of the host factors might be dispensable for the host but may be crit. for virus replication; therefore such cellular factors may serve as targets for development of antiviral therapeutics.  Mitogen activated protein kinase (MAPK) is a major cell signaling pathway that is known to be activated by diverse group of viruses.  MAPK interacting kinase 1 (MNK1) has been shown to regulate both cap-dependent and internal ribosomal entry sites (IRES)-mediated mRNA translation.  In this review we have discuss the role of MAPK in virus replication, particularly the role of MNK1 in replication and translation of viral genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtSkgR0ZtErbVg90H21EOLACvtfcHk0lgOBaWpWcg43g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFSgtL%252FP&md5=7be6860d1d54000f55b84f8f1cfa27fb</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2018.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2018.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DKhandelwal%26aufirst%3DN.%26aulast%3DThachamvally%26aufirst%3DR.%26aulast%3DTripathi%26aufirst%3DB.%2BN.%26aulast%3DBarua%26aufirst%3DS.%26aulast%3DKashyap%26aufirst%3DS.%2BK.%26aulast%3DMaherchandani%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DN.%26atitle%3DRole%2520of%2520MAPK%252FMNK1%2520Signaling%2520in%2520Virus%2520Replication%26jtitle%3DVirus%2520Res.%26date%3D2018%26volume%3D253%26spage%3D48%26epage%3D61%26doi%3D10.1016%2Fj.virusres.2018.05.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gromeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrikov, M. I.</span></span> <span> </span><span class="NLM_article-title">Mitogen-Activated Protein Kinase-Interacting Kinase Regulates MTOR/AKT Signaling and Controls the Serine/Arginine-Rich Protein Kinase-Responsive Type 1 Internal Ribosome Entry Site-Mediated Translation and Viral Oncolysis</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">13149</span>– <span class="NLM_lpage">13160</span>, <span class="refDoi"> DOI: 10.1128/JVI.01884-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1128%2FJVI.01884-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=25187540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSls7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=13149-13160&author=M.+C.+Brownauthor=M.+Gromeierauthor=M.+I.+Dobrikov&title=Mitogen-Activated+Protein+Kinase-Interacting+Kinase+Regulates+MTOR%2FAKT+Signaling+and+Controls+the+Serine%2FArginine-Rich+Protein+Kinase-Responsive+Type+1+Internal+Ribosome+Entry+Site-Mediated+Translation+and+Viral+Oncolysis&doi=10.1128%2FJVI.01884-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogen-activated protein kinase-interacting kinase regulates mTOR/AKT signaling and controls the serine/arginine-rich protein kinase-responsive type 1 internal ribosome entry site-mediated translation and viral oncolysis</span></div><div class="casAuthors">Brown, Michael C.; Dobrikov, Mikhail I.; Gromeier, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">13149-13160, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Translation machinery is a major recipient of the principal mitogenic signaling networks involving Raf-ERK1/2 and phosphoinositol 3-kinase (PI3K)-mechanistic target of rapamycin (mTOR).  Picornavirus internal ribosomal entry site (IRES)-mediated translation and cytopathogenic effects are susceptible to the status of such signaling cascades in host cells.  We detd. that tumor-specific cytotoxicity of the poliovirus/rhinovirus chimera PVSRIPO is facilitated by Raf-ERK1/2 signals to the mitogen-activated protein kinase (MAPK)-interacting kinase (MNK) and its effects on the partitioning/activity of the Ser/Arg (SR)-rich protein kinase (SRPK).  Here, we show that MNK regulates SRPK via mTOR and AKT.  Our investigations revealed a MNK-controlled mechanism acting on mTORC2-AKT.  The resulting suppression of AKT signaling attenuates SRPK activity to enhance picornavirus type 1 IRES translation and favor PVSRIPO tumor cell toxicity and killing.  Importance: Oncolytic immunotherapy with PVSRIPO, the type 1 live-attenuated poliovirus (PV) (Sabin) vaccine contg. a human rhinovirus type 2 (HRV2) IRES, is demonstrating early promise in clin. trials with intratumoral infusion in recurrent glioblastoma (GBM).  Our investigations demonstrate that the core mechanistic principle of PVSRIPO, tumor-selective translation and cytotoxicity, relies on constitutive ERK1/2-MNK signals that counteract the deleterious effects of runaway AKT-SRPK activity in malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppMVd5QcFh5bVg90H21EOLACvtfcHk0lgTqe9st4iL-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSls7bM&md5=6e68db194e00a8731edd9ac8cd3eaafe</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1128%2FJVI.01884-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01884-14%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DM.%2BC.%26aulast%3DGromeier%26aufirst%3DM.%26aulast%3DDobrikov%26aufirst%3DM.%2BI.%26atitle%3DMitogen-Activated%2520Protein%2520Kinase-Interacting%2520Kinase%2520Regulates%2520MTOR%252FAKT%2520Signaling%2520and%2520Controls%2520the%2520Serine%252FArginine-Rich%2520Protein%2520Kinase-Responsive%2520Type%25201%2520Internal%2520Ribosome%2520Entry%2520Site-Mediated%2520Translation%2520and%2520Viral%2520Oncolysis%26jtitle%3DJ.%2520Virol.%26date%3D2014%26volume%3D88%26spage%3D13149%26epage%3D13160%26doi%3D10.1128%2FJVI.01884-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desjardins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gromeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herndon, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaubier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcsherry, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muscat, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randazzo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlahovic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLendon, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashely, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span> <span> </span><span class="NLM_article-title">Recurrent Glioblastoma Treated with Recombinant Poliovirus</span>. <i>New Eng. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1716435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1056%2FNEJMoa1716435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=29943666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlert7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=150-161&author=A.+Desjardinsauthor=M.+Gromeierauthor=J.+E.+Herndonauthor=N.+Beaubierauthor=D.+P.+Bolognesiauthor=A.+H.+Friedmanauthor=H.+S.+Friedmanauthor=F.+Mcsherryauthor=A.+M.+Muscatauthor=S.+Nairauthor=K.+B.+Petersauthor=D.+Randazzoauthor=J.+H.+Sampsonauthor=G.+Vlahovicauthor=W.+T.+Harrisonauthor=R.+E.+McLendonauthor=D.+Ashelyauthor=D.+D.+Bigner&title=Recurrent+Glioblastoma+Treated+with+Recombinant+Poliovirus&doi=10.1056%2FNEJMoa1716435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent glioblastoma treated with recombinant poliovirus</span></div><div class="casAuthors">Desjardins, Annick; Gromeier, Matthias; Herndon, James E., II; Beaubier, Nike; Bolognesi, Dani P.; Friedman, Allan H.; Friedman, Henry S.; McSherry, Frances; Muscat, Andrea M.; Nair, Smita; Peters, Katherine B.; Randazzo, Dina; Sampson, John H.; Vlahovic, Gordana; Harrison, William T.; McLendon, Roger E.; Ashley, David; Bigner, Darell D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">150-161</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The prognosis of patients with recurrent World Health Organization (WHO) grade IV malignant glioma is dismal, and there is currently no effective therapy.  We conducted a dose-finding and toxicity study in this population of patients, evaluating convection-enhanced, intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO).  PVSRIPO recognizes the poliovirus receptor CD155, which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment. methods We enrolled consecutive adult patients who had recurrent supratentorial WHO grade IV malignant glioma, confirmed on histopathol. testing, with measurable disease (contrast-enhancing tumor of ≥1 cm and ≤5.5 cm in the greatest dimension).  The study evaluated seven doses, ranging between 107 and 1010 50% tissue-culture infectious doses (TCID50), first in a dose-escalation phase and then in a dose-expansion phase. results From May 2012 through May 2017, a total of 61 patients were enrolled and received a dose of PVSRIPO.  Dose level -1 (5.0 × 107 TCID50) was identified as the phase 2 dose.  One dose-limiting toxic effect was obsd.; a patient in whom dose level 5 (1010 TCID50) was administered had a grade 4 intracranial hemorrhage immediately after the catheter was removed.  To mitigate locoregional inflammation of the infused tumor with prolonged glucocorticoid use, dose level 5 was deescalated to reach the phase 2 dose.  In the dose-expansion phase, 19% of the patients had a PVSRIPO-related adverse event of grade 3 or higher.  Overall survival among the patients who received PVSRIPO reached a plateau of 21% (95% confidence interval, 11 to 33) at 24 mo that was sustained at 36 mo. conclusions Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential.  The survival rate among patients who received PVSRIPO immunotherapy was higher at 24 and 36 mo than the rate among historical controls.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnOQKU8p5sX7Vg90H21EOLACvtfcHk0lgTqe9st4iL-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlert7zF&md5=388ccb28cb2f2855a2da81d7ce20a66b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1716435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1716435%26sid%3Dliteratum%253Aachs%26aulast%3DDesjardins%26aufirst%3DA.%26aulast%3DGromeier%26aufirst%3DM.%26aulast%3DHerndon%26aufirst%3DJ.%2BE.%26aulast%3DBeaubier%26aufirst%3DN.%26aulast%3DBolognesi%26aufirst%3DD.%2BP.%26aulast%3DFriedman%26aufirst%3DA.%2BH.%26aulast%3DFriedman%26aufirst%3DH.%2BS.%26aulast%3DMcsherry%26aufirst%3DF.%26aulast%3DMuscat%26aufirst%3DA.%2BM.%26aulast%3DNair%26aufirst%3DS.%26aulast%3DPeters%26aufirst%3DK.%2BB.%26aulast%3DRandazzo%26aufirst%3DD.%26aulast%3DSampson%26aufirst%3DJ.%2BH.%26aulast%3DVlahovic%26aufirst%3DG.%26aulast%3DHarrison%26aufirst%3DW.%2BT.%26aulast%3DMcLendon%26aufirst%3DR.%2BE.%26aulast%3DAshely%26aufirst%3DD.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26atitle%3DRecurrent%2520Glioblastoma%2520Treated%2520with%2520Recombinant%2520Poliovirus%26jtitle%3DNew%2520Eng.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D150%26epage%3D161%26doi%3D10.1056%2FNEJMoa1716435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kosciuczuk, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleiro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroczynska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckerdt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blyth, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abedin, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platanias, L. C.</span></span> <span> </span><span class="NLM_article-title">Merestinib Blocks Mnk Kinase Activity in Acute Myeloid Leukemia Progenitors and Exhibits Antileukemic Effects in vitro and in vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-02-698704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1182%2Fblood-2016-02-698704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=27307295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVymu7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=410-414&author=E.+M.+Kosciuczukauthor=D.+Saleiroauthor=B.+Kroczynskaauthor=E.+M.+Beauchampauthor=F.+Eckerdtauthor=G.+T.+Blythauthor=S.+M.+Abedinauthor=F.+J.+Gilesauthor=J.+K.+Altmanauthor=L.+C.+Platanias&title=Merestinib+Blocks+Mnk+Kinase+Activity+in+Acute+Myeloid+Leukemia+Progenitors+and+Exhibits+Antileukemic+Effects+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2016-02-698704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo</span></div><div class="casAuthors">Kosciuczuk, Ewa M.; Saleiro, Diana; Kroczynska, Barbara; Beauchamp, Elspeth M.; Eckerdt, Frank; Blyth, Gavin T.; Abedin, Sameem M.; Giles, Francis J.; Altman, Jessica K.; Platanias, Leonidas C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">410-414</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mitogen-activated protein kinase interacting protein kinases (Mnks) play important roles in the development and progression of acute myeloid leukemia (AML) by regulating eukaryotic translation initiation factor 4E (eIF4E) activation.  Inhibiting Mnk1/2-induced phosphorylation of eIF4E may represent a unique approach for the treatment of AML.  We provide evidence for antileukemic effects of merestinib, an orally bioavailable multikinase inhibitor with suppressive effects on Mnk activity.  Our studies show that merestinib effectively blocks eIF4E phosphorylation in AML cells and suppresses primitive leukemic progenitors from AML patients in vitro and in an AML xenograft model in vivo.  Our findings provide evidence for potent preclin. antileukemic properties of merestinib and support its clin. development for the treatment of patients with AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEFrhJ4BiK57Vg90H21EOLACvtfcHk0lgEK93_Kaw15A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVymu7jE&md5=e1034d2ea79d51ffc297d86a6ae4b737</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-02-698704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-02-698704%26sid%3Dliteratum%253Aachs%26aulast%3DKosciuczuk%26aufirst%3DE.%2BM.%26aulast%3DSaleiro%26aufirst%3DD.%26aulast%3DKroczynska%26aufirst%3DB.%26aulast%3DBeauchamp%26aufirst%3DE.%2BM.%26aulast%3DEckerdt%26aufirst%3DF.%26aulast%3DBlyth%26aufirst%3DG.%2BT.%26aulast%3DAbedin%26aufirst%3DS.%2BM.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DPlatanias%26aufirst%3DL.%2BC.%26atitle%3DMerestinib%2520Blocks%2520Mnk%2520Kinase%2520Activity%2520in%2520Acute%2520Myeloid%2520Leukemia%2520Progenitors%2520and%2520Exhibits%2520Antileukemic%2520Effects%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D410%26epage%3D414%26doi%3D10.1182%2Fblood-2016-02-698704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A Quantitative Analysis of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+Quantitative+Analysis+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lgEK93_Kaw15A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520Quantitative%2520Analysis%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumarasiri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basnet, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">962</span>– <span class="NLM_lpage">972</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1002%2Fcmdc.201300552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=24677692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitlShsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=962-972&author=S.+Diabauthor=T.+Teoauthor=M.+Kumarasiriauthor=P.+Liauthor=M.+Yuauthor=F.+Lamauthor=S.+K.+Basnetauthor=M.+J.+Sykesauthor=H.+Albrechtauthor=R.+Milneauthor=S.+Wang&title=Discovery+of+5-%282-%28phenylamino%29pyrimidin-4-yl%29thiazol-2%283H%29-one+Derivatives+as+Potent+Mnk2+Inhibitors%3A+Synthesis%2C+SAR+Analysis+and+Biological+Evaluation&doi=10.1002%2Fcmdc.201300552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-(2-(Phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation</span></div><div class="casAuthors">Diab, Sarah; Teo, Theodosia; Kumarasiri, Malika; Li, Peng; Yu, Mingfeng; Lam, Frankie; Basnet, Sunita K. C.; Sykes, Matthew J.; Albrecht, Hugo; Milne, Robert; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">962-972</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Phosphorylation of eIF4E by human mitogen-activated protein kinase (MAPK)-interacting kinases (Mnks) is crucial for human tumorigenesis and development.  Targeting Mnks may provide a novel anticancer therapeutic strategy.  However, the lack of selective Mnk inhibitors has so far hampered pharmacol. target validation and clin. drug development.  Herein, we report, for the first time, the discovery of a series of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivs. as Mnk inhibitors.  Several derivs. demonstrate very potent Mnk2 inhibitory activity.  The most active and selective compds. were tested against a panel of cancer cell lines, and the results confirm the cell-type-specific effect of these Mnk inhibitors.  Detailed cellular mechanistic studies reveal that Mnk inhibitors are capable of reducing the expression level of anti-apoptotic protein Mcl-1, and of promoting apoptosis in MV4-11 acute myeloid leukemia cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrsENPnEmtz7Vg90H21EOLACvtfcHk0lgNZ5mUeBScNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitlShsrc%253D&md5=b412a7296fae370913dace6479e9f4b4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300552%26sid%3Dliteratum%253Aachs%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DBasnet%26aufirst%3DS.%2BK.%26aulast%3DSykes%26aufirst%3DM.%2BJ.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DMilne%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%25205-%25282-%2528phenylamino%2529pyrimidin-4-yl%2529thiazol-2%25283H%2529-one%2520Derivatives%2520as%2520Potent%2520Mnk2%2520Inhibitors%253A%2520Synthesis%252C%2520SAR%2520Analysis%2520and%2520Biological%2520Evaluation%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D962%26epage%3D972%26doi%3D10.1002%2Fcmdc.201300552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hung, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestre, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span> <span> </span><span class="NLM_article-title">Application of Fragment Growing and Fragment Linking to the Discovery of Inhibitors of Mycobacterium Tuberculosis Pantothenate Synthetase</span>. <i>Angew. Chem. Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">8452</span>– <span class="NLM_lpage">8456</span>, <span class="refDoi"> DOI: 10.1002/anie.200903821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1002%2Fanie.200903821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWmur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=8452-8456&author=A.+W.+Hungauthor=H.+L.+Silvestreauthor=S.+Wenauthor=A.+Ciulliauthor=T.+L.+Blundellauthor=C.+Abell&title=Application+of+Fragment+Growing+and+Fragment+Linking+to+the+Discovery+of+Inhibitors+of+Mycobacterium+Tuberculosis+Pantothenate+Synthetase&doi=10.1002%2Fanie.200903821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Fragment Growing and Fragment Linking to the Discovery of Inhibitors of Mycobacterium tuberculosis Pantothenate Synthetase</span></div><div class="casAuthors">Hung, Alvin W.; Silvestre, H. Leonardo; Wen, Shijun; Ciulli, Alessio; Blundell, Tom L.; Abell, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">8452-8456, S8452/1-S8452/26</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Despite the fact that nearly 2 million people a year are killed by Mycobacterium tuberculosis (TB), we still lack a robust pipeline of potential therapies to combat this burden.  Fragment-based approaches have provided a new paradigm in the development of high-quality chem. ligands and have great potential to contribute as starting points in the development of drugs against TB.  To date, studies on pantothenate synthetase (PS) inhibition have focused on the synthesis of analogs of the pantoyl adenylate reaction intermediate or the identification of hits from high-throughput screening.  We describe a combination of fragment-growing and fragment-linking approaches that led to the discovery of a new series of inhibitors of M. tuberculosis PS for the further validation of PS as a potential drug target for TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjhska_U-KXbVg90H21EOLACvtfcHk0lhy6zcZjBFMXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWmur%252FK&md5=821f86e9e1d7cbd848741962e3ac47dd</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fanie.200903821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200903821%26sid%3Dliteratum%253Aachs%26aulast%3DHung%26aufirst%3DA.%2BW.%26aulast%3DSilvestre%26aufirst%3DH.%2BL.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DCiulli%26aufirst%3DA.%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26aulast%3DAbell%26aufirst%3DC.%26atitle%3DApplication%2520of%2520Fragment%2520Growing%2520and%2520Fragment%2520Linking%2520to%2520the%2520Discovery%2520of%2520Inhibitors%2520of%2520Mycobacterium%2520Tuberculosis%2520Pantothenate%2520Synthetase%26jtitle%3DAngew.%2520Chem.%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D8452%26epage%3D8456%26doi%3D10.1002%2Fanie.200903821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, R.</span></span> <span> </span><span class="NLM_article-title">Fragment-based Lead Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">660</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1038/nrd1467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1038%2Fnrd1467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=15286733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=660-672&author=D.+C.+Reesauthor=M.+Congreveauthor=C.+W.+Murrayauthor=R.+Carr&title=Fragment-based+Lead+Discovery&doi=10.1038%2Fnrd1467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-based lead discovery</span></div><div class="casAuthors">Rees, David C.; Congreve, Miles; Murray, Christopher W.; Carr, Robin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">660-672</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fragment-based lead discovery is gaining momentum in both large pharmaceutical companies and biotechnol. labs. as a complementary approach to traditional screening.  This is because fragment-based approaches require significantly fewer compds. to be screened and synthesized, and are showing a high success rate in generating chem. series with lead-like properties.  Compared with traditional screening hits, the starting fragments have considerably lower mol. mass, and although the binding interactions of these fragments with a target protein are weak, they are structurally understood through x-ray crystallog. or NMR, and they exhibit high 'ligand efficiency'.  Here, the authors use examples from 25 different protein targets to describe chem. strategies that exploit this structural knowledge to rapidly develop fragments into high-affinity leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbKeUzFFIlhbVg90H21EOLACvtfcHk0lhy6zcZjBFMXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOht7Y%253D&md5=8d49ac7f698c9b9d573ee3c3485eced8</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrd1467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1467%26sid%3Dliteratum%253Aachs%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DCarr%26aufirst%3DR.%26atitle%3DFragment-based%2520Lead%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D660%26epage%3D672%26doi%3D10.1038%2Fnrd1467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="note"><p class="first last">All animal studies were conducted at the Experimental Therapeutics Centre, Singapore, with the prior approval of the local Institutional Animal Care Committee (IACUC approval no. 181304).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Drug Discovery: Advancing Fragments in the Absence of Crystal Structures</span>. <i>Cell. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2018.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1016%2Fj.chembiol.2018.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=30482678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWisrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=9-15&author=D.+A.+Erlansonauthor=B.+J.+Davisauthor=W.+Jahnke&title=Fragment-Based+Drug+Discovery%3A+Advancing+Fragments+in+the+Absence+of+Crystal+Structures&doi=10.1016%2Fj.chembiol.2018.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Drug Discovery: Advancing Fragments in the Absence of Crystal Structures</span></div><div class="casAuthors">Erlanson, Daniel A.; Davis, Ben J.; Jahnke, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-15</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Fragment-based drug discovery typically requires an interplay between screening methods, structural methods, and medicinal chem.  X-ray crystallog. is generally the method of choice to obtain three-dimensional structures of the bound ligand/protein complex, but this can sometimes be difficult, particularly for early, low-affinity fragment hits.  In this Perspective, we discuss strategies to advance and evolve fragments in the absence of crystal structures of protein-fragment complexes, although the structure of the unliganded protein may be available.  The strategies can involve other structural techniques, such as NMR spectroscopy, mol. modeling, or a variety of chem. approaches.  Often, these strategies are aimed at guiding evolution of initial fragment hits to a stage where crystal structures can be obtained for further structure-based optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmStmkIpx6bLVg90H21EOLACvtfcHk0lhy6zcZjBFMXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWisrzI&md5=2f5fb9d063b7ccabb4f7eb611c00ce30</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DDavis%26aufirst%3DB.%2BJ.%26aulast%3DJahnke%26aufirst%3DW.%26atitle%3DFragment-Based%2520Drug%2520Discovery%253A%2520Advancing%2520Fragments%2520in%2520the%2520Absence%2520of%2520Crystal%2520Structures%26jtitle%3DCell.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26spage%3D9%26epage%3D15%26doi%3D10.1016%2Fj.chembiol.2018.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seetoh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Then, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span> <span> </span><span class="NLM_article-title">Application of Fragment-Based Drug Discovery against DNA Gyrase B</span>. <i>Chem. Plus Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">1250</span>– <span class="NLM_lpage">1254</span>, <span class="refDoi"> DOI: 10.1002/cplu.201500197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1002%2Fcplu.201500197" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2015&pages=1250-1254&author=G.+Chenauthor=F.+M.+Ngauthor=Y.+W.+Tanauthor=A.+Poulsenauthor=W.+Seetohauthor=G.+Linauthor=C.+Kangauthor=S.+W.+Thenauthor=N.+H.+Ahmadauthor=Y.+L.+Wongauthor=H.+Q.+Ngauthor=C.+S.+Chiaauthor=Q.+Y.+Lauauthor=J.+Hillauthor=A.+W.+Hungauthor=T.+H.+Keller&title=Application+of+Fragment-Based+Drug+Discovery+against+DNA+Gyrase+B&doi=10.1002%2Fcplu.201500197"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fcplu.201500197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcplu.201500197%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26aulast%3DNg%26aufirst%3DF.%2BM.%26aulast%3DTan%26aufirst%3DY.%2BW.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSeetoh%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DKang%26aufirst%3DC.%26aulast%3DThen%26aufirst%3DS.%2BW.%26aulast%3DAhmad%26aufirst%3DN.%2BH.%26aulast%3DWong%26aufirst%3DY.%2BL.%26aulast%3DNg%26aufirst%3DH.%2BQ.%26aulast%3DChia%26aufirst%3DC.%2BS.%26aulast%3DLau%26aufirst%3DQ.%2BY.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DHung%26aufirst%3DA.%2BW.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26atitle%3DApplication%2520of%2520Fragment-Based%2520Drug%2520Discovery%2520against%2520DNA%2520Gyrase%2520B%26jtitle%3DChem.%2520Plus%2520Chem.%26date%3D2015%26volume%3D80%26spage%3D1250%26epage%3D1254%26doi%3D10.1002%2Fcplu.201500197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wach, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almo, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Herin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, D. W.</span></span> <span> </span><span class="NLM_article-title">Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">852</span>– <span class="NLM_lpage">856</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00230</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00230" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFKms7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=852-856&author=Y.+Wangauthor=J.+Y.+Wachauthor=P.+Sheehanauthor=C.+Zhongauthor=C.+Zhanauthor=R.+Harrisauthor=S.+C.+Almoauthor=J.+Bishopauthor=S.+J.+Haggartyauthor=A.+Ramekauthor=K.+N.+Berryauthor=C.+O%E2%80%99Herinauthor=A.+N.+Koehlerauthor=A.+W.+Hungauthor=D.+W.+Young&title=Diversity-Oriented+Synthesis+as+a+Strategy+for+Fragment+Evolution+against+GSK3%CE%B2&doi=10.1021%2Facsmedchemlett.6b00230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β</span></div><div class="casAuthors">Wang, Yikai; Wach, Jean-Yves; Sheehan, Patrick; Zhong, Cheng; Zhan, Chenyang; Harris, Richard; Almo, Steven C.; Bishop, Joshua; Haggarty, Stephen J.; Ramek, Alexander; Berry, Kayla N.; O'Herin, Conor; Koehler, Angela N.; Hung, Alvin W.; Young, Damian W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">852-856</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Traditional fragment-based drug discovery (FBDD) relies heavily on structural anal. of the hits bound to their targets.  Herein, we present a complementary approach based on diversity-oriented synthesis (DOS).  A DOS-based fragment collection was able to produce initial hit compds. against the target GSK3β, allow the systematic synthesis of related fragment analogs to explore fragment-level structure-activity relationship, and finally lead to the synthesis of a more potent compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSSD8IpGmjLVg90H21EOLACvtfcHk0ljezqkzb7RiVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFKms7vJ&md5=54b88fe62b0fbd6a0821a84a664c0d31</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00230%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWach%26aufirst%3DJ.%2BY.%26aulast%3DSheehan%26aufirst%3DP.%26aulast%3DZhong%26aufirst%3DC.%26aulast%3DZhan%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26aulast%3DBishop%26aufirst%3DJ.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DRamek%26aufirst%3DA.%26aulast%3DBerry%26aufirst%3DK.%2BN.%26aulast%3DO%25E2%2580%2599Herin%26aufirst%3DC.%26aulast%3DKoehler%26aufirst%3DA.%2BN.%26aulast%3DHung%26aufirst%3DA.%2BW.%26aulast%3DYoung%26aufirst%3DD.%2BW.%26atitle%3DDiversity-Oriented%2520Synthesis%2520as%2520a%2520Strategy%2520for%2520Fragment%2520Evolution%2520against%2520GSK3%25CE%25B2%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D852%26epage%3D856%26doi%3D10.1021%2Facsmedchemlett.6b00230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tee, D. H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, N. H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poh, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurul, Dinie.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendharkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangthongpitag, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepramaniam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, A. W.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4386</span>– <span class="NLM_lpage">4396</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00060</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00060" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXot1eqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4386-4396&author=J.+Kwiatkowskiauthor=B.+Liuauthor=D.+H.+Y.+Teeauthor=G.+Chenauthor=N.+H.+B.+Ahmadauthor=Y.+X.+Wongauthor=Z.+Y.+Pohauthor=S.+H.+Angauthor=E.+S.+W.+Tanauthor=E.+H.+Ongauthor=Dinie.+Nurulauthor=A.+Poulsenauthor=V.+Pendharkarauthor=K.+Sangthongpitagauthor=M.+A.+Leeauthor=S.+Sepramaniamauthor=S.+Y.+Hoauthor=J.+Cherianauthor=J.+Hillauthor=T.+H.+Kellerauthor=A.+W.+Hung&title=Fragment-Based+Drug+Discovery+of+Potent+Protein+Kinase+C+Iota+Inhibitors&doi=10.1021%2Facs.jmedchem.8b00060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors</span></div><div class="casAuthors">Kwiatkowski, Jacek; Liu, Boping; Tee, Doris Hui Ying; Chen, Guoying; Binte Ahmad, Nur Huda; Wong, Yun Xuan; Poh, Zhi Ying; Ang, Shi Hua; Tan, Eldwin Sum Wai; Ong, Esther H. Q.; Dinie, Nurul; Poulsen, Anders; Pendharkar, Vishal; Sangthongpitag, Kanda; Lee, May Ann; Sepramaniam, Sugunavathi; Ho, Soo Yei; Cherian, Joseph; Hill, Jeffrey; Keller, Thomas H.; Hung, Alvin W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4386-4396</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein kinase C iota (PKC-ι) is an atypical kinase implicated in the promotion of different cancer types.  A biochem. screen of a fragment library has identified several hits from which an azaindole-based scaffold was chosen for optimization.  Driven by a structure-activity relationship and supported by mol. modeling, a weakly bound fragment was systematically grown into a potent and selective inhibitor against PKC-ι.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVKGgW092g1bVg90H21EOLACvtfcHk0ljiDSa1QZFcLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXot1eqtbk%253D&md5=efeeb545b2a8a88ff9d42d246fd2de4c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00060%26sid%3Dliteratum%253Aachs%26aulast%3DKwiatkowski%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTee%26aufirst%3DD.%2BH.%2BY.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DAhmad%26aufirst%3DN.%2BH.%2BB.%26aulast%3DWong%26aufirst%3DY.%2BX.%26aulast%3DPoh%26aufirst%3DZ.%2BY.%26aulast%3DAng%26aufirst%3DS.%2BH.%26aulast%3DTan%26aufirst%3DE.%2BS.%2BW.%26aulast%3DOng%26aufirst%3DE.%2BH.%26aulast%3DNurul%26aufirst%3DDinie.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DPendharkar%26aufirst%3DV.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DM.%2BA.%26aulast%3DSepramaniam%26aufirst%3DS.%26aulast%3DHo%26aufirst%3DS.%2BY.%26aulast%3DCherian%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DHung%26aufirst%3DA.%2BW.%26atitle%3DFragment-Based%2520Drug%2520Discovery%2520of%2520Potent%2520Protein%2520Kinase%2520C%2520Iota%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4386%26epage%3D4396%26doi%3D10.1021%2Facs.jmedchem.8b00060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baburajendran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tee, D. H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poh, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahad, N. D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, A. W.</span></span> <span> </span><span class="NLM_article-title">Fragment-based Discovery of a Small-molecule Protein Kinase C-iota Inhibitor Binding Post-kinase Domain Residues</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00546</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00546" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFCqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=318-323&author=J.+Kwiatkowskiauthor=N.+Baburajendranauthor=A.+Poulsenauthor=B.+Liuauthor=D.+H.+Y.+Teeauthor=Y.+X.+Wongauthor=Z.+Y.+Pohauthor=E.+Ongauthor=N.+D.+B.+Rahadauthor=J.+Cherianauthor=A.+E.+Janssonauthor=J.+Hillauthor=T.+H.+Kellerauthor=A.+W.+Hung&title=Fragment-based+Discovery+of+a+Small-molecule+Protein+Kinase+C-iota+Inhibitor+Binding+Post-kinase+Domain+Residues&doi=10.1021%2Facsmedchemlett.8b00546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-based Discovery of a Small-Molecule Protein Kinase C-iota Inhibitor Binding Post-kinase Domain Residues</span></div><div class="casAuthors">Kwiatkowski, Jacek; Baburajendran, Nithya; Poulsen, Anders; Liu, Boping; Tee, Doris Hui Ying; Wong, Yun Xuan; Poh, Zhi Ying; Ong, Esther HQ; Dinie, Nurul; Cherian, Joseph; Jansson, Anna Elisabet; Hill, Jeffrey; Keller, Thomas H.; Hung, Alvin W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">318-323</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The atypical protein kinase C-iota (PKC-ι) enzyme is implicated in various cancers and has been put forward as an attractive target for developing anticancer therapy.  A high concn. biochem. screen identified pyridine fragment weakly inhibiting PKC-ι with IC50 = 424 μM.  Driven by structure-activity relationships and guided by docking hypothesis, the weakly bound fragment was eventually optimized into a potent inhibitor of PKC-ι (IC50= 270 nM).  Through the course of the optimization, an intermediate compd. was crystd. with the protein, and careful anal. of the x-ray crystal structure revealed a unique binding mode involving the post-kinase domain (C-terminal tail) of PKC-ι.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1BrjXnhc9LLVg90H21EOLACvtfcHk0ljiDSa1QZFcLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFCqtbw%253D&md5=58ba46895acd8e659d67620700f77917</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00546%26sid%3Dliteratum%253Aachs%26aulast%3DKwiatkowski%26aufirst%3DJ.%26aulast%3DBaburajendran%26aufirst%3DN.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTee%26aufirst%3DD.%2BH.%2BY.%26aulast%3DWong%26aufirst%3DY.%2BX.%26aulast%3DPoh%26aufirst%3DZ.%2BY.%26aulast%3DOng%26aufirst%3DE.%26aulast%3DRahad%26aufirst%3DN.%2BD.%2BB.%26aulast%3DCherian%26aufirst%3DJ.%26aulast%3DJansson%26aufirst%3DA.%2BE.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DHung%26aufirst%3DA.%2BW.%26atitle%3DFragment-based%2520Discovery%2520of%2520a%2520Small-molecule%2520Protein%2520Kinase%2520C-iota%2520Inhibitor%2520Binding%2520Post-kinase%2520Domain%2520Residues%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D318%26epage%3D323%26doi%3D10.1021%2Facsmedchemlett.8b00546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':[],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Jin</span>, <span class="hlFld-ContribAuthor ">Rilei  Yu</span>, <span class="hlFld-ContribAuthor ">Xuemin  Wang</span>, <span class="hlFld-ContribAuthor ">Christopher G.  Proud</span>, <span class="hlFld-ContribAuthor ">Tao  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Progress in developing MNK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>219 </em>, 113420. <a href="https://doi.org/10.1016/j.ejmech.2021.113420" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113420</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113420%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProgress%252Bin%252Bdeveloping%252BMNK%252Binhibitors%26aulast%3DJin%26aufirst%3DXin%26date%3D2021%26volume%3D219%26spage%3D113420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0005.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0018.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selected published MNK inhibitors. <b>eFT508</b><a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and <b>ETC-206</b><a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> are clinical candidates targeting MNK. Merestinib<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and <b>AST-487</b><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> target MNK nonselectively and show efficacy in animal models relevant to MNK-dependent disease progression. Compounds <b>53e</b> and <b>54e</b><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> are derivatives of <b>AST-487</b>, and both compounds show in vivo efficacy and suppression of leukemic stem cell renewal. Compound <b>8e</b> is a submicromolar MNK inhibitor suppressing acute myelocytic leukemia (MV4-11) cell growth and reducing expression of antiapoptotic Mcl-2 protein; in addition to MNK, CDK2 and CDK9 inhibition likely contributes to cellular activity.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Compound <b>9e</b> exhibits potent MNK inhibition in biochemical and cellular assays; however, no specific disease-relevant biological data has been revealed.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0019.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Assessment of fragment hits <b>4</b> and <b>6</b>. Minor modifications around the scaffold quickly revealed opportunities and limitations of the vectors for fragment growing. Compound <b>13</b> was chosen as the basis for subsequent fragment optimization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0010.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Docking of fragment 13 into MNK2; two possible orientations of <b>13</b> in the binding site are shown on (a) (<b>I</b>) and (b) (<b>II</b>). The yellow spheres indicate hydrophobic regions in the binding site; (c) the main interactions between <b>13</b> and MNK2 in binding mode <b>I</b> are the hydrogen bond with Met-162, the water-mediated hydrogen bond with Asp-226 and Glu-129 (only in binding conformation <b>I</b> and providing possibility of displacing the water), π–π interaction with Phe-159, and hydrophobic interactions with Cys-225, Leu-90, Leu-212, and Val-98; (d) grid is superimposed on the binding site showing areas favorable for binding ligand atoms with the following properties: hydrophobic (yellow), acceptor or negatively charged (red), and donor or positively charged (blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0016.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vivo pharmacokinetic properties of benzamide <b>21</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Selectivity of MNK1 and 2 inhibitors <b>43</b> and <b>49</b> in a panel of 104 kinases. Increasing the steric bulk on the phenolic oxygen resulted in a marked improvement in selectivity. KINOMEscan was performed by DiscoverX. The results are visualized using TREEspot. Kinases are sorted according to the phylogenetic tree, and the degree of inhibition is proportional to the size of the red sphere. S scores are as follows: S(35) = 0.102, S(10) = 0.031 for <b>43</b> and S(35) = 0.031, S(10) = 0.01 for <b>49</b>. IC<sub>50</sub>s for compound <b>49</b> were as follows: MNK2 = 0.025 μM, MNK1 = 0.19 μM, and eIF4E phosphorylation = 1.3 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vivo PK of compound 43 at 5 mg/kg (PO) and 1 mg/kg (IV). The compound shows good PO <i>C</i><sub>max</sub> and excellent bioavailability of 73%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0017.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. X-ray analysis of MNK2 in complex with compound 36; PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JLR">6JLR</a>. (a) Key interactions observed were the hydrogen bond of the central pyridine with the hinge-binding residue Met-162 and edge-to-face π–π interaction of the benzamide moiety with Phe-159 and Phe-227; (b) view of the binding site of MNK2 in complex with <b>36</b> with the surface applied; and (c) overlay of the X-ray crystal structure of <b>36</b> and the simulated binding pose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Fragment optimization timeline. Analysis of the progression of the fragment growing campaign against MNK1 and MNK2. With respect to the 3-phenylpyridine scaffold, ∼200 compounds were tested against MNK1 and MNK2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0011.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Pyridine-Benzamides (<b>13</b>, <b>15</b>–<b>18</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) pyridine-3-boronic acid pinacol ester (1.1 equiv), ArBr (1 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (5 mol %), K<sub>3</sub>PO<sub>4</sub> (3 equiv), dioxane/water (4/1), 100 °C, 0.5–2 h.</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0022.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of Compounds <b>27</b>–<b>32</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) benzamide-4-boronic acid (1.1 equiv), pyridine bromide (1 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (5 mol %), K<sub>3</sub>PO<sub>4</sub> (3 equiv), dioxane/water (4/1), 100 °C, 0.5–2 h.</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Syntheses of Compounds <b>14</b>, <b>19</b>–<b>26</b>, <b>32</b>–<b>36</b>, and <b>49</b>–<b>50</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (BPin)<sub>2</sub> (1.2 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, AcOK (1.5 equiv), dioxane, 90 °C, 2 h; (b) 3-bromopyridine (1.1 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane/water (4/1), 100 °C, 0.5–2 h; (c) <b>i</b>: R-Br (3 equiv), K<sub>2</sub>CO<sub>3</sub> (3 equiv), dimethylformamide (DMF), 90 °C, 2–4 h; <b>ii</b> for <b>28</b> and <b>29</b> deprotection of the amino functionality was necessary: 10% trifluoroacetic acid (TFA) in CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h; (d) ArB(OH)<sub>2</sub> (1.2 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane/water (4/1), 100 °C, 0.5–2 h; (e) EtBr (4 equiv), NaH (4 equiv), DMF, 0–90 °C, 2 h.</p></p></figure><figure data-id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/medium/jm9b01582_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0020.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Syntheses of Compounds <b>37</b>–<b>48</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01582/20200115/images/large/jm9b01582_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01582&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>i</i>-PrBr (3 equiv), K<sub>2</sub>CO<sub>3</sub> (3 equiv), DMF, 90 °C, 2–4 h; (b) (BPin)<sub>2</sub> (1.2 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, AcOK, dioxane, 90 °C, 2 h; (c) 3-bromo-5-chloropyridine (0.9 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane/water (4/1), 100 °C, 0.5–1 h; (d) ArB(OH)<sub>2</sub> (1.2 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane/water (4/1), 100 °C, 0.5–2 h; (e) ArBr (1.1 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane/water (4/1), 100 °C, 0.5–2 h; (f) sodium azide (2 equiv), ammonium chloride (2 equiv), DMF, 100 °C, 4 h; (g) <b>V</b> (0.9 equiv), <b>VIII</b> (1 equiv), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub> (3 equiv), dioxane/water (4/1), 100 °C, 2 h.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36431" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36431" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 37 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waskiewicz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalingam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimball, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, J. A.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of the Cap-binding Protein Eukaryotic Translation Initiation Factor 4E by Protein Kinase Mnk1 in vivo</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1871</span>– <span class="NLM_lpage">1880</span>, <span class="refDoi"> DOI: 10.1128/MCB.19.3.1871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1128%2FMCB.19.3.1871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10022874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADyaK1MXhsFeqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=1871-1880&author=A.+J.+Waskiewiczauthor=J.+C.+Johnsonauthor=B.+Pennauthor=M.+Mahalingamauthor=S.+R.+Kimballauthor=J.+A.+Cooper&title=Phosphorylation+of+the+Cap-binding+Protein+Eukaryotic+Translation+Initiation+Factor+4E+by+Protein+Kinase+Mnk1+in+vivo&doi=10.1128%2FMCB.19.3.1871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo</span></div><div class="casAuthors">Waskiewicz, Andrew Jan; Johnson, Jeffrey C.; Penn, Bennett; Mahalingam, Malathy; Kimball, Scot R.; Cooper, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1871-1880</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Eukaryotic translation initiation factor 4E (eIF4E) binds to the mRNA 5' cap and brings the mRNA into a complex with other protein synthesis initiation factors and ribosomes.  The activity of mammalian eIF4E is important for the translation of capped mRNAs and is thought to be regulated by two mechanisms.  First, eIF4E is sequestered by binding proteins, such as 4EBP1, in quiescent cells.  Mitogens induce the release of eIF4E by stimulating the phosphorylation of 4EBP1.  Second, mitogens and stresses induce the phosphorylation of eIF4E at Ser 209, increasing the affinity of eIF4E for capped mRNA and for an assocd. scaffolding protein, eIF4G.  We previously showed that a mitogen- and stress-activated kinase, Mnk1, phosphorylates eIF4E in vitro at the physiol. site.  Here we show that Mnk1 regulates eIF4E phosphorylation in vivo.  Mnk1 binds directly to eIF4G and copurifies with eIF4G and eIF4E.  We identified activating phosphorylation sites in Mnk1 and developed dominant-neg. and activated mutants.  Expression of dominant-neg. Mnk1 reduces mitogen-induced eIF4E phosphorylation, while expression of activated Mnk1 increases basal eIF4E phosphorylation.  Activated mutant Mnk1 also induces extensive phosphorylation of eIF4E in cells overexpressing 4EBP1.  This suggests that phosphorylation of eIF4E is catalyzed by Mnk1 or a very similar kinase in cells and is independent of other mitogenic signals that release eIF4E from 4EBP1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyB7rKOyL2XLVg90H21EOLACvtfcHk0lglkkYTL4Mo-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsFeqtLo%253D&md5=b4b07e97e90a0c03e5b0d2320ac12508</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1128%2FMCB.19.3.1871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.19.3.1871%26sid%3Dliteratum%253Aachs%26aulast%3DWaskiewicz%26aufirst%3DA.%2BJ.%26aulast%3DJohnson%26aufirst%3DJ.%2BC.%26aulast%3DPenn%26aufirst%3DB.%26aulast%3DMahalingam%26aufirst%3DM.%26aulast%3DKimball%26aufirst%3DS.%2BR.%26aulast%3DCooper%26aufirst%3DJ.%2BA.%26atitle%3DPhosphorylation%2520of%2520the%2520Cap-binding%2520Protein%2520Eukaryotic%2520Translation%2520Initiation%2520Factor%25204E%2520by%2520Protein%2520Kinase%2520Mnk1%2520in%2520vivo%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D1871%26epage%3D1880%26doi%3D10.1128%2FMCB.19.3.1871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polunovsky, V. A.</span></span> <span> </span><span class="NLM_article-title">eIF4E-Mediated Translational Control of Cancer Incidence</span>. <i>Biochim. Biophys. Acta, Gene Regul. Mech.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1849</i></span>,  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1016/j.bbagrm.2014.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1016%2Fj.bbagrm.2014.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Kltb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1849&publication_year=2015&pages=774-780&author=P.+B.+Bittermanauthor=V.+A.+Polunovsky&title=eIF4E-Mediated+Translational+Control+of+Cancer+Incidence&doi=10.1016%2Fj.bbagrm.2014.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">eIF4E-mediated translational control of cancer incidence</span></div><div class="casAuthors">Bitterman, Peter B.; Polunovsky, Vitaly A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Regulatory Mechanisms</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1849</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">774-780</span>CODEN:
                <span class="NLM_cas:coden">BBAGC6</span>;
        ISSN:<span class="NLM_cas:issn">1874-9399</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mitogen activated translation initiation factor eIF4E mediates normal cell proliferation, yet induces tumorigenesis when deregulated and overexpressed.  It remains unknown, how activated eIF4E directs such distinct biol. outputs.  Our exptl. data provide evidence that distinct threshold levels of eIF4E govern its biol. output in lactating mammary glands and that eIF4E overexpression in the context of cell population expansion can initiate malignant transformation by enabling cells to evade DNA damage checkpoints caused by hyperproliferative oncogenic stimuli.  These findings point at the cellular level of eIF4E as an important sensor for normal or pro-neoplastic propagation of cells.  Here, we describe a model that links the pro-neoplastic function of eIF4F to its ability to disable oncogene-activated tumor surveillance programs; and propose a novel therapeutic strategy for cancer prevention based upon targeting aberrant eIF4E with safe doses of small-mol. antagonists to ensure the maintenance of eIF4E levels below the pro-neoplastic threshold.  This article is part of a Special Issue entitled: Translation and Cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIKLe6m68gmLVg90H21EOLACvtfcHk0lglkkYTL4Mo-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Kltb%252FM&md5=a6522861c1834d11c677c6e9cfb74b6a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagrm.2014.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagrm.2014.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26aulast%3DPolunovsky%26aufirst%3DV.%2BA.%26atitle%3DeIF4E-Mediated%2520Translational%2520Control%2520of%2520Cancer%2520Incidence%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Regul.%2520Mech.%26date%3D2015%26volume%3D1849%26spage%3D774%26epage%3D780%26doi%3D10.1016%2Fj.bbagrm.2014.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumarasiri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">MAP Kinase-Interacting Kinases—Emerging Targets against Cancer</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2014.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1016%2Fj.chembiol.2014.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=24613018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslyitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=441-452&author=S.+Diabauthor=M.+Kumarasiriauthor=M.+Yuauthor=T.+Teoauthor=C.+Proudauthor=R.+Milneauthor=S.+Wang&title=MAP+Kinase-Interacting+Kinases%E2%80%94Emerging+Targets+against+Cancer&doi=10.1016%2Fj.chembiol.2014.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">MAP Kinase-Interacting Kinases-Emerging Targets against Cancer</span></div><div class="casAuthors">Diab, Sarah; Kumarasiri, Malika; Yu, Mingfeng; Teo, Theodosia; Proud, Christopher; Milne, Robert; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK)-interacting kinases (Mnks) regulate the initiation of translation through phosphorylation of eukaryotic initiation factor 4E (eIF4E).  Mnk-mediated eIF4E activation promotes cancer development and progression.  While the phosphorylation of eIF4E is necessary for oncogenic transformation, the kinase activity of Mnks seems dispensable for normal development.  For this reason, pharmacol. inhibition of Mnks could represent an ideal mechanism-based and nontoxic therapeutic strategy for cancer treatment.  In this review, we discuss the current understanding of Mnk biol. roles, structures, and functions, as well as clin. implications.  Importantly, we propose different strategies for identification of highly selective small mol. inhibitors of Mnks, including exploring a structural feature of their kinase domain, DFD motif, which is unique within the human kinome.  We also argue that a combined targeting of Mnks and other pathways should be considered given the complexity of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8J4FNfWRq27Vg90H21EOLACvtfcHk0lj7oxRwcptVCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslyitb0%253D&md5=472ef0f62dc9dc457139367b3a573c49</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2014.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2014.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DProud%26aufirst%3DC.%26aulast%3DMilne%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DMAP%2520Kinase-Interacting%2520Kinases%25E2%2580%2594Emerging%2520Targets%2520against%2520Cancer%26jtitle%3DChem.%2520Biol.%26date%3D2014%26volume%3D21%26spage%3D441%26epage%3D452%26doi%3D10.1016%2Fj.chembiol.2014.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe-Fukunaga, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukunaga, R.</span></span> <span> </span><span class="NLM_article-title">Mnk2 and Mnk1 Are Essential for Constitutive and Inducible Phosphorylation of Eukaryotic Initiation Factor 4E but Not for Cell Growth or Development</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6539</span>– <span class="NLM_lpage">6549</span>, <span class="refDoi"> DOI: 10.1128/MCB.24.15.6539-6549.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1128%2FMCB.24.15.6539-6549.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=15254222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlKltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=6539-6549&author=T.+Uedaauthor=R.+Watanabe-Fukunagaauthor=H.+Fukuyamaauthor=S.+Nagataauthor=R.+Fukunaga&title=Mnk2+and+Mnk1+Are+Essential+for+Constitutive+and+Inducible+Phosphorylation+of+Eukaryotic+Initiation+Factor+4E+but+Not+for+Cell+Growth+or+Development&doi=10.1128%2FMCB.24.15.6539-6549.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development</span></div><div class="casAuthors">Ueda, Takeshi; Watanabe-Fukunaga, Rie; Fukuyama, Hidehiro; Nagata, Shigekazu; Fukunaga, Rikiro</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6539-6549</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Mnk1 and Mnk2 are protein kinases that are directly phosphorylated and activated by extracellular signal-regulated kinase (ERK) or p38 mitogen-activated protein (MAP) kinases and implicated in the regulation of protein synthesis through their phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) at Ser209.  To investigate their physiol. functions, we generated mice lacking the Mnk1 or Mnk2 gene or both; the resulting KO mice were viable, fertile, and developed normally.  In embryonic fibroblasts prepd. from Mnk1-Mnk2 DKO mice, eIF4E was not detectably phosphorylated at Ser209, even when the ERK and/or p38 MAP kinases were activated.  Anal. of embryonic fibroblasts from single KO mice revealed that Mnk1 is responsible for the inducible phosphorylation of eIF4E in response to MAP kinase activation, whereas Mnk2 mainly contributes to eIF4E's basal, constitutive phosphorylation.  Lipopolysaccharide (LPS)- or insulin-induced upregulation of eIF4E phosphorylation in the spleen, liver, or skeletal muscle was abolished in Mnk1-/- mice, whereas the basal eIF4E phosphorylation levels were decreased in Mnk2-/- mice.  In Mnk1-Mnk2 DKO mice, no phosphorylated eIF4E was detected in any tissue studied, even after LPS or insulin injection.  However, neither general protein synthesis nor cap-dependent translation, as assayed by a bicistronic reporter assay system, was affected in Mnk-deficient embryonic fibroblasts, despite the absence of phosphorylated eIF4E.  Thus, Mnk1 and Mnk2 are exclusive eIF4E kinases both in cultured fibroblasts and adult tissues, and they regulate inducible and constitutive eIF4E phosphorylation, resp.  These results strongly suggest that eIF4E phosphorylation at Ser209 is not essential for cell growth during development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6LIGS-bIJs7Vg90H21EOLACvtfcHk0lj7oxRwcptVCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlKltLw%253D&md5=8ad9391afbf76148f4609f38d60b82aa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.15.6539-6549.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.15.6539-6549.2004%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DWatanabe-Fukunaga%26aufirst%3DR.%26aulast%3DFukuyama%26aufirst%3DH.%26aulast%3DNagata%26aufirst%3DS.%26aulast%3DFukunaga%26aufirst%3DR.%26atitle%3DMnk2%2520and%2520Mnk1%2520Are%2520Essential%2520for%2520Constitutive%2520and%2520Inducible%2520Phosphorylation%2520of%2520Eukaryotic%2520Initiation%2520Factor%25204E%2520but%2520Not%2520for%2520Cell%2520Growth%2520or%2520Development%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D6539%26epage%3D6549%26doi%3D10.1128%2FMCB.24.15.6539-6549.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saw, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzieri, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuah, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, S. T.</span></span> <span> </span><span class="NLM_article-title">Targeting of the MNK-eIF4E Axis in Blast Crisis Chronic Myeloid Leukemia Inhibits Leukemia Stem Cell Function</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">E2298</span>– <span class="NLM_lpage">E2307</span>, <span class="refDoi"> DOI: 10.1073/pnas.1301838110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1073%2Fpnas.1301838110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=23737503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOrtLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=E2298-E2307&author=S.+Limauthor=T.+Y.+Sawauthor=M.+Zhangauthor=M.+R.+Janesauthor=K.+Nacroauthor=J.+Hillauthor=A.+Q.+Limauthor=C.+T.+Changauthor=D.+A.+Frumanauthor=D.+A.+Rizzieriauthor=S.+Y.+Tanauthor=H.+Fanauthor=C.+T.+Chuahauthor=S.+T.+Ong&title=Targeting+of+the+MNK-eIF4E+Axis+in+Blast+Crisis+Chronic+Myeloid+Leukemia+Inhibits+Leukemia+Stem+Cell+Function&doi=10.1073%2Fpnas.1301838110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function</span></div><div class="casAuthors">Lim, Sharon; Saw, Tzuen Yih; Zhang, Min; Janes, Matthew R.; Nacro, Kassoum; Hill, Jeffrey; Lim, An Qi; Chang, Chia-Tien; Fruman, David A.; Rizzieri, David A.; Tan, Soo Yong; Fan, Hung; Chuah, Charles T. H.; Ong, S. Tiong</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">E2298-E2307, SE2298/1-SE2298/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Chronic myeloid leukemia responds well to therapy targeting the oncogenic fusion protein BCR-ABL1 in chronic phase, but is resistant to treatment after it progresses to blast crisis (BC).  BC is characterized by elevated β-catenin signaling in granulocyte macrophage progenitors (GMPs), which enables this population to function as leukemia stem cells (LSCs) and act as a reservoir for resistance.  Because normal hematopoietic stem cells (HSCs) and LSCs depend on β-catenin signaling for self-renewal, strategies to specifically target BC will require identification of drugable factors capable of distinguishing between self-renewal in BC LSCs and normal HSCs.  Here, we show that the MAP kinase interacting serine/threonine kinase (MNK)-eukaryotic translation initiation factor 4E (eIF4E) axis is overexpressed in BC GMPs but not normal HSCs, and that MNK kinase-dependent eIF4E phosphorylation at serine 209 activates β-catenin signaling in BC GMPs.  Mechanistically, eIF4E overexpression and phosphorylation leads to increased β-catenin protein synthesis, whereas MNK-dependent eIF4E phosphorylation is required for nuclear translocation and activation of β-catenin.  Accordingly, we found that a panel of small mol. MNK kinase inhibitors prevented eIF4E phosphorylation, β-catenin activation, and BC LSC function in vitro and in vivo.  Our findings identify the MNK-eIF4E axis as a specific and crit. regulator of BC self-renewal, and suggest that pharmacol. inhibition of the MNK kinases may be therapeutically useful in BC chronic myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsgaGxrYdhi7Vg90H21EOLACvtfcHk0lgPkMjet1HX9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOrtLvO&md5=941bd3adbe64ba804179d77829636e40</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1301838110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1301838110%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%26aulast%3DSaw%26aufirst%3DT.%2BY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DNacro%26aufirst%3DK.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DA.%2BQ.%26aulast%3DChang%26aufirst%3DC.%2BT.%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRizzieri%26aufirst%3DD.%2BA.%26aulast%3DTan%26aufirst%3DS.%2BY.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DChuah%26aufirst%3DC.%2BT.%26aulast%3DOng%26aufirst%3DS.%2BT.%26atitle%3DTargeting%2520of%2520the%2520MNK-eIF4E%2520Axis%2520in%2520Blast%2520Crisis%2520Chronic%2520Myeloid%2520Leukemia%2520Inhibits%2520Leukemia%2520Stem%2520Cell%2520Function%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2013%26volume%3D110%26spage%3DE2298%26epage%3DE2307%26doi%3D10.1073%2Fpnas.1301838110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Mnk-eIF4E Pathway Sensitizes the Efficacy to Chemotherapy in Anaplastic Thyroid Cancer</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.2217/fon-2016-0320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.2217%2Ffon-2016-0320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=27785922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFChtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=489-498&author=K.+Huauthor=J.+Zhangauthor=M.+Yuauthor=C.+Xiong&title=Inhibition+of+Mnk-eIF4E+Pathway+Sensitizes+the+Efficacy+to+Chemotherapy+in+Anaplastic+Thyroid+Cancer&doi=10.2217%2Ffon-2016-0320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Mnk-eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer</span></div><div class="casAuthors">Hu, Kun; Zhang, Juan; Yu, Min; Xiong, Chang'e</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">489-498</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Aim: We investigated whether MAPK-interacting kinase (Mnk) inhibition sensitizes anaplastic thyroid cancer (ATC) cellular response to chemotherapy.  Materials & methods: In vitro and in vivo methods were used to examine the combinatory effects of cisplatin with Mnk inhibition and its underlying mechanism.  Results: Mnk inhibition by pharmacol. or genetic approaches inhibits proliferation and induces apoptosis of ATC cells and enhances the effects of cisplatin in in vitro and in vivo.  Mechanistically, cisplatin increases eIF4E phosphorylation in a dose- and time-dependent manner in ATC cells.  Mnk inhibitors sensitize the efficacy of cisplatin by inhibiting cisplatin-induced eIF4E phosphorylation.  Conclusion: Targeting Mnk-eIF4E pathway provides a therapeutic strategy by sensitizing ATC response to chemotherapeutic drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon-gxGzHGDx7Vg90H21EOLACvtfcHk0lgPkMjet1HX9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFChtL8%253D&md5=829b3f57e9a27b7f47cb512d22be53f6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2217%2Ffon-2016-0320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2016-0320%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DXiong%26aufirst%3DC.%26atitle%3DInhibition%2520of%2520Mnk-eIF4E%2520Pathway%2520Sensitizes%2520the%2520Efficacy%2520to%2520Chemotherapy%2520in%2520Anaplastic%2520Thyroid%2520Cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2017%26volume%3D13%26spage%3D489%26epage%3D498%26doi%3D10.2217%2Ffon-2016-0320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span> <span> </span><span class="NLM_article-title">Inhibiting the MNK-eIF4E-beta-catenin Axis Increases the Responsiveness of Aggressive Breast Cancer Cells to Chemotherapy</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2906</span>– <span class="NLM_lpage">2915</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.18632%2Foncotarget.13772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=27926520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A280%3ADC%252BC2sjksVSmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=2906-2915&author=Z.+Liauthor=Y.+Sunauthor=M.+Quauthor=H.+Wanauthor=F.+Caiauthor=P.+Zhang&title=Inhibiting+the+MNK-eIF4E-beta-catenin+Axis+Increases+the+Responsiveness+of+Aggressive+Breast+Cancer+Cells+to+Chemotherapy&doi=10.18632%2Foncotarget.13772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting the MNK-eIF4E-β-catenin axis increases the responsiveness of aggressive breast cancer cells to chemotherapy</span></div><div class="casAuthors">Li Zhiqiang; Sun Yang; Wan Hongxing; Qu Miao; Cai Fang; Zhang Peng</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2906-2915</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Advanced breast cancer (eg. stage IV) is resistant to chemotherapy.  In this work, we identified potentially druggable targets that are critically involved in chemoresistance.  We showed that eIF4E is highly phosphorylated at serine 209 in breast cancer patients in response to chemotherapy, which significantly correlated with poorer clinical responses and outcomes.  Depletion of eIF4E enhanced the anti-proliferative and pro-apoptotic effects of chemotherapeutic drugs in breast cancer cells.  Chemotherapy activated the Wnt/β-catenin signaling in an eIF4E-dependent manner.  However, MNK inhibitors prevented chemotherapeutic drug-induced eIF4E phosphorylation and β-catenin activation, which enhanced the breast cancer cell response to chemotherapy in vitro and in vivo.  These findings indicate MNK-eIF4E-β-catenin is an activator of the breast cancer cell response to chemotherapy and highlights the therapeutic value of inhibiting MNK to overcome chemoresistance in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFLMaYGUFFINy3lHz94U-GfW6udTcc2eYdILIng5E2QLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjksVSmtw%253D%253D&md5=4a2f75dc03a3918b7f261b655a9855d8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13772%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DCai%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DP.%26atitle%3DInhibiting%2520the%2520MNK-eIF4E-beta-catenin%2520Axis%2520Increases%2520the%2520Responsiveness%2520of%2520Aggressive%2520Breast%2520Cancer%2520Cells%2520to%2520Chemotherapy%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D2906%26epage%3D2915%26doi%3D10.18632%2Foncotarget.13772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zha, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, M.</span></span> <span> </span><span class="NLM_article-title">Inhibiting ERK/Mnk/eIF4E Broadly Sensitizes Ovarian Cancer Response to Chemotherapy</span>. <i>Clin. Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1007/s12094-017-1724-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1007%2Fs12094-017-1724-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=28766096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1KqtL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=374-381&author=S.+Liuauthor=J.+Zhaauthor=M.+Lei&title=Inhibiting+ERK%2FMnk%2FeIF4E+Broadly+Sensitizes+Ovarian+Cancer+Response+to+Chemotherapy&doi=10.1007%2Fs12094-017-1724-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy</span></div><div class="casAuthors">Liu, S.; Zha, J.; Lei, M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">374-381</span>CODEN:
                <span class="NLM_cas:coden">CTOLAM</span>;
        ISSN:<span class="NLM_cas:issn">1699-048X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Italia S.r.l.</span>)
        </div><div class="casAbstract">To investigate whether ERK/MNK/eIF4E contributes chemoresistance in ovarian cancer.  The phosphorylated levels of Erk, Mnk, and eIF4E were systematically analyzed in ovarian cancer patients before and after chemotherapy, and ovarian cancer cells exposed to short- and long-term chemo-agent treatment.  The roles of Erk/Mnk/eIF4E were investigated using pharmacol. and genetic approaches.  Increased phosphorylation levels of ERK, Mnk1, and eIF4E were obsd. in ovarian cancer cell exposed to chemotherapeutic agents, and paclitaxel-resistant SK-OV-3-r cells, and is a common response of ovarian cancer patients undergoing chemotherapy.  MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner. eIF4E overexpression promotes ovarian cancer cell growth without affecting migration.  In addn., ovarian cancer cells with eIF4E overexpression are more resistant to chemotherapeutic agents in aspect of growth inhibition and apoptosis induction compared to control cells.  In contrast, eIF4E depletion augments chemotherapeutic agents' effect in ovarian cancer cells.  These demonstrate that eIF4E play roles in growth and chemoresistance in ovarian cancer.  MEK inhibitor U0126 also significantly enhances chemotherapeutic agents' inhibitory effects.  Our work shows that ERK/Mnk/eIF4E activation is critically involved in ovarian cancer chemoresistance and inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy9L6zDnxpNbVg90H21EOLACvtfcHk0lgHm8iaCe3_Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1KqtL3K&md5=c05ae9a8db7d198ccdab8b8e9a87d568</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs12094-017-1724-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12094-017-1724-0%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZha%26aufirst%3DJ.%26aulast%3DLei%26aufirst%3DM.%26atitle%3DInhibiting%2520ERK%252FMnk%252FeIF4E%2520Broadly%2520Sensitizes%2520Ovarian%2520Cancer%2520Response%2520to%2520Chemotherapy%26jtitle%3DClin.%2520Transl.%2520Oncol.%26date%3D2018%26volume%3D20%26spage%3D374%26epage%3D381%26doi%3D10.1007%2Fs12094-017-1724-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Targeting the eIF4E/beta-catenin Axis Sensitizes Cervical Carcinoma Squamous Cells to Chemotherapy</span>. <i>Am. J. Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1203</span>– <span class="NLM_lpage">1212</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=28386346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFelsrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1203-1212&author=H.+Xuauthor=Z.+Wangauthor=L.+Xuauthor=G.+Moauthor=G.+Duanauthor=Y.+Wangauthor=Z.+Sunauthor=H.+Chen&title=Targeting+the+eIF4E%2Fbeta-catenin+Axis+Sensitizes+Cervical+Carcinoma+Squamous+Cells+to+Chemotherapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the eIF4E/β-catenin axis sensitizes cervical carcinoma squamous cells to chemotherapy</span></div><div class="casAuthors">Xu, Hai; Wang, Zhiyin; Xu, Lang; Mo, Guoyan; Duan, Gangfeng; Wang, Yali; Sun, Zhengang; Chen, Hao</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Translational Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1203-1212</span>CODEN:
                <span class="NLM_cas:coden">AJTRA7</span>;
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Chemotherapy has improved the clin. outcomes of cervical cancer patients.  However, patients develop chemoresistance, whose underlying mechanisms are not well understood.  In this study, we investigated the phosphorylation levels of eukaryotic translation initiation factor 4E (eIF4E) in cervical cancer cells subjected to chemotherapy.  Results showed that chemotherapeutic drugs significantly increased eIF4E phosphorylation at S209 in HeLa and SiHa cells.  Upregulation of phosphorylated eIF4E (p-eIF4E) levels has also been shown in cisplatin-resistant HeLa cells and has been obsd. to be a common response of cervical cancer patients undergoing chemotherapy.  We further showed that chemotherapeutic drugs increase β-catenin activity and mRNA levels of Wnt/β-catenin target genes in cervical cancer cells but not in eIF4E-depleted cells, suggesting that chemotherapeutic drugs activate Wnt/β-catenin signaling in an eIF4E-dependent manner.  Inhibiting eIF4E via siRNA knockdown or Wnt/β-catenin using the Wnt inhibitor pyrvinium effectively enhanced the anti-proliferative and pro-apoptotic effects of cisplatin in cervical cancer cells both in vitro and in vivo.  Our findings demonstrate that eIF4E/β-catenin signaling plays a pos. regulatory role in the resistance of cervical cancer cell to chemotherapy and thus highlight the therapeutic value of eIF4E or β-catenin inhibition in overcoming chemoresistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaWWocBFM5A7Vg90H21EOLACvtfcHk0lhgEA60lgh0_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFelsrjO&md5=07445b6e9ec17f389f32b7a0fb5e92ca</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DMo%26aufirst%3DG.%26aulast%3DDuan%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DTargeting%2520the%2520eIF4E%252Fbeta-catenin%2520Axis%2520Sensitizes%2520Cervical%2520Carcinoma%2520Squamous%2520Cells%2520to%2520Chemotherapy%26jtitle%3DAm.%2520J.%2520Transl.%2520Res.%26date%3D2017%26volume%3D9%26spage%3D1203%26epage%3D1212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-b.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-m.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.-b.</span></span> <span> </span><span class="NLM_article-title">MNK1 Inhibitor CGP57380 Overcomes MTOR Inhibitor-Induced Activation of EIF4E: The Mechanism of Synergic Killing of Human T-ALL Cells</span>. <i>Acta Pharmacologica Sinica</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1894</span>– <span class="NLM_lpage">1901</span>, <span class="refDoi"> DOI: 10.1038/s41401-018-0161-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1038%2Fs41401-018-0161-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=30297804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVyhurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=1894-1901&author=X.-b.+Huangauthor=C.-m.+Yangauthor=Q.-M.+Hanauthor=X.-J.+Yeauthor=W.+Leiauthor=W.-b.+Qian&title=MNK1+Inhibitor+CGP57380+Overcomes+MTOR+Inhibitor-Induced+Activation+of+EIF4E%3A+The+Mechanism+of+Synergic+Killing+of+Human+T-ALL+Cells&doi=10.1038%2Fs41401-018-0161-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells</span></div><div class="casAuthors">Huang, Xian-bo; Yang, Chun-mei; Han, Qing-mei; Ye, Xiu-jin; Lei, Wen; Qian, Wen-bin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1894-1901</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Although the treatment of adult T-cell acute lymphoblastic leukemia (T-ALL) has been significantly improved, the heterogeneous genetic landscape of the disease often causes relapse.  Aberrant activation of mammalian target of rapamycin (mTOR) pathway in T-ALL is responsible for treatment failure and relapse, suggesting that mTOR inhibition may represents a new therapeutic strategy.  In this study, we investigated whether the mTOR complex 1 (mTORC1) inhibitor everolimus could be used as a therapeutic agent against human T-ALL.  We showed that rapamycin and its analog RAD001 (everolimus) exerted only mild inhibition on the viability of Jurkat, CEM and Molt-4 cell lines (for everolimus the max. inhibition was <40% at 100 nM), but greatly enhanced the phosphorylation of eIF4E, a downstream substrate of MAPK-interacting kinase (MNK) that was involved in promoting cell survival.  Furthermore, we demonstrated in Jurkat cells that mTOR inhibitor-induced eIF4E phosphorylation was independent of insulin-like growth factor-1/insulin-like growth factor-1 receptor axis, but was secondary to mTOR inhibition.  Then we examd. the antileukemia effects of CGP57380, a MNK1 inhibitor, and we found that CGP57380 (4-16 μM) dose-dependently suppressed the expression of both phosphor-MNK1 and phosphor-eIF4E, thereby inhibiting downstream targets such as c-Myc and survivin in T-ALL cells.  Importantly, CGP57380 produced a synergistic growth inhibitory effect with everolimus in T-ALL cells, and treatment with this targeted therapy overcame everolimus-induced eIF4E phosphorylation.  In conclusion, our results suggest that dual-targeting of mTOR and MNK1/eIF4E signaling pathways may represent a novel therapeutic strategy for the treatment of human T-ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY6QPQhjjBz7Vg90H21EOLACvtfcHk0lhgEA60lgh0_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVyhurjK&md5=557809deb55f8915f93f6f02ab7091be</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fs41401-018-0161-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-018-0161-0%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.-b.%26aulast%3DYang%26aufirst%3DC.-m.%26aulast%3DHan%26aufirst%3DQ.-M.%26aulast%3DYe%26aufirst%3DX.-J.%26aulast%3DLei%26aufirst%3DW.%26aulast%3DQian%26aufirst%3DW.-b.%26atitle%3DMNK1%2520Inhibitor%2520CGP57380%2520Overcomes%2520MTOR%2520Inhibitor-Induced%2520Activation%2520of%2520EIF4E%253A%2520The%2520Mechanism%2520of%2520Synergic%2520Killing%2520of%2520Human%2520T-ALL%2520Cells%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26date%3D2018%26volume%3D39%26spage%3D1894%26epage%3D1901%26doi%3D10.1038%2Fs41401-018-0161-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alnemah, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span> <span> </span><span class="NLM_article-title">CGP57380 Enhances Efficacy of RAD001 in Non-Small Cell Lung Cancer through Abrogating MTOR Inhibition-Induced Phosphorylation of EIF4E and Activating Mitochondrial Apoptotic Pathway</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">27787</span>– <span class="NLM_lpage">27801</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.18632%2Foncotarget.8497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=27050281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A280%3ADC%252BC28fntV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=27787-27801&author=Q.+Wenauthor=W.+Wangauthor=J.+Luoauthor=S.+Chuauthor=L.+Chenauthor=L.+Xuauthor=H.+Zangauthor=M.+M.+Alnemahauthor=J.+Maauthor=S.+Fan&title=CGP57380+Enhances+Efficacy+of+RAD001+in+Non-Small+Cell+Lung+Cancer+through+Abrogating+MTOR+Inhibition-Induced+Phosphorylation+of+EIF4E+and+Activating+Mitochondrial+Apoptotic+Pathway&doi=10.18632%2Foncotarget.8497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway</span></div><div class="casAuthors">Wen Qiuyuan; Wang Weiyuan; Luo Jiadi; Chu Shuzhou; Chen Lingjiao; Xu Lina; Zang Hongjing; Alnemah Mohannad Ma; Fan Songqing; Ma Jian</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">27787-801</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) is a potentially important therapeutic target in a broad range of cancer types. mTOR inhibitors such as rapamycin and its analogs (rapalogs) have been proven effective as anticancer agents in non-small cell lung cancer (NSCLC), whereas they strongly enhance phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) and activation of Akt, which cause resistance to mTOR-targeted therapy after an initial response.  Rapamycin induces eIF4E phosphorylation by activating MAPK-interacting kinases (Mnks), and therefore targeting Mnk/eIF4E pathway represents a potential therapeutic strategy for the treatment of NSCLC.  Here, our results showed that over-expression of p-Mnk1 and p-eIF4E was significantly associated with poor overall survival of NSCLC patients and high expression of p-Mnk1 might act as an independent prognostic biomarker for these patients.  Meanwhile, inhibiting Mnk1 expression by Mnk inhibitor (CGP57380) could abrogate rapalogs (RAD001)-induced eIF4E phosphorylation and Akt activation.  Furthermore, combination of CGP57380 and RAD001 could induce NSCLC cells apoptosis via activating intrinsic mitochondrial pathway, and exert synergistic antitumor efficacy both in vitro and in vivo.  In conclusion, combination of targeting both mTOR and Mnk/eIF4E signaling pathways to enhance effectiveness of mTOR-targeted cancer therapy might be significant innovation for the personalized treatment of NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFBfYlcnA1Rzjk2McQZ6XmfW6udTcc2eaWI2h3PRJbv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fntV2ktg%253D%253D&md5=f9c54c7e35d37d04d0d039039883c5fb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8497%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DChu%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DZang%26aufirst%3DH.%26aulast%3DAlnemah%26aufirst%3DM.%2BM.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DS.%26atitle%3DCGP57380%2520Enhances%2520Efficacy%2520of%2520RAD001%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520through%2520Abrogating%2520MTOR%2520Inhibition-Induced%2520Phosphorylation%2520of%2520EIF4E%2520and%2520Activating%2520Mitochondrial%2520Apoptotic%2520Pathway%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D27787%26epage%3D27801%26doi%3D10.18632%2Foncotarget.8497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Significance of MNK1 in Prognostic Prediction and Chemotherapy Development of Epithelial Ovarian Cancer</span>. <i>Clin. Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1116</span>, <span class="refDoi"> DOI: 10.1007/s12094-017-1646-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1007%2Fs12094-017-1646-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=28332091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslOlu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=1107-1116&author=S.+Houauthor=P.+Duauthor=P.+Wangauthor=C.+Wangauthor=P.+Liuauthor=H.+Liu&title=Significance+of+MNK1+in+Prognostic+Prediction+and+Chemotherapy+Development+of+Epithelial+Ovarian+Cancer&doi=10.1007%2Fs12094-017-1646-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer</span></div><div class="casAuthors">Hou, S.; Du, P.; Wang, P.; Wang, C.; Liu, P.; Liu, H.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1107-1116</span>CODEN:
                <span class="NLM_cas:coden">CTOLAM</span>;
        ISSN:<span class="NLM_cas:issn">1699-048X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Italia S.r.l.</span>)
        </div><div class="casAbstract">Background: Ovarian cancer is the most lethal gynecol. malignancy worldwide with surgery as the only curative treatment.  Long-term overall survival (OS) of ovarian cancer is far from satisfactory, even though significant improvement has been made in post-operative chemotherapy.  One of the most important death cause is the chemoresistance due to consecutive chemotherapy.  Therefore, understanding the mol. mechanisms involved in ovarian cancer development and identification of novel therapeutic targets are urgently required.  Methods: Immunohistochem. (IHC) staining was used to explore the expression pattern of mitogen-activated protein kinase (MAPK)-interacting kinase 1 (MNK1) in tumor tissues from 138 epithelial ovarian cancer (EOC) patients.  Clinicopathol. data were subjected to Kaplan-Meier survival and Cox multivariate analyses to evaluate the prognostic value of MNK1 in EOC.  Overexpression and silencing procedures were performed on OVCAR-5 cells to investigate the mechanisms of MNK1 in regulating EOC development.  The anti-tumor effects of CGP57380, a specific MNK inhibitor, were examd. by cell viability assay.  Results: Higher MNK1 expression showed significant relationship with advanced FIGO stage and pos. lymph node metastasis of EOC.  Univariate and multivariate analyses revealed that MNK1 was an independent prognostic factor for OS of EOC patients.  In vitro study demonstrated that MNK1 can promote cell proliferation through regulating the phosphorylation level of eukaryotic initiation factor 4E.  In addn., inhibition of MNK1 by CGP57380 significantly down-regulated the OVCAR-5 cell viability.  Conclusion: High MNK1 expression in EOC tissues indicates poor clin. outcomes, and MNK1 can act as a potential target for novel chemotherapy development towards EOC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9D2pcdqzgXbVg90H21EOLACvtfcHk0ljviogTBRn9RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslOlu7k%253D&md5=b92796f616edab6ee14557021bb1d77f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs12094-017-1646-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12094-017-1646-x%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DSignificance%2520of%2520MNK1%2520in%2520Prognostic%2520Prediction%2520and%2520Chemotherapy%2520Development%2520of%2520Epithelial%2520Ovarian%2520Cancer%26jtitle%3DClin.%2520Transl.%2520Oncol.%26date%3D2017%26volume%3D19%26spage%3D1107%26epage%3D1116%26doi%3D10.1007%2Fs12094-017-1646-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dreas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikulski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabritius, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzózka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rzymski, T.</span></span> <span> </span><span class="NLM_article-title">Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3025</span>– <span class="NLM_lpage">3053</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170203123427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.2174%2F0929867324666170203123427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=28164761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1SqsrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=3025-3053&author=A.+Dreasauthor=M.+Mikulskiauthor=M.+Milikauthor=C.+H.+Fabritiusauthor=K.+Brz%C3%B3zkaauthor=T.+Rzymski&title=Mitogen-activated+Protein+Kinase+%28MAPK%29+Interacting+Kinases+1+and+2+%28MNK1+and+MNK2%29+as+Targets+for+Cancer+Therapy%3A+Recent+Progress+in+the+Development+of+MNK+Inhibitors&doi=10.2174%2F0929867324666170203123427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors</span></div><div class="casAuthors">Dreas, Agnieszka; Mikulski, Maciej; Milik, Mariusz; Fabritius, Charles-Henry; Brzozka, Krzysztof; Rzymski, Tomasz</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3025-3053</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">MAP kinase-interacting kinases (MNK1 and MNK2) are often activated downstream of ERK and p38 MAPK in the MAP kinase family.  The role of MNKs in the development and progression of solid tumors and hematol. malignancies has been widely discussed, particularly in the context of cap dependent translation, regulated by phosphorylation of eIF4E.  MNK/eIF4E axis is involved in the expression of pro angiogenic, antiapoptotic, cell cycle, and motility proteins, such as MCL1, VEGF, MMP3, SNAIL, SMAD2, β-catenin or cyclin D1, and is essential during Ras and c Myc-induced transformation.  MNK1/2 emerged as eligible targets for drug discovery in oncol., based on the antitumor effects obsd. in genetic knockout and RNA interference expts. and at the same time lack of adverse effects in dual knockout animals. </P><P> There is a high interest in the development of pharmacol. inhibitors of MNK1/2 as not only tools for further basic research studies but also potential drugs in diseases characterized by deregulated translation.  Unfortunately, the role of MNK1/2 in cancer still remains elusive due to the absence of potent and selective probes.  Moreover, in many instances, hypotheses have been built reliant upon unspecific MNK1/2 inhibitors such as CGP57380 or cercosporamide.  Lately, the first two clin. programs targeting MNKs in oncol. have been revealed (eFT508 and BAY 1143269), although several other MNK programs are currently running at the preclin. stage.  This review aims to provide an overview of recent progress in the development of MNK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjWDeCrlHD07Vg90H21EOLACvtfcHk0ljviogTBRn9RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1SqsrnI&md5=c2a37d37d69521b11a38bb100e7964af</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170203123427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170203123427%26sid%3Dliteratum%253Aachs%26aulast%3DDreas%26aufirst%3DA.%26aulast%3DMikulski%26aufirst%3DM.%26aulast%3DMilik%26aufirst%3DM.%26aulast%3DFabritius%26aufirst%3DC.%2BH.%26aulast%3DBrz%25C3%25B3zka%26aufirst%3DK.%26aulast%3DRzymski%26aufirst%3DT.%26atitle%3DMitogen-activated%2520Protein%2520Kinase%2520%2528MAPK%2529%2520Interacting%2520Kinases%25201%2520and%25202%2520%2528MNK1%2520and%2520MNK2%2529%2520as%2520Targets%2520for%2520Cancer%2520Therapy%253A%2520Recent%2520Progress%2520in%2520the%2520Development%2520of%2520MNK%2520Inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26volume%3D24%26spage%3D3025%26epage%3D3053%26doi%3D10.2174%2F0929867324666170203123427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santag, S.</span>; <span class="NLM_string-name">Siegel, F.</span>; <span class="NLM_string-name">Wegner, A. M.</span>; <span class="NLM_string-name">Schneider, C.</span>; <span class="NLM_string-name">Boemer, U.</span>; <span class="NLM_string-name">Eis, K.</span>; <span class="NLM_string-name">Puehler, F.</span>; <span class="NLM_string-name">Michels, M.</span>; <span class="NLM_string-name">von Nussbaum, F.</span>; <span class="NLM_string-name">Ziegelbauer, K.</span>; <span class="NLM_string-name">Mumberg, D.</span>; <span class="NLM_string-name">Petersen, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical Anti-Tumor Efficacy and Mode of Action of a Novel, Orally Available, Selective MKNK1 Inhibitor (BAY1143269)</span>. Annual Meeting of the American Association for Cancer Research <span class="NLM_year">2015</span>. 1143269.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+Santag&author=F.+Siegel&author=A.+M.+Wegner&author=C.+Schneider&author=U.+Boemer&author=K.+Eis&author=F.+Puehler&author=M.+Michels&author=F.+von+Nussbaum&author=K.+Ziegelbauer&author=D.+Mumberg&author=K.+Petersen&title=Preclinical+Anti-Tumor+Efficacy+and+Mode+of+Action+of+a+Novel%2C+Orally+Available%2C+Selective+MKNK1+Inhibitor+%28BAY1143269%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DSantag%26aufirst%3DS.%26atitle%3DPreclinical%2520Anti-Tumor%2520Efficacy%2520and%2520Mode%2520of%2520Action%2520of%2520a%2520Novel%252C%2520Orally%2520Available%252C%2520Selective%2520MKNK1%2520Inhibitor%2520%2528BAY1143269%2529%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelaziz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basnet, S. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noll, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekonnen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.2174/1573406415666181219111511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.2174%2F1573406415666181219111511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=30569866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslWrs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=602-623&author=A.+M.+Abdelazizauthor=S.+Diabauthor=S.+Islamauthor=S.+K.+C.+Basnetauthor=B.+Nollauthor=P.+Liauthor=L.+B.+Mekonnenauthor=J.+Luauthor=H.+Albrechtauthor=R.+W.+Milneauthor=C.+Gerberauthor=M.+Yuauthor=S.+Wang&title=Discovery+of+N-phenyl-4-%281H-pyrrol-3-yl%29pyrimidin-2-amine+Derivatives+as+Potent+Mnk2+Inhibitors%3A+Design%2C+Synthesis%2C+SAR+Analysis%2C+and+Evaluation+of+in+vitro+Anti-leukaemic+Activity&doi=10.2174%2F1573406415666181219111511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity</span></div><div class="casAuthors">Abdelaziz, Ahmed M.; Diab, Sarah; Islam, Saiful; Basnet, Sunita K. C.; Noll, Benjamin; Li, Peng; Mekonnen, Laychiluh B.; Lu, Jingfeng; Albrecht, Hugo; Milne, Robert W.; Gerber, Cobus; Yu, Mingfeng; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">602-623</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Aberrant expression of eukaryotic translation initiation factor 4E (eIF4E) is common in many types of cancer including acute myeloid leukemia (AML).  Phosphorylation of eIF4E by MAPK-interacting kinases (Mnks) is essential for the eIF4E-mediated oncogenic activity.  As such, the pharmacol. inhibition of Mnks can be an effective strategy for the treatment of cancer.  Methods: A series of N-phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine derivs. was designed and synthesized.  The Mnk inhibitory activity of these derivs. as well as their anti-proliferative activity against MV4-11 AML cells was detd.  Results: These compds. were identified as potent Mnk2 inhibitors.  Most of them demonstrated potent anti-proliferative activity against MV4-11 AML cells.  The cellular mechanistic studies of the representative inhibitors revealed that they reduced the level of phosphorylated eIF4E and induced apoptosis by down-regulating the anti-apoptotic protein myeloid cell leukemia 1 (Mcl-1) and by cleaving poly(ADP-ribose)polymerase (PARP).  The lead compd. 7k possessed desirable pharmacokinetic properties and oral bioavailability.  Conclusion: This work proposes that exploration of the structural diversity in the context of Nphenyl- 4-(1H-pyrrol-3-yl)pyrimidin-2-amine would offer potent and selective Mnk inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou_LM2pLMYxbVg90H21EOLACvtfcHk0lgcUt8qW4NjQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslWrs7zN&md5=fac36273eab8d9ee46dd221f488250eb</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F1573406415666181219111511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573406415666181219111511%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelaziz%26aufirst%3DA.%2BM.%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DIslam%26aufirst%3DS.%26aulast%3DBasnet%26aufirst%3DS.%2BK.%2BC.%26aulast%3DNoll%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DMekonnen%26aufirst%3DL.%2BB.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DMilne%26aufirst%3DR.%2BW.%26aulast%3DGerber%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520N-phenyl-4-%25281H-pyrrol-3-yl%2529pyrimidin-2-amine%2520Derivatives%2520as%2520Potent%2520Mnk2%2520Inhibitors%253A%2520Design%252C%2520Synthesis%252C%2520SAR%2520Analysis%252C%2520and%2520Evaluation%2520of%2520in%2520vitro%2520Anti-leukaemic%2520Activity%26jtitle%3DMed.%2520Chem.%26date%3D2019%26volume%3D15%26spage%3D602%26epage%3D623%26doi%3D10.2174%2F1573406415666181219111511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poh, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaraj, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joy, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwek, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wee, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choong, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendharkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangthongpitag, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3063</span>– <span class="NLM_lpage">3078</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVaisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3063-3078&author=J.+Cherianauthor=K.+Nacroauthor=Z.+Y.+Pohauthor=S.+Guoauthor=D.+A.+Jeyarajauthor=Y.+X.+Wongauthor=M.+Hoauthor=H.+Y.+Yangauthor=J.+K.+Joyauthor=Z.+P.+Kwekauthor=B.+Liuauthor=J.+L.+Weeauthor=E.+H.+Ongauthor=M.+L.+Choongauthor=A.+Poulsenauthor=M.+A.+Leeauthor=V.+Pendharkarauthor=L.+J.+Dingauthor=V.+Manoharanauthor=Y.+S.+Chewauthor=K.+Sangthongpitagauthor=S.+Limauthor=S.+T.+Ongauthor=J.+Hillauthor=T.+H.+Keller&title=Structure-Activity+Relationship+Studies+of+Mitogen+Activated+Protein+Kinase+Interacting+Kinase+%28MNK%29+1+and+2+and+BCR-ABL1+Inhibitors+Targeting+Chronic+Myeloid+Leukemic+Cells&doi=10.1021%2Facs.jmedchem.5b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells</span></div><div class="casAuthors">Cherian, Joseph; Nacro, Kassoum; Poh, Zhi Ying; Guo, Samantha; Jeyaraj, Duraiswamy A.; Wong, Yun Xuan; Ho, Melvyn; Yang, Hai Yan; Joy, Joma Kanikadu; Kwek, Zekui Perlyn; Liu, Boping; Wee, John Liang Kuan; Ong, Esther HQ; Choong, Meng Ling; Poulsen, Anders; Lee, May Ann; Pendharkar, Vishal; Ding, Li Jun; Manoharan, Vithya; Chew, Yun Shan; Sangthongpitag, Kanda; Lim, Sharon; Ong, S. Tiong; Hill, Jeffrey; Keller, Thomas H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3063-3078</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin. used BCR-ABL1 inhibitors for the treatment of chronic myeloid leukemia do not eliminate leukemic stem cells (LSC).  It has been shown that MNK1 and 2 inhibitors prevent phosphorylation of eIF4E and eliminate the self-renewal capacity of LSCs.  Herein, the authors describe the identification of novel dual MNK1 and 2 and BCR-ABL1 inhibitors, starting from the known kinase inhibitor.  Initial structure-activity relationship studies resulted in a compd. with loss of BCR-ABL1 inhibition.  Further modification led to orally bioavailable dual MNK1 and 2 and BCR-ABL1 inhibitors I and II, which are efficacious in a mouse xenograft model and also reduce the level of phosphorylated eukaryotic translation initiation factor 4E in the tumor tissues.  Kinase selectivity of these compds. is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4wVNbiR5xDrVg90H21EOLACvtfcHk0liLW1Mj0IVskg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVaisbk%253D&md5=4adfe2099cc1bb7fa5e0db8cb9358844</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCherian%26aufirst%3DJ.%26aulast%3DNacro%26aufirst%3DK.%26aulast%3DPoh%26aufirst%3DZ.%2BY.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DJeyaraj%26aufirst%3DD.%2BA.%26aulast%3DWong%26aufirst%3DY.%2BX.%26aulast%3DHo%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DJoy%26aufirst%3DJ.%2BK.%26aulast%3DKwek%26aufirst%3DZ.%2BP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DWee%26aufirst%3DJ.%2BL.%26aulast%3DOng%26aufirst%3DE.%2BH.%26aulast%3DChoong%26aufirst%3DM.%2BL.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DM.%2BA.%26aulast%3DPendharkar%26aufirst%3DV.%26aulast%3DDing%26aufirst%3DL.%2BJ.%26aulast%3DManoharan%26aufirst%3DV.%26aulast%3DChew%26aufirst%3DY.%2BS.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DLim%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DS.%2BT.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26atitle%3DStructure-Activity%2520Relationship%2520Studies%2520of%2520Mitogen%2520Activated%2520Protein%2520Kinase%2520Interacting%2520Kinase%2520%2528MNK%2529%25201%2520and%25202%2520and%2520BCR-ABL1%2520Inhibitors%2520Targeting%2520Chronic%2520Myeloid%2520Leukemic%2520Cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3063%26epage%3D3078%26doi%3D10.1021%2Facs.jmedchem.5b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basnet, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Unveiling New Chemical Scaffolds as Mnk Inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.4155/fmc.15.190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.4155%2Ffmc.15.190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=26910782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtlKjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=271-285&author=S.+Diabauthor=P.+Liauthor=S.+K.+Basnetauthor=J.+Luauthor=M.+Yuauthor=H.+Albrechtauthor=R.+W.+Milneauthor=S.+Wang&title=Unveiling+New+Chemical+Scaffolds+as+Mnk+Inhibitors&doi=10.4155%2Ffmc.15.190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Unveiling new chemical scaffolds as Mnk inhibitors</span></div><div class="casAuthors">Diab, Sarah; Li, Peng; Basnet, Sunita; Lu, Jingfeng; Yu, Mingfeng; Albrecht, Hugo; Milne, Robert W.; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-285</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The discovery of small mols. that selectively inhibit Mnks is considered of paramount importance towards deciphering the exact role of these proteins in carcinogenesis and to further validate them as anti-cancer drug targets.  However, the dearth of structural information of Mnks is a major hurdle.  This study unveils the 7H-pyrrolo[2,3-d]pyrimidine derivs. as potent inhibitors of Mnks.  ATP and substrate competition assays showed that this scaffold interacts with the ATP binding site, but not with the substrate site.  Screened against a panel of cancer cells, Mnk inhibitors were most potent against MV4-11 acute myeloid leukemia cells.  The induction of apoptosis was shown to be mediated by downregulation of Mcl-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOx0Xl19uq77Vg90H21EOLACvtfcHk0liTHIL9IQp6sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtlKjsrg%253D&md5=96a4d887691ff1162b703dffc2ccc352</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4155%2Ffmc.15.190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.15.190%26sid%3Dliteratum%253Aachs%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DBasnet%26aufirst%3DS.%2BK.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DMilne%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DUnveiling%2520New%2520Chemical%2520Scaffolds%2520as%2520Mnk%2520Inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D271%26epage%3D285%26doi%3D10.4155%2Ffmc.15.190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanidi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, C. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1&2) Utilizing Structure-Based Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3034</span>– <span class="NLM_lpage">3045</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01657</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01657" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1eit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3034-3045&author=W.+Hanauthor=Y.+Dingauthor=Y.+Xuauthor=K.+Pfisterauthor=S.+Zhuauthor=B.+Warneauthor=M.+Doyleauthor=M.+Aikawaauthor=P.+Amiriauthor=B.+Appletonauthor=D.+D.+Stuartauthor=A.+Fanidiauthor=C.+M.+Shafer&title=Discovery+of+a+Selective+and+Potent+Inhibitor+of+Mitogen-Activated+Protein+Kinase-Interacting+Kinases+1+and+2+%28MNK1%262%29+Utilizing+Structure-Based+Drug+Design&doi=10.1021%2Facs.jmedchem.5b01657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design</span></div><div class="casAuthors">Han, Wooseok; Ding, Yu; Xu, Yongjin; Pfister, Keith; Zhu, Shejin; Warne, Bob; Doyle, Mike; Aikawa, Mina; Amiri, Payman; Appleton, Brent; Stuart, Darrin D.; Fanidi, Abdallah; Shafer, Cynthia M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3034-3045</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of a highly potent and selective small mol. inhibitor I for in vitro target validation of MNK1/2 kinases is described.  The aminopyrazine benzimidazole series was derived from an HTS hit and optimized by utilization of a docking model, conformation anal., and binding pocket comparison against antitargets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBT5jenqIBHLVg90H21EOLACvtfcHk0liTHIL9IQp6sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1eit7s%253D&md5=b4c3eb8122635da657fa52daddb6879a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01657%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DWarne%26aufirst%3DB.%26aulast%3DDoyle%26aufirst%3DM.%26aulast%3DAikawa%26aufirst%3DM.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DAppleton%26aufirst%3DB.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26aulast%3DFanidi%26aufirst%3DA.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26atitle%3DDiscovery%2520of%2520a%2520Selective%2520and%2520Potent%2520Inhibitor%2520of%2520Mitogen-Activated%2520Protein%2520Kinase-Interacting%2520Kinases%25201%2520and%25202%2520%2528MNK1%25262%2529%2520Utilizing%2520Structure-Based%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3034%26epage%3D3045%26doi%3D10.1021%2Facs.jmedchem.5b01657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albarran, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacios, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbano-Cuadrado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reymundo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrionero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fominaya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, J. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of Mitogen-Activated Protein Kinase-Interacting Kinase 1 Inhibitors by a Comprehensive Fragment-Oriented Virtual Screening Approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6618</span>– <span class="NLM_lpage">6628</span>, <span class="refDoi"> DOI: 10.1021/jm1005513</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1005513" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCns7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6618-6628&author=J.+Oyarzabalauthor=N.+Zarichauthor=M.+I.+Albarranauthor=I.+Palaciosauthor=M.+Urbano-Cuadradoauthor=G.+Mateosauthor=I.+Reymundoauthor=O.+Rabalauthor=A.+Salgadoauthor=A.+Corrioneroauthor=J.+Fominayaauthor=J.+Pastorauthor=J.+R.+Bischoff&title=Discovery+of+Mitogen-Activated+Protein+Kinase-Interacting+Kinase+1+Inhibitors+by+a+Comprehensive+Fragment-Oriented+Virtual+Screening+Approach&doi=10.1021%2Fjm1005513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Mitogen-Activated Protein Kinase-Interacting Kinase 1 Inhibitors by a Comprehensive Fragment-Oriented Virtual Screening Approach</span></div><div class="casAuthors">Oyarzabal, Julen; Zarich, Natasha; Albarran, Maria Isabel; Palacios, Irene; Urbano-Cuadrado, Manuel; Mateos, Genoveva; Reymundo, Isabel; Rabal, Obdulia; Salgado, Antonio; Corrionero, Ana; Fominaya, Jesus; Pastor, Joaquin; Bischoff, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6618-6628</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1 and MNK2) phosphorylate the oncogene eIF4E on serine 209.  This phosphorylation has been reported to be required for its oncogenic activity.  To investigate if pharmacol. inhibition of MNK1 could be useful for the treatment of cancers, we pursued a comprehensive virtual screening approach to rapidly identify pharmacol. tools for target validation and to find optimal starting points for a plausible medicinal chem. project.  A collection of 1236 compds., selected from a library of 42 168 compds. and a database of 18.8 million structures, were assayed.  Of the identified hits, 26 were found to have IC50 values less than 10 μM (2.10% hit rate).  The most potent compd. had an IC50 value of 117 nM, and 73.1% of these hits were fragments.  The hits were characterized by a high ligand efficiency (0.32-0.52 kcal/mol per heavy atom).  Ten different chem. scaffolds were represented, giving a chemotype/hit ratio of 0.38.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWli1zSitx8LVg90H21EOLACvtfcHk0lhS3JjOsfVMLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCns7nM&md5=2ce8787b149c9175c52b01b2ea4adb3b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm1005513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1005513%26sid%3Dliteratum%253Aachs%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DZarich%26aufirst%3DN.%26aulast%3DAlbarran%26aufirst%3DM.%2BI.%26aulast%3DPalacios%26aufirst%3DI.%26aulast%3DUrbano-Cuadrado%26aufirst%3DM.%26aulast%3DMateos%26aufirst%3DG.%26aulast%3DReymundo%26aufirst%3DI.%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DSalgado%26aufirst%3DA.%26aulast%3DCorrionero%26aufirst%3DA.%26aulast%3DFominaya%26aufirst%3DJ.%26aulast%3DPastor%26aufirst%3DJ.%26aulast%3DBischoff%26aufirst%3DJ.%2BR.%26atitle%3DDiscovery%2520of%2520Mitogen-Activated%2520Protein%2520Kinase-Interacting%2520Kinase%25201%2520Inhibitors%2520by%2520a%2520Comprehensive%2520Fragment-Oriented%2520Virtual%2520Screening%2520Approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6618%26epage%3D6628%26doi%3D10.1021%2Fjm1005513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flower, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proud, C. G.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Activity of Mnk1 and Mnk2 Selective Inhibitors Containing Thieno[2,3-d]pyrimidine Scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.10.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1016%2Fj.ejmech.2018.10.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=30496989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlKjs7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2019&pages=735-751&author=X.+Jinauthor=J.+Merrettauthor=S.+Tongauthor=B.+Flowerauthor=J.+Xieauthor=R.+Yuauthor=S.+Tianauthor=L.+Gaoauthor=J.+Zhaoauthor=X.+Wangauthor=T.+Jiangauthor=C.+G.+Proud&title=Design%2C+Synthesis+and+Activity+of+Mnk1+and+Mnk2+Selective+Inhibitors+Containing+Thieno%5B2%2C3-d%5Dpyrimidine+Scaffold&doi=10.1016%2Fj.ejmech.2018.10.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold</span></div><div class="casAuthors">Jin, Xin; Merrett, James; Tong, Sheng; Flower, Bartholomew; Xie, Jianling; Yu, Rilei; Tian, Shuye; Gao, Ling; Zhao, Jiajun; Wang, Xuemin; Jiang, Tao; Proud, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">735-751</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1 and MNK2) phosphorylate eukaryotic initiation factor 4E (eIF4E) and play important roles in promoting tumorigenesis and metabolic disease.  Thus, inhibiting these enzymes might be valuable in the treatment of such conditions.  We designed and synthesized a series of 4-((4-fluoro-2-isopropoxyphenyl)amino)-5-methylthieno[2,3-d]pyrimidine derivs., and evaluated their inhibitory activity against the MNKs.  We found 15 compds. that were active as MNK inhibitors and that one in particular, designated MNK-7g, which was potent against MNK1 and substantially more potent against MNK2.  The compd. MNK-7g did not affect other signaling pathways tested and had no adverse effects on cell viability.  As expected from earlier studies, MNK-7g also inhibited cell migration.  Therefore, the compd. MNK-7g, which forms an ionic bond with Asp226 in MNK2 and possesses a substituted aniline in a thieno[2,3-d] pyrimidine structure, is a promising starting point for the future development of novel drugs for treating or managing cancer and metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1WLYsoUMgW7Vg90H21EOLACvtfcHk0lhS3JjOsfVMLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlKjs7fN&md5=6d291e57bcacfad40145b96d3442209c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.10.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.10.070%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DX.%26aulast%3DMerrett%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DS.%26aulast%3DFlower%26aufirst%3DB.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DR.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Activity%2520of%2520Mnk1%2520and%2520Mnk2%2520Selective%2520Inhibitors%2520Containing%2520Thieno%255B2%252C3-d%255Dpyrimidine%2520Scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D162%26spage%3D735%26epage%3D751%26doi%3D10.1016%2Fj.ejmech.2018.10.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, E. Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, I. N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemison, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaghafi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpf, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webber, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegerski, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span> <span> </span><span class="NLM_article-title">Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1&2) Inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3516</span>– <span class="NLM_lpage">3540</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01795</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01795" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3516-3540&author=S.+H.+Reichauthor=P.+A.+Sprengelerauthor=G.+G.+Chiangauthor=J.+R.+Applemanauthor=J.+Chenauthor=J.+Clarineauthor=B.+Eamauthor=J.+T.+Ernstauthor=Q.+Hanauthor=V.+K.+Goelauthor=E.+Z.+R.+Hanauthor=V.+Huangauthor=I.+N.+J.+Hungauthor=A.+Jemisonauthor=K.+A.+Jessenauthor=J.+Molterauthor=D.+Murphyauthor=M.+Nealauthor=G.+S.+Parkerauthor=M.+Shaghafiauthor=S.+Sperryauthor=J.+Stauntonauthor=C.+R.+Stumpfauthor=P.+A.+Thompsonauthor=C.+Tranauthor=S.+E.+Webberauthor=C.+J.+Wegerskiauthor=H.+Zhengauthor=K.+R.+Webster&title=Structure-based+Design+of+Pyridone-Aminal+eFT508+Targeting+Dysregulated+Translation+by+Selective+Mitogen-activated+Protein+Kinase+Interacting+Kinases+1+and+2+%28MNK1%262%29+Inhibition&doi=10.1021%2Facs.jmedchem.7b01795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition</span></div><div class="casAuthors">Reich, Siegfried H.; Sprengeler, Paul A.; Chiang, Gary G.; Appleman, James R.; Chen, Joan; Clarine, Jeff; Eam, Boreth; Ernst, Justin T.; Han, Qing; Goel, Vikas K.; Han, Edward Z. R.; Huang, Vera; Hung, Ivy N. J.; Jemison, Adrianna; Jessen, Katti A.; Molter, Jolene; Murphy, Douglas; Neal, Melissa; Parker, Gregory S.; Shaghafi, Michael; Sperry, Samuel; Staunton, Jocelyn; Stumpf, Craig R.; Thompson, Peggy A.; Tran, Chinh; Webber, Stephen E.; Wegerski, Christopher J.; Zheng, Hong; Webster, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3516-3540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulated translation of mRNA plays a major role in tumorigenesis.  Mitogen-activated protein kinase interacting kinases (MNK)1/2 are key regulators of mRNA translation integrating signals from oncogenic and immune signaling pathways through phosphorylation of eIF4E and other mRNA binding proteins.  Modulation of these key effector proteins regulates mRNA, which controls tumor/stromal cell signaling.  Compd. 23 (eFT508, 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro-[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione hydrochloride), an exquisitely selective, potent dual MNK1/2 inhibitor, was designed to assess the potential for control of oncogene signaling at the level of mRNA translation.  The crystal structure-guided design leverages stereoelectronic interactions unique to MNK culminating in a novel pyridone-aminal structure described for the first time in the kinase literature.  Compd. 23 has potent in vivo antitumor activity in models of diffuse large cell B-cell lymphoma and solid tumors, suggesting that controlling dysregulated translation has real therapeutic potential.  Compd. 23 is currently being evaluated in Phase 2 clin. trials in solid tumors and lymphoma.  Compd. 23 is the first highly selective dual MNK inhibitor targeting dysregulated translation being assessed clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAp-3GOuZu8bVg90H21EOLACvtfcHk0lh9IpNf6tGB2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGhs7s%253D&md5=1254b674aa7e6d2037a06bc10e64e4da</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01795%26sid%3Dliteratum%253Aachs%26aulast%3DReich%26aufirst%3DS.%2BH.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DAppleman%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DClarine%26aufirst%3DJ.%26aulast%3DEam%26aufirst%3DB.%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DGoel%26aufirst%3DV.%2BK.%26aulast%3DHan%26aufirst%3DE.%2BZ.%2BR.%26aulast%3DHuang%26aufirst%3DV.%26aulast%3DHung%26aufirst%3DI.%2BN.%2BJ.%26aulast%3DJemison%26aufirst%3DA.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DMolter%26aufirst%3DJ.%26aulast%3DMurphy%26aufirst%3DD.%26aulast%3DNeal%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DG.%2BS.%26aulast%3DShaghafi%26aufirst%3DM.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DStaunton%26aufirst%3DJ.%26aulast%3DStumpf%26aufirst%3DC.%2BR.%26aulast%3DThompson%26aufirst%3DP.%2BA.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DWegerski%26aufirst%3DC.%2BJ.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3DStructure-based%2520Design%2520of%2520Pyridone-Aminal%2520eFT508%2520Targeting%2520Dysregulated%2520Translation%2520by%2520Selective%2520Mitogen-activated%2520Protein%2520Kinase%2520Interacting%2520Kinases%25201%2520and%25202%2520%2528MNK1%25262%2529%2520Inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3516%26epage%3D3540%26doi%3D10.1021%2Facs.jmedchem.7b01795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckerdt, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arslan, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clymer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horbinsky, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davuluru, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platanias, L. C.</span></span> <span> </span><span class="NLM_article-title">MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">993</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-16-0172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1158%2F1541-7786.MCR-16-0172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=27364770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGisbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=984-993&author=J.+B.+Bellauthor=F.+D.+Eckerdtauthor=K.+Alleyauthor=L.+P.+Magnussonauthor=H.+Hussainauthor=Y.+Biauthor=A.+D.+Arslanauthor=J.+Clymerauthor=A.+A.+Alvarezauthor=S.+Goldmanauthor=S.-Y.+Chengauthor=I.+Nakanoauthor=C.+Horbinskyauthor=R.+V.+Davuluruauthor=C.+D.+Jamesauthor=L.+C.+Platanias&title=MNK+Inhibition+Disrupts+Mesenchymal+Glioma+Stem+Cells+and+Prolongs+Survival+in+a+Mouse+Model+of+Glioblastoma&doi=10.1158%2F1541-7786.MCR-16-0172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma</span></div><div class="casAuthors">Bell, Jonathan B.; Eckerdt, Frank D.; Alley, Kristen; Magnusson, Lisa P.; Hussain, Hridi; Bi, Yingtao; Arslan, Ahmet Dirim; Clymer, Jessica; Alvarez, Angel A.; Goldman, Stewart; Cheng, Shi-Yuan; Nakano, Ichiro; Horbinski, Craig; Davuluri, Ramana V.; James, C. David; Platanias, Leonidas C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">984-993</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Glioblastoma multiforme remains the deadliest malignant brain tumor, with glioma stem cells (GSC) contributing to treatment resistance and tumor recurrence.  We have identified MAPK-interacting kinases (MNK) as potential targets for the GSC population in glioblastoma multiforme.  Isoform-level subtyping using The Cancer Genome Atlas revealed that both MNK genes (MKNK1 and MKNK2) are upregulated in mesenchymal glioblastoma multiforme as compared with other subtypes.  Expression of MKNK1 is assocd. with increased glioma grade and correlated with the mesenchymal GSC marker, CD44, and coexpression of MKNK1 and CD44 predicts poor survival in glioblastoma multiforme.  In established and patient-derived cell lines, pharmacol. MNK inhibition using LY2801653 (merestinib) inhibited phosphorylation of the eukaryotic translation initiation factor 4E, a crucial effector for MNK-induced mRNA translation in cancer cells and a marker of transformation.  Importantly, merestinib inhibited growth of GSCs grown as neurospheres as detd. by extreme limiting diln. anal.  When the effects of merestinib were assessed in vivo using an intracranial xenograft mouse model, improved overall survival was obsd. in merestinib-treated mice.  Taken together, these data provide strong preclin. evidence that pharmacol. MNK inhibition targets mesenchymal glioblastoma multiforme and its GSC population.  These findings raise the possibility of MNK inhibition as a viable therapeutic approach to target the mesenchymal subtype of glioblastoma multiforme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzbXOivkr8_7Vg90H21EOLACvtfcHk0li1XZyAFIs4JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGisbbM&md5=690d5b41dbbdfa81a470c54e09ad3a92</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-16-0172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-16-0172%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DJ.%2BB.%26aulast%3DEckerdt%26aufirst%3DF.%2BD.%26aulast%3DAlley%26aufirst%3DK.%26aulast%3DMagnusson%26aufirst%3DL.%2BP.%26aulast%3DHussain%26aufirst%3DH.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DArslan%26aufirst%3DA.%2BD.%26aulast%3DClymer%26aufirst%3DJ.%26aulast%3DAlvarez%26aufirst%3DA.%2BA.%26aulast%3DGoldman%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DS.-Y.%26aulast%3DNakano%26aufirst%3DI.%26aulast%3DHorbinsky%26aufirst%3DC.%26aulast%3DDavuluru%26aufirst%3DR.%2BV.%26aulast%3DJames%26aufirst%3DC.%2BD.%26aulast%3DPlatanias%26aufirst%3DL.%2BC.%26atitle%3DMNK%2520Inhibition%2520Disrupts%2520Mesenchymal%2520Glioma%2520Stem%2520Cells%2520and%2520Prolongs%2520Survival%2520in%2520a%2520Mouse%2520Model%2520of%2520Glioblastoma%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2016%26volume%3D14%26spage%3D984%26epage%3D993%26doi%3D10.1158%2F1541-7786.MCR-16-0172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chennamaneni, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M. W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaraj, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joy, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wee, J. L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Retna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendharkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuddagiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangthongpitag, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choong, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kannan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuah, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacro, K.</span></span> <span> </span><span class="NLM_article-title">Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4348</span>– <span class="NLM_lpage">4369</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01714</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01714" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXot1eqsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4348-4369&author=H.+Yangauthor=L.+R.+Chennamaneniauthor=M.+W.+T.+Hoauthor=S.+H.+Angauthor=E.+S.+W.+Tanauthor=D.+A.+Jeyarajauthor=Y.+S.+Yeapauthor=B.+Liuauthor=E.+H.+Ongauthor=J.+K.+Joyauthor=J.+L.+K.+Weeauthor=P.+Kwekauthor=P.+Retnaauthor=N.+Dinieauthor=T.+T.+H.+Nguyenauthor=S.+J.+Taiauthor=V.+Manoharanauthor=V.+Pendharkarauthor=C.+B.+Lowauthor=Y.+S.+Chewauthor=S.+Vuddagiriauthor=K.+Sangthongpitagauthor=M.+L.+Choongauthor=M.+A.+Leeauthor=S.+Kannanauthor=C.+S.+Vermaauthor=A.+Poulsenauthor=S.+Limauthor=C.+Chuahauthor=T.+S.+Ongauthor=J.+Hillauthor=A.+Matterauthor=K.+Nacro&title=Optimization+of+Selective+Mitogen-Activated+Protein+Kinase+Interacting+Kinases+1+and+2+Inhibitors+for+the+Treatment+of+Blast+Crisis+Leukemia&doi=10.1021%2Facs.jmedchem.7b01714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia</span></div><div class="casAuthors">Yang, Haiyan; Chennamaneni, Lohitha Rao; Ho, Melvyn Wai Tuck; Ang, Shi Hua; Tan, Eldwin Sum Wai; Jeyaraj, Duraiswamy Athisayamani; Yeap, Yoon Sheng; Liu, Boping; Ong, Esther Hq; Joy, Joma Kanikadu; Wee, John Liang Kuan; Kwek, Perlyn; Retna, Priya; Dinie, Nurul; Nguyen, Thuy Thi Hanh; Tai, Shi Jing; Manoharan, Vithya; Pendharkar, Vishal; Low, Choon Bing; Chew, Yun Shan; Vuddagiri, Susmitha; Sangthongpitag, Kanda; Choong, Meng Ling; Lee, May Ann; Kannan, Srinivasaraghavan; Verma, Chandra S.; Poulsen, Anders; Lim, Sharon; Chuah, Charles; Ong, Tiong Sin; Hill, Jeffrey; Matter, Alex; Nacro, Kassoum</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4348-4369</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by bcr-abl1, a constitutively active tyrosine kinase fusion gene responsible for an abnormal proliferation of leukemic stem cells (LSCs).  Inhibition of BCR-ABL1 kinase activity offers long-term relief to CML patients.  However, for a proportion of them, BCR-ABL1 inhibition will become ineffective at treating the disease, and CML will progress to blast crisis (BC) CML with poor prognosis.  BC-CML is often assocd. with excessive phosphorylated eukaryotic translation initiation factor 4E (eIF4E), which renders LSCs capable of proliferating via self-renewal, oblivious to BCR-ABL1 inhibition.  In vivo, eIF4E is exclusively phosphorylated on Ser209 by MNK1/2.  Consequently, a selective inhibitor of MNK1/2 should reduce the level of phosphorylated eIF4E and re-sensitize LSCs to BCR-ABL1 inhibition, thus hindering the proliferation of BC LSCs.  We report herein the structure-activity relationships and pharmacokinetic properties of a selective MNK1/2 inhibitor clin. candidate, ETC-206, which in combination with dasatinib prevents BC-CML LSC self-renewal in vitro and enhances dasatinib antitumor activity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwF5EekxyqUrVg90H21EOLACvtfcHk0li1XZyAFIs4JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXot1eqsbw%253D&md5=6818f494dd765080aec49cc11a9c34bb</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01714%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DChennamaneni%26aufirst%3DL.%2BR.%26aulast%3DHo%26aufirst%3DM.%2BW.%2BT.%26aulast%3DAng%26aufirst%3DS.%2BH.%26aulast%3DTan%26aufirst%3DE.%2BS.%2BW.%26aulast%3DJeyaraj%26aufirst%3DD.%2BA.%26aulast%3DYeap%26aufirst%3DY.%2BS.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DOng%26aufirst%3DE.%2BH.%26aulast%3DJoy%26aufirst%3DJ.%2BK.%26aulast%3DWee%26aufirst%3DJ.%2BL.%2BK.%26aulast%3DKwek%26aufirst%3DP.%26aulast%3DRetna%26aufirst%3DP.%26aulast%3DDinie%26aufirst%3DN.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%2BH.%26aulast%3DTai%26aufirst%3DS.%2BJ.%26aulast%3DManoharan%26aufirst%3DV.%26aulast%3DPendharkar%26aufirst%3DV.%26aulast%3DLow%26aufirst%3DC.%2BB.%26aulast%3DChew%26aufirst%3DY.%2BS.%26aulast%3DVuddagiri%26aufirst%3DS.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DChoong%26aufirst%3DM.%2BL.%26aulast%3DLee%26aufirst%3DM.%2BA.%26aulast%3DKannan%26aufirst%3DS.%26aulast%3DVerma%26aufirst%3DC.%2BS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DLim%26aufirst%3DS.%26aulast%3DChuah%26aufirst%3DC.%26aulast%3DOng%26aufirst%3DT.%2BS.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26aulast%3DNacro%26aufirst%3DK.%26atitle%3DOptimization%2520of%2520Selective%2520Mitogen-Activated%2520Protein%2520Kinase%2520Interacting%2520Kinases%25201%2520and%25202%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Blast%2520Crisis%2520Leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4348%26epage%3D4369%26doi%3D10.1021%2Facs.jmedchem.7b01714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thachamvally, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashyap, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maherchandani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span> <span> </span><span class="NLM_article-title">Role of MAPK/MNK1 Signaling in Virus Replication</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>253</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.virusres.2018.05.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1016%2Fj.virusres.2018.05.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=29864503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFSgtL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=2018&pages=48-61&author=R.+Kumarauthor=N.+Khandelwalauthor=R.+Thachamvallyauthor=B.+N.+Tripathiauthor=S.+Baruaauthor=S.+K.+Kashyapauthor=S.+Maherchandaniauthor=N.+Kumar&title=Role+of+MAPK%2FMNK1+Signaling+in+Virus+Replication&doi=10.1016%2Fj.virusres.2018.05.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Role of MAPK/MNK1 signaling in virus replication</span></div><div class="casAuthors">Kumar, Ram; Khandelwal, Nitin; Thachamvally, Riyesh; Tripathi, Bhupendra Nath; Barua, Sanjay; Kashyap, Sudhir Kumar; Maherchandani, Sunil; Kumar, Naveen</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-61</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Viruses are obligate intracellular parasites; they heavily depend on the host cell machinery to effectively replicate and produce new progeny virus particles.  Following viral infection, diverse cell signaling pathways are initiated by the cells, with the major goal of establishing an antiviral state.  However, viruses have been shown to exploit cellular signaling pathways for their own effective replication.  Genome-wide siRNA screens have also identified numerous host factors that either support (proviral) or inhibit (antiviral) virus replication.  Some of the host factors might be dispensable for the host but may be crit. for virus replication; therefore such cellular factors may serve as targets for development of antiviral therapeutics.  Mitogen activated protein kinase (MAPK) is a major cell signaling pathway that is known to be activated by diverse group of viruses.  MAPK interacting kinase 1 (MNK1) has been shown to regulate both cap-dependent and internal ribosomal entry sites (IRES)-mediated mRNA translation.  In this review we have discuss the role of MAPK in virus replication, particularly the role of MNK1 in replication and translation of viral genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtSkgR0ZtErbVg90H21EOLACvtfcHk0lhOKzVzmLQOXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFSgtL%252FP&md5=7be6860d1d54000f55b84f8f1cfa27fb</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2018.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2018.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DKhandelwal%26aufirst%3DN.%26aulast%3DThachamvally%26aufirst%3DR.%26aulast%3DTripathi%26aufirst%3DB.%2BN.%26aulast%3DBarua%26aufirst%3DS.%26aulast%3DKashyap%26aufirst%3DS.%2BK.%26aulast%3DMaherchandani%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DN.%26atitle%3DRole%2520of%2520MAPK%252FMNK1%2520Signaling%2520in%2520Virus%2520Replication%26jtitle%3DVirus%2520Res.%26date%3D2018%26volume%3D253%26spage%3D48%26epage%3D61%26doi%3D10.1016%2Fj.virusres.2018.05.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gromeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrikov, M. I.</span></span> <span> </span><span class="NLM_article-title">Mitogen-Activated Protein Kinase-Interacting Kinase Regulates MTOR/AKT Signaling and Controls the Serine/Arginine-Rich Protein Kinase-Responsive Type 1 Internal Ribosome Entry Site-Mediated Translation and Viral Oncolysis</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">13149</span>– <span class="NLM_lpage">13160</span>, <span class="refDoi"> DOI: 10.1128/JVI.01884-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1128%2FJVI.01884-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=25187540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSls7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=13149-13160&author=M.+C.+Brownauthor=M.+Gromeierauthor=M.+I.+Dobrikov&title=Mitogen-Activated+Protein+Kinase-Interacting+Kinase+Regulates+MTOR%2FAKT+Signaling+and+Controls+the+Serine%2FArginine-Rich+Protein+Kinase-Responsive+Type+1+Internal+Ribosome+Entry+Site-Mediated+Translation+and+Viral+Oncolysis&doi=10.1128%2FJVI.01884-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogen-activated protein kinase-interacting kinase regulates mTOR/AKT signaling and controls the serine/arginine-rich protein kinase-responsive type 1 internal ribosome entry site-mediated translation and viral oncolysis</span></div><div class="casAuthors">Brown, Michael C.; Dobrikov, Mikhail I.; Gromeier, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">13149-13160, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Translation machinery is a major recipient of the principal mitogenic signaling networks involving Raf-ERK1/2 and phosphoinositol 3-kinase (PI3K)-mechanistic target of rapamycin (mTOR).  Picornavirus internal ribosomal entry site (IRES)-mediated translation and cytopathogenic effects are susceptible to the status of such signaling cascades in host cells.  We detd. that tumor-specific cytotoxicity of the poliovirus/rhinovirus chimera PVSRIPO is facilitated by Raf-ERK1/2 signals to the mitogen-activated protein kinase (MAPK)-interacting kinase (MNK) and its effects on the partitioning/activity of the Ser/Arg (SR)-rich protein kinase (SRPK).  Here, we show that MNK regulates SRPK via mTOR and AKT.  Our investigations revealed a MNK-controlled mechanism acting on mTORC2-AKT.  The resulting suppression of AKT signaling attenuates SRPK activity to enhance picornavirus type 1 IRES translation and favor PVSRIPO tumor cell toxicity and killing.  Importance: Oncolytic immunotherapy with PVSRIPO, the type 1 live-attenuated poliovirus (PV) (Sabin) vaccine contg. a human rhinovirus type 2 (HRV2) IRES, is demonstrating early promise in clin. trials with intratumoral infusion in recurrent glioblastoma (GBM).  Our investigations demonstrate that the core mechanistic principle of PVSRIPO, tumor-selective translation and cytotoxicity, relies on constitutive ERK1/2-MNK signals that counteract the deleterious effects of runaway AKT-SRPK activity in malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppMVd5QcFh5bVg90H21EOLACvtfcHk0lh1WZJZADpLWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSls7bM&md5=6e68db194e00a8731edd9ac8cd3eaafe</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1128%2FJVI.01884-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01884-14%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DM.%2BC.%26aulast%3DGromeier%26aufirst%3DM.%26aulast%3DDobrikov%26aufirst%3DM.%2BI.%26atitle%3DMitogen-Activated%2520Protein%2520Kinase-Interacting%2520Kinase%2520Regulates%2520MTOR%252FAKT%2520Signaling%2520and%2520Controls%2520the%2520Serine%252FArginine-Rich%2520Protein%2520Kinase-Responsive%2520Type%25201%2520Internal%2520Ribosome%2520Entry%2520Site-Mediated%2520Translation%2520and%2520Viral%2520Oncolysis%26jtitle%3DJ.%2520Virol.%26date%3D2014%26volume%3D88%26spage%3D13149%26epage%3D13160%26doi%3D10.1128%2FJVI.01884-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desjardins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gromeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herndon, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaubier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcsherry, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muscat, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randazzo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlahovic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLendon, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashely, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span> <span> </span><span class="NLM_article-title">Recurrent Glioblastoma Treated with Recombinant Poliovirus</span>. <i>New Eng. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1716435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1056%2FNEJMoa1716435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=29943666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlert7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=150-161&author=A.+Desjardinsauthor=M.+Gromeierauthor=J.+E.+Herndonauthor=N.+Beaubierauthor=D.+P.+Bolognesiauthor=A.+H.+Friedmanauthor=H.+S.+Friedmanauthor=F.+Mcsherryauthor=A.+M.+Muscatauthor=S.+Nairauthor=K.+B.+Petersauthor=D.+Randazzoauthor=J.+H.+Sampsonauthor=G.+Vlahovicauthor=W.+T.+Harrisonauthor=R.+E.+McLendonauthor=D.+Ashelyauthor=D.+D.+Bigner&title=Recurrent+Glioblastoma+Treated+with+Recombinant+Poliovirus&doi=10.1056%2FNEJMoa1716435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent glioblastoma treated with recombinant poliovirus</span></div><div class="casAuthors">Desjardins, Annick; Gromeier, Matthias; Herndon, James E., II; Beaubier, Nike; Bolognesi, Dani P.; Friedman, Allan H.; Friedman, Henry S.; McSherry, Frances; Muscat, Andrea M.; Nair, Smita; Peters, Katherine B.; Randazzo, Dina; Sampson, John H.; Vlahovic, Gordana; Harrison, William T.; McLendon, Roger E.; Ashley, David; Bigner, Darell D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">150-161</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The prognosis of patients with recurrent World Health Organization (WHO) grade IV malignant glioma is dismal, and there is currently no effective therapy.  We conducted a dose-finding and toxicity study in this population of patients, evaluating convection-enhanced, intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO).  PVSRIPO recognizes the poliovirus receptor CD155, which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment. methods We enrolled consecutive adult patients who had recurrent supratentorial WHO grade IV malignant glioma, confirmed on histopathol. testing, with measurable disease (contrast-enhancing tumor of ≥1 cm and ≤5.5 cm in the greatest dimension).  The study evaluated seven doses, ranging between 107 and 1010 50% tissue-culture infectious doses (TCID50), first in a dose-escalation phase and then in a dose-expansion phase. results From May 2012 through May 2017, a total of 61 patients were enrolled and received a dose of PVSRIPO.  Dose level -1 (5.0 × 107 TCID50) was identified as the phase 2 dose.  One dose-limiting toxic effect was obsd.; a patient in whom dose level 5 (1010 TCID50) was administered had a grade 4 intracranial hemorrhage immediately after the catheter was removed.  To mitigate locoregional inflammation of the infused tumor with prolonged glucocorticoid use, dose level 5 was deescalated to reach the phase 2 dose.  In the dose-expansion phase, 19% of the patients had a PVSRIPO-related adverse event of grade 3 or higher.  Overall survival among the patients who received PVSRIPO reached a plateau of 21% (95% confidence interval, 11 to 33) at 24 mo that was sustained at 36 mo. conclusions Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential.  The survival rate among patients who received PVSRIPO immunotherapy was higher at 24 and 36 mo than the rate among historical controls.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnOQKU8p5sX7Vg90H21EOLACvtfcHk0ljSpu8elMLIQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlert7zF&md5=388ccb28cb2f2855a2da81d7ce20a66b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1716435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1716435%26sid%3Dliteratum%253Aachs%26aulast%3DDesjardins%26aufirst%3DA.%26aulast%3DGromeier%26aufirst%3DM.%26aulast%3DHerndon%26aufirst%3DJ.%2BE.%26aulast%3DBeaubier%26aufirst%3DN.%26aulast%3DBolognesi%26aufirst%3DD.%2BP.%26aulast%3DFriedman%26aufirst%3DA.%2BH.%26aulast%3DFriedman%26aufirst%3DH.%2BS.%26aulast%3DMcsherry%26aufirst%3DF.%26aulast%3DMuscat%26aufirst%3DA.%2BM.%26aulast%3DNair%26aufirst%3DS.%26aulast%3DPeters%26aufirst%3DK.%2BB.%26aulast%3DRandazzo%26aufirst%3DD.%26aulast%3DSampson%26aufirst%3DJ.%2BH.%26aulast%3DVlahovic%26aufirst%3DG.%26aulast%3DHarrison%26aufirst%3DW.%2BT.%26aulast%3DMcLendon%26aufirst%3DR.%2BE.%26aulast%3DAshely%26aufirst%3DD.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26atitle%3DRecurrent%2520Glioblastoma%2520Treated%2520with%2520Recombinant%2520Poliovirus%26jtitle%3DNew%2520Eng.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D150%26epage%3D161%26doi%3D10.1056%2FNEJMoa1716435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kosciuczuk, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleiro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroczynska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckerdt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blyth, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abedin, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platanias, L. C.</span></span> <span> </span><span class="NLM_article-title">Merestinib Blocks Mnk Kinase Activity in Acute Myeloid Leukemia Progenitors and Exhibits Antileukemic Effects in vitro and in vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-02-698704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1182%2Fblood-2016-02-698704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=27307295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVymu7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=410-414&author=E.+M.+Kosciuczukauthor=D.+Saleiroauthor=B.+Kroczynskaauthor=E.+M.+Beauchampauthor=F.+Eckerdtauthor=G.+T.+Blythauthor=S.+M.+Abedinauthor=F.+J.+Gilesauthor=J.+K.+Altmanauthor=L.+C.+Platanias&title=Merestinib+Blocks+Mnk+Kinase+Activity+in+Acute+Myeloid+Leukemia+Progenitors+and+Exhibits+Antileukemic+Effects+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2016-02-698704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo</span></div><div class="casAuthors">Kosciuczuk, Ewa M.; Saleiro, Diana; Kroczynska, Barbara; Beauchamp, Elspeth M.; Eckerdt, Frank; Blyth, Gavin T.; Abedin, Sameem M.; Giles, Francis J.; Altman, Jessica K.; Platanias, Leonidas C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">410-414</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mitogen-activated protein kinase interacting protein kinases (Mnks) play important roles in the development and progression of acute myeloid leukemia (AML) by regulating eukaryotic translation initiation factor 4E (eIF4E) activation.  Inhibiting Mnk1/2-induced phosphorylation of eIF4E may represent a unique approach for the treatment of AML.  We provide evidence for antileukemic effects of merestinib, an orally bioavailable multikinase inhibitor with suppressive effects on Mnk activity.  Our studies show that merestinib effectively blocks eIF4E phosphorylation in AML cells and suppresses primitive leukemic progenitors from AML patients in vitro and in an AML xenograft model in vivo.  Our findings provide evidence for potent preclin. antileukemic properties of merestinib and support its clin. development for the treatment of patients with AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEFrhJ4BiK57Vg90H21EOLACvtfcHk0ljSpu8elMLIQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVymu7jE&md5=e1034d2ea79d51ffc297d86a6ae4b737</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-02-698704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-02-698704%26sid%3Dliteratum%253Aachs%26aulast%3DKosciuczuk%26aufirst%3DE.%2BM.%26aulast%3DSaleiro%26aufirst%3DD.%26aulast%3DKroczynska%26aufirst%3DB.%26aulast%3DBeauchamp%26aufirst%3DE.%2BM.%26aulast%3DEckerdt%26aufirst%3DF.%26aulast%3DBlyth%26aufirst%3DG.%2BT.%26aulast%3DAbedin%26aufirst%3DS.%2BM.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DPlatanias%26aufirst%3DL.%2BC.%26atitle%3DMerestinib%2520Blocks%2520Mnk%2520Kinase%2520Activity%2520in%2520Acute%2520Myeloid%2520Leukemia%2520Progenitors%2520and%2520Exhibits%2520Antileukemic%2520Effects%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D410%26epage%3D414%26doi%3D10.1182%2Fblood-2016-02-698704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A Quantitative Analysis of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+Quantitative+Analysis+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lgw-d28vDDRjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520Quantitative%2520Analysis%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diab, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumarasiri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basnet, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">962</span>– <span class="NLM_lpage">972</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1002%2Fcmdc.201300552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=24677692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitlShsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=962-972&author=S.+Diabauthor=T.+Teoauthor=M.+Kumarasiriauthor=P.+Liauthor=M.+Yuauthor=F.+Lamauthor=S.+K.+Basnetauthor=M.+J.+Sykesauthor=H.+Albrechtauthor=R.+Milneauthor=S.+Wang&title=Discovery+of+5-%282-%28phenylamino%29pyrimidin-4-yl%29thiazol-2%283H%29-one+Derivatives+as+Potent+Mnk2+Inhibitors%3A+Synthesis%2C+SAR+Analysis+and+Biological+Evaluation&doi=10.1002%2Fcmdc.201300552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-(2-(Phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation</span></div><div class="casAuthors">Diab, Sarah; Teo, Theodosia; Kumarasiri, Malika; Li, Peng; Yu, Mingfeng; Lam, Frankie; Basnet, Sunita K. C.; Sykes, Matthew J.; Albrecht, Hugo; Milne, Robert; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">962-972</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Phosphorylation of eIF4E by human mitogen-activated protein kinase (MAPK)-interacting kinases (Mnks) is crucial for human tumorigenesis and development.  Targeting Mnks may provide a novel anticancer therapeutic strategy.  However, the lack of selective Mnk inhibitors has so far hampered pharmacol. target validation and clin. drug development.  Herein, we report, for the first time, the discovery of a series of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivs. as Mnk inhibitors.  Several derivs. demonstrate very potent Mnk2 inhibitory activity.  The most active and selective compds. were tested against a panel of cancer cell lines, and the results confirm the cell-type-specific effect of these Mnk inhibitors.  Detailed cellular mechanistic studies reveal that Mnk inhibitors are capable of reducing the expression level of anti-apoptotic protein Mcl-1, and of promoting apoptosis in MV4-11 acute myeloid leukemia cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrsENPnEmtz7Vg90H21EOLACvtfcHk0lgw-d28vDDRjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitlShsrc%253D&md5=b412a7296fae370913dace6479e9f4b4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300552%26sid%3Dliteratum%253Aachs%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DBasnet%26aufirst%3DS.%2BK.%26aulast%3DSykes%26aufirst%3DM.%2BJ.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DMilne%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%25205-%25282-%2528phenylamino%2529pyrimidin-4-yl%2529thiazol-2%25283H%2529-one%2520Derivatives%2520as%2520Potent%2520Mnk2%2520Inhibitors%253A%2520Synthesis%252C%2520SAR%2520Analysis%2520and%2520Biological%2520Evaluation%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D962%26epage%3D972%26doi%3D10.1002%2Fcmdc.201300552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hung, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestre, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span> <span> </span><span class="NLM_article-title">Application of Fragment Growing and Fragment Linking to the Discovery of Inhibitors of Mycobacterium Tuberculosis Pantothenate Synthetase</span>. <i>Angew. Chem. Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">8452</span>– <span class="NLM_lpage">8456</span>, <span class="refDoi"> DOI: 10.1002/anie.200903821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1002%2Fanie.200903821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWmur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=8452-8456&author=A.+W.+Hungauthor=H.+L.+Silvestreauthor=S.+Wenauthor=A.+Ciulliauthor=T.+L.+Blundellauthor=C.+Abell&title=Application+of+Fragment+Growing+and+Fragment+Linking+to+the+Discovery+of+Inhibitors+of+Mycobacterium+Tuberculosis+Pantothenate+Synthetase&doi=10.1002%2Fanie.200903821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Fragment Growing and Fragment Linking to the Discovery of Inhibitors of Mycobacterium tuberculosis Pantothenate Synthetase</span></div><div class="casAuthors">Hung, Alvin W.; Silvestre, H. Leonardo; Wen, Shijun; Ciulli, Alessio; Blundell, Tom L.; Abell, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">8452-8456, S8452/1-S8452/26</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Despite the fact that nearly 2 million people a year are killed by Mycobacterium tuberculosis (TB), we still lack a robust pipeline of potential therapies to combat this burden.  Fragment-based approaches have provided a new paradigm in the development of high-quality chem. ligands and have great potential to contribute as starting points in the development of drugs against TB.  To date, studies on pantothenate synthetase (PS) inhibition have focused on the synthesis of analogs of the pantoyl adenylate reaction intermediate or the identification of hits from high-throughput screening.  We describe a combination of fragment-growing and fragment-linking approaches that led to the discovery of a new series of inhibitors of M. tuberculosis PS for the further validation of PS as a potential drug target for TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjhska_U-KXbVg90H21EOLACvtfcHk0lhy-vb5-BxfEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWmur%252FK&md5=821f86e9e1d7cbd848741962e3ac47dd</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fanie.200903821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200903821%26sid%3Dliteratum%253Aachs%26aulast%3DHung%26aufirst%3DA.%2BW.%26aulast%3DSilvestre%26aufirst%3DH.%2BL.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DCiulli%26aufirst%3DA.%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26aulast%3DAbell%26aufirst%3DC.%26atitle%3DApplication%2520of%2520Fragment%2520Growing%2520and%2520Fragment%2520Linking%2520to%2520the%2520Discovery%2520of%2520Inhibitors%2520of%2520Mycobacterium%2520Tuberculosis%2520Pantothenate%2520Synthetase%26jtitle%3DAngew.%2520Chem.%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D8452%26epage%3D8456%26doi%3D10.1002%2Fanie.200903821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, R.</span></span> <span> </span><span class="NLM_article-title">Fragment-based Lead Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">660</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1038/nrd1467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1038%2Fnrd1467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=15286733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=660-672&author=D.+C.+Reesauthor=M.+Congreveauthor=C.+W.+Murrayauthor=R.+Carr&title=Fragment-based+Lead+Discovery&doi=10.1038%2Fnrd1467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-based lead discovery</span></div><div class="casAuthors">Rees, David C.; Congreve, Miles; Murray, Christopher W.; Carr, Robin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">660-672</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fragment-based lead discovery is gaining momentum in both large pharmaceutical companies and biotechnol. labs. as a complementary approach to traditional screening.  This is because fragment-based approaches require significantly fewer compds. to be screened and synthesized, and are showing a high success rate in generating chem. series with lead-like properties.  Compared with traditional screening hits, the starting fragments have considerably lower mol. mass, and although the binding interactions of these fragments with a target protein are weak, they are structurally understood through x-ray crystallog. or NMR, and they exhibit high 'ligand efficiency'.  Here, the authors use examples from 25 different protein targets to describe chem. strategies that exploit this structural knowledge to rapidly develop fragments into high-affinity leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbKeUzFFIlhbVg90H21EOLACvtfcHk0lhy-vb5-BxfEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOht7Y%253D&md5=8d49ac7f698c9b9d573ee3c3485eced8</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrd1467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1467%26sid%3Dliteratum%253Aachs%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DCarr%26aufirst%3DR.%26atitle%3DFragment-based%2520Lead%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D660%26epage%3D672%26doi%3D10.1038%2Fnrd1467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="note"><p class="first last">All animal studies were conducted at the Experimental Therapeutics Centre, Singapore, with the prior approval of the local Institutional Animal Care Committee (IACUC approval no. 181304).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Drug Discovery: Advancing Fragments in the Absence of Crystal Structures</span>. <i>Cell. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2018.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1016%2Fj.chembiol.2018.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=30482678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWisrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=9-15&author=D.+A.+Erlansonauthor=B.+J.+Davisauthor=W.+Jahnke&title=Fragment-Based+Drug+Discovery%3A+Advancing+Fragments+in+the+Absence+of+Crystal+Structures&doi=10.1016%2Fj.chembiol.2018.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Drug Discovery: Advancing Fragments in the Absence of Crystal Structures</span></div><div class="casAuthors">Erlanson, Daniel A.; Davis, Ben J.; Jahnke, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-15</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Fragment-based drug discovery typically requires an interplay between screening methods, structural methods, and medicinal chem.  X-ray crystallog. is generally the method of choice to obtain three-dimensional structures of the bound ligand/protein complex, but this can sometimes be difficult, particularly for early, low-affinity fragment hits.  In this Perspective, we discuss strategies to advance and evolve fragments in the absence of crystal structures of protein-fragment complexes, although the structure of the unliganded protein may be available.  The strategies can involve other structural techniques, such as NMR spectroscopy, mol. modeling, or a variety of chem. approaches.  Often, these strategies are aimed at guiding evolution of initial fragment hits to a stage where crystal structures can be obtained for further structure-based optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmStmkIpx6bLVg90H21EOLACvtfcHk0lhy-vb5-BxfEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWisrzI&md5=2f5fb9d063b7ccabb4f7eb611c00ce30</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DDavis%26aufirst%3DB.%2BJ.%26aulast%3DJahnke%26aufirst%3DW.%26atitle%3DFragment-Based%2520Drug%2520Discovery%253A%2520Advancing%2520Fragments%2520in%2520the%2520Absence%2520of%2520Crystal%2520Structures%26jtitle%3DCell.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26spage%3D9%26epage%3D15%26doi%3D10.1016%2Fj.chembiol.2018.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seetoh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Then, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span> <span> </span><span class="NLM_article-title">Application of Fragment-Based Drug Discovery against DNA Gyrase B</span>. <i>Chem. Plus Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">1250</span>– <span class="NLM_lpage">1254</span>, <span class="refDoi"> DOI: 10.1002/cplu.201500197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=10.1002%2Fcplu.201500197" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2015&pages=1250-1254&author=G.+Chenauthor=F.+M.+Ngauthor=Y.+W.+Tanauthor=A.+Poulsenauthor=W.+Seetohauthor=G.+Linauthor=C.+Kangauthor=S.+W.+Thenauthor=N.+H.+Ahmadauthor=Y.+L.+Wongauthor=H.+Q.+Ngauthor=C.+S.+Chiaauthor=Q.+Y.+Lauauthor=J.+Hillauthor=A.+W.+Hungauthor=T.+H.+Keller&title=Application+of+Fragment-Based+Drug+Discovery+against+DNA+Gyrase+B&doi=10.1002%2Fcplu.201500197"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fcplu.201500197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcplu.201500197%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26aulast%3DNg%26aufirst%3DF.%2BM.%26aulast%3DTan%26aufirst%3DY.%2BW.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSeetoh%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DKang%26aufirst%3DC.%26aulast%3DThen%26aufirst%3DS.%2BW.%26aulast%3DAhmad%26aufirst%3DN.%2BH.%26aulast%3DWong%26aufirst%3DY.%2BL.%26aulast%3DNg%26aufirst%3DH.%2BQ.%26aulast%3DChia%26aufirst%3DC.%2BS.%26aulast%3DLau%26aufirst%3DQ.%2BY.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DHung%26aufirst%3DA.%2BW.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26atitle%3DApplication%2520of%2520Fragment-Based%2520Drug%2520Discovery%2520against%2520DNA%2520Gyrase%2520B%26jtitle%3DChem.%2520Plus%2520Chem.%26date%3D2015%26volume%3D80%26spage%3D1250%26epage%3D1254%26doi%3D10.1002%2Fcplu.201500197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wach, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almo, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Herin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, D. W.</span></span> <span> </span><span class="NLM_article-title">Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">852</span>– <span class="NLM_lpage">856</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00230</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00230" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFKms7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=852-856&author=Y.+Wangauthor=J.+Y.+Wachauthor=P.+Sheehanauthor=C.+Zhongauthor=C.+Zhanauthor=R.+Harrisauthor=S.+C.+Almoauthor=J.+Bishopauthor=S.+J.+Haggartyauthor=A.+Ramekauthor=K.+N.+Berryauthor=C.+O%E2%80%99Herinauthor=A.+N.+Koehlerauthor=A.+W.+Hungauthor=D.+W.+Young&title=Diversity-Oriented+Synthesis+as+a+Strategy+for+Fragment+Evolution+against+GSK3%CE%B2&doi=10.1021%2Facsmedchemlett.6b00230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β</span></div><div class="casAuthors">Wang, Yikai; Wach, Jean-Yves; Sheehan, Patrick; Zhong, Cheng; Zhan, Chenyang; Harris, Richard; Almo, Steven C.; Bishop, Joshua; Haggarty, Stephen J.; Ramek, Alexander; Berry, Kayla N.; O'Herin, Conor; Koehler, Angela N.; Hung, Alvin W.; Young, Damian W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">852-856</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Traditional fragment-based drug discovery (FBDD) relies heavily on structural anal. of the hits bound to their targets.  Herein, we present a complementary approach based on diversity-oriented synthesis (DOS).  A DOS-based fragment collection was able to produce initial hit compds. against the target GSK3β, allow the systematic synthesis of related fragment analogs to explore fragment-level structure-activity relationship, and finally lead to the synthesis of a more potent compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSSD8IpGmjLVg90H21EOLACvtfcHk0lhDolCvMpgKrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFKms7vJ&md5=54b88fe62b0fbd6a0821a84a664c0d31</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00230%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWach%26aufirst%3DJ.%2BY.%26aulast%3DSheehan%26aufirst%3DP.%26aulast%3DZhong%26aufirst%3DC.%26aulast%3DZhan%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26aulast%3DBishop%26aufirst%3DJ.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DRamek%26aufirst%3DA.%26aulast%3DBerry%26aufirst%3DK.%2BN.%26aulast%3DO%25E2%2580%2599Herin%26aufirst%3DC.%26aulast%3DKoehler%26aufirst%3DA.%2BN.%26aulast%3DHung%26aufirst%3DA.%2BW.%26aulast%3DYoung%26aufirst%3DD.%2BW.%26atitle%3DDiversity-Oriented%2520Synthesis%2520as%2520a%2520Strategy%2520for%2520Fragment%2520Evolution%2520against%2520GSK3%25CE%25B2%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D852%26epage%3D856%26doi%3D10.1021%2Facsmedchemlett.6b00230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tee, D. H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, N. H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poh, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurul, Dinie.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendharkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangthongpitag, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepramaniam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, A. W.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4386</span>– <span class="NLM_lpage">4396</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00060</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00060" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1cXot1eqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4386-4396&author=J.+Kwiatkowskiauthor=B.+Liuauthor=D.+H.+Y.+Teeauthor=G.+Chenauthor=N.+H.+B.+Ahmadauthor=Y.+X.+Wongauthor=Z.+Y.+Pohauthor=S.+H.+Angauthor=E.+S.+W.+Tanauthor=E.+H.+Ongauthor=Dinie.+Nurulauthor=A.+Poulsenauthor=V.+Pendharkarauthor=K.+Sangthongpitagauthor=M.+A.+Leeauthor=S.+Sepramaniamauthor=S.+Y.+Hoauthor=J.+Cherianauthor=J.+Hillauthor=T.+H.+Kellerauthor=A.+W.+Hung&title=Fragment-Based+Drug+Discovery+of+Potent+Protein+Kinase+C+Iota+Inhibitors&doi=10.1021%2Facs.jmedchem.8b00060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors</span></div><div class="casAuthors">Kwiatkowski, Jacek; Liu, Boping; Tee, Doris Hui Ying; Chen, Guoying; Binte Ahmad, Nur Huda; Wong, Yun Xuan; Poh, Zhi Ying; Ang, Shi Hua; Tan, Eldwin Sum Wai; Ong, Esther H. Q.; Dinie, Nurul; Poulsen, Anders; Pendharkar, Vishal; Sangthongpitag, Kanda; Lee, May Ann; Sepramaniam, Sugunavathi; Ho, Soo Yei; Cherian, Joseph; Hill, Jeffrey; Keller, Thomas H.; Hung, Alvin W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4386-4396</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein kinase C iota (PKC-ι) is an atypical kinase implicated in the promotion of different cancer types.  A biochem. screen of a fragment library has identified several hits from which an azaindole-based scaffold was chosen for optimization.  Driven by a structure-activity relationship and supported by mol. modeling, a weakly bound fragment was systematically grown into a potent and selective inhibitor against PKC-ι.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVKGgW092g1bVg90H21EOLACvtfcHk0lj_VaiXXWq7eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXot1eqtbk%253D&md5=efeeb545b2a8a88ff9d42d246fd2de4c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00060%26sid%3Dliteratum%253Aachs%26aulast%3DKwiatkowski%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTee%26aufirst%3DD.%2BH.%2BY.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DAhmad%26aufirst%3DN.%2BH.%2BB.%26aulast%3DWong%26aufirst%3DY.%2BX.%26aulast%3DPoh%26aufirst%3DZ.%2BY.%26aulast%3DAng%26aufirst%3DS.%2BH.%26aulast%3DTan%26aufirst%3DE.%2BS.%2BW.%26aulast%3DOng%26aufirst%3DE.%2BH.%26aulast%3DNurul%26aufirst%3DDinie.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DPendharkar%26aufirst%3DV.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DM.%2BA.%26aulast%3DSepramaniam%26aufirst%3DS.%26aulast%3DHo%26aufirst%3DS.%2BY.%26aulast%3DCherian%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DHung%26aufirst%3DA.%2BW.%26atitle%3DFragment-Based%2520Drug%2520Discovery%2520of%2520Potent%2520Protein%2520Kinase%2520C%2520Iota%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4386%26epage%3D4396%26doi%3D10.1021%2Facs.jmedchem.8b00060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baburajendran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tee, D. H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poh, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahad, N. D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, A. W.</span></span> <span> </span><span class="NLM_article-title">Fragment-based Discovery of a Small-molecule Protein Kinase C-iota Inhibitor Binding Post-kinase Domain Residues</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00546</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00546" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFCqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=318-323&author=J.+Kwiatkowskiauthor=N.+Baburajendranauthor=A.+Poulsenauthor=B.+Liuauthor=D.+H.+Y.+Teeauthor=Y.+X.+Wongauthor=Z.+Y.+Pohauthor=E.+Ongauthor=N.+D.+B.+Rahadauthor=J.+Cherianauthor=A.+E.+Janssonauthor=J.+Hillauthor=T.+H.+Kellerauthor=A.+W.+Hung&title=Fragment-based+Discovery+of+a+Small-molecule+Protein+Kinase+C-iota+Inhibitor+Binding+Post-kinase+Domain+Residues&doi=10.1021%2Facsmedchemlett.8b00546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-based Discovery of a Small-Molecule Protein Kinase C-iota Inhibitor Binding Post-kinase Domain Residues</span></div><div class="casAuthors">Kwiatkowski, Jacek; Baburajendran, Nithya; Poulsen, Anders; Liu, Boping; Tee, Doris Hui Ying; Wong, Yun Xuan; Poh, Zhi Ying; Ong, Esther HQ; Dinie, Nurul; Cherian, Joseph; Jansson, Anna Elisabet; Hill, Jeffrey; Keller, Thomas H.; Hung, Alvin W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">318-323</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The atypical protein kinase C-iota (PKC-ι) enzyme is implicated in various cancers and has been put forward as an attractive target for developing anticancer therapy.  A high concn. biochem. screen identified pyridine fragment weakly inhibiting PKC-ι with IC50 = 424 μM.  Driven by structure-activity relationships and guided by docking hypothesis, the weakly bound fragment was eventually optimized into a potent inhibitor of PKC-ι (IC50= 270 nM).  Through the course of the optimization, an intermediate compd. was crystd. with the protein, and careful anal. of the x-ray crystal structure revealed a unique binding mode involving the post-kinase domain (C-terminal tail) of PKC-ι.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1BrjXnhc9LLVg90H21EOLACvtfcHk0lj_VaiXXWq7eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFCqtbw%253D&md5=58ba46895acd8e659d67620700f77917</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00546%26sid%3Dliteratum%253Aachs%26aulast%3DKwiatkowski%26aufirst%3DJ.%26aulast%3DBaburajendran%26aufirst%3DN.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTee%26aufirst%3DD.%2BH.%2BY.%26aulast%3DWong%26aufirst%3DY.%2BX.%26aulast%3DPoh%26aufirst%3DZ.%2BY.%26aulast%3DOng%26aufirst%3DE.%26aulast%3DRahad%26aufirst%3DN.%2BD.%2BB.%26aulast%3DCherian%26aufirst%3DJ.%26aulast%3DJansson%26aufirst%3DA.%2BE.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DHung%26aufirst%3DA.%2BW.%26atitle%3DFragment-based%2520Discovery%2520of%2520a%2520Small-molecule%2520Protein%2520Kinase%2520C-iota%2520Inhibitor%2520Binding%2520Post-kinase%2520Domain%2520Residues%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D318%26epage%3D323%26doi%3D10.1021%2Facsmedchemlett.8b00546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HW7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HW7','PDB','2HW7'); return false;">PDB: 2HW7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JLR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JLR','PDB','6JLR'); return false;">PDB: 6JLR</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i66"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01582">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_22512"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01582?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01582</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Full protein sequences from Uniprot crystalized residues in black (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_001.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (compounds <b>1</b>–<b>49</b>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_002.csv">CSV</a>)</p></li><li><p class="inline">Inhibitory activity of additional compounds; in vitro and in vivo PK compilation and mouse PK for compounds <b>44</b> and <b>48</b>; molecular modeling and analysis of MNK isoform similarity; X-ray crystal structure details; synthesis and characterization of additional compounds; HPLC spectrograms for advanced compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_003.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_001.pdb">jm9b01582_si_001.pdb (340.78 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_002.csv">jm9b01582_si_002.csv (2.77 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01582/suppl_file/jm9b01582_si_003.pdf">jm9b01582_si_003.pdf (757.88 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">X-ray crystal structure of compound <b>36</b> in complex with MNK2, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6JLR">6JLR</a>. Authors will release the atomic coordinates upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01582&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01582%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-2%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01582" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667987fc0f28d1c3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
